

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2005/010912

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/559,225
Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 12 August 2005 (12.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

THE UNITED STATES OF AMERICA**TO ALL TO WHOM THESE PRESENTS SHALL COME:****UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office***August 02, 2005*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/559,225**FILING DATE: April 01, 2004****RELATED PCT APPLICATION NUMBER: PCT/US05/10912**

Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 961008047 US

U.S. PTO
00104
22154
00104
00104040104
00104
00104**INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Steven	MAH	San Diego, California
Andreas	BRAUN	San Diego, California
Stefan M.	KAMMERER	San Diego, California

Additional inventors are being named on the 1 separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

Direct all correspondence to: CORRESPONDENCE ADDRESS

 Customer Number: 25225

OR

 Firm or
Individual Name

Address

City	State	Zip
Country	Telephone	Fax

ENCLOSED APPLICATION PARTS (check all that apply)

Specification Number of Pages 138 CD(s), Number _____

Drawing(s) Number of Sheets 1 Other _____

Application Data Sheet. See 37 CFR 1.76 (4 pages) (specify): Return Receipt Postcard

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

Applicant claims small entity status. See 37 CFR 1.27.

A check or money order is enclosed to cover the filing fees.

The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 03-1952

Payment by credit card. Form PTO-2038 is attached.

FILING FEE
AMOUNT (\$)

80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

 No Yes, the name of the U.S. Government agency _____ and the Government contract number are: _____

[Page 1 of 2]

Respectfully submitted,

Date April 1, 2004

SIGNATURE

TYPED OR

REGISTRATION NO.

PRINTED NAME

Bruce D. Grant

47,608

TELEPHONE

(858) 720-7962

Docket Number:

524593009200

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 961008047 US, in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 4/1/04

Signature:
(Deborah Wykes)

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/06. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle if any)	Family or Surname	Residence (City and either State or Foreign Country)
Matthew Roberts Rikard Henry Maria L.	NELSON RENELAND LANGDOWN	San Marcos, California San Diego, California San Diego, California

[Page 2 of 2]

METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

Field of the Invention

[0001] The invention relates to genetic methods for identifying risk of osteoarthritis and treatments that specifically target such diseases.

Background

[0002] Osteoarthritis (OA) is a chronic disease usually affecting weight-bearing synovial joints. There are approximately 20 million Americans affected by OA and it is the leading cause of disability in the United States. In addition to extensive human suffering, OA also accounts for nearly all knee replacements and more than half of all hip replacements in the United States. Despite its prevalence, OA is poorly understood and there are few treatments available besides anti-inflammatory drugs and joint replacement.

[0003] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0004] OA is characterized by the breakdown of cartilage in joints. Cartilage in joints cushions the ends of bones, and cartilage breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rheum. 32:241-246 (1989)).

Summary

[0005] It has been discovered that certain polymorphic variations in human genomic DNA are associated with osteoarthritis. In particular, polymorphic variants in a locus containing a *APOL3* region in human genomic DNA have been associated with risk of osteoarthritis.

[0006] Thus, featured herein are methods for identifying a subject at risk of osteoarthritis and/or a risk of osteoarthritis in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in or around the loci described herein in a human nucleic acid sample. In an embodiment, two or more polymorphic variations are detected in two or more regions of which one is the *APOL3* region. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected.

[0007] Also featured are nucleic acids that include one or more polymorphic variations associated with occurrence of osteoarthritis, as well as polypeptides encoded by these nucleic acids. In addition, provided are methods for identifying candidate therapeutic molecules for treating osteoarthritis, as well as methods for treating osteoarthritis in a subject by identifying a subject at risk of osteoarthritis and treating the subject with a suitable prophylactic, treatment or therapeutic molecule.

[0008] Also provided are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *APOL3* nucleic acid, with a RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid designed from a *APOL3* nucleotide sequence. In an embodiment, the RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid is designed from a *APOL3* nucleotide sequence that includes one or more polymorphic variations associated with osteoarthritis, and in some instances, specifically interacts with such a nucleotide sequence. Further, provided are arrays of nucleic acids bound to a solid surface, in which one or more nucleic acid molecules of the array have a *APOL3* nucleotide sequence, or a fragment or substantially identical nucleic acid thereof, or a complementary nucleic acid of the foregoing. Featured also are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *APOL3* polypeptide, with an antibody that specifically binds to the polypeptide. In an embodiment, the antibody specifically binds to an epitope in the polypeptide that includes a non-synonymous amino acid modification associated with osteoarthritis (e.g., results in an amino acid substitution in the encoded polypeptide associated with osteoarthritis).

Brief Description of the Drawings

[0009] Figure 1 shows proximal SNPs in a *APOL3* region in genomic DNA. The position of each SNP in the chromosome is shown on the x-axis and the y-axis provides the negative logarithm of the p-value comparing the estimated allele to that of the control group. Also shown in the figure are exons and introns of the gene region in the approximate chromosomal positions.

Detailed Description

[0010] It has been discovered that a polymorphic variant in a locus containing a *APOL3* region is associated with occurrence of osteoarthritis in subjects. Thus, detecting genetic determinants associated with an increased risk of osteoarthritis occurrence can lead to early identification of a predisposition to osteoarthritis and early prescription of preventative measures. Also, associating a *APOL3* polymorphic variant with osteoarthritis has provided new targets for screening molecules useful in treatments of osteoarthritis.

Osteoarthritis and Sample Selection

[0011] Osteoarthritis (OA), or degenerative joint disease, is one of the oldest and most common types of arthritis. It is characterized by the breakdown of the joint's cartilage. Cartilage is the part of the joint that cushions the ends of bones, and its breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. *Arthritis Rheum.* 32:241-246 (1989)).

[0012] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0013] Osteoarthritis affects an estimated 20.7 million Americans, mostly after age 45, with women more commonly affected than men. Physicians make a diagnosis of OA based on a physical exam and history of symptoms. X-rays are used to confirm diagnosis. Most people over 60 reflect the disease on X-ray, and about one-third have actual symptoms.

[0014] There are many factors that can cause OA. Obesity may lead to osteoarthritis of the knees. In addition, people with joint injuries due to sports, work-related activity or accidents may be at increased risk of developing OA.

[0015] Genetics has a role in the development of OA. Some people may be born with defective cartilage or with slight defects in the way that joints fit together. As a person ages, these defects may cause early cartilage breakdown in the joint or the inability to repair damaged or deteriorated cartilage in the joint.

[0016] Inclusion or exclusion of samples for an osteoarthritis pool may be based upon the following criteria: ethnicity (e.g., samples derived from an individual characterized as Caucasian); parental ethnicity (e.g., samples derived from an individual of British paternal and maternal descent); relevant phenotype information for the individual (e.g., case samples derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic). Control samples may be selected based on relevant phenotype information for the individual (e.g., derived from individuals free of OA at several sites (knee, hand, hip etc)); and no family history of OA and/or rheumatoid arthritis. Additional phenotype information collected for both cases and controls may include age of the individual, gender, family history of OA, diagnosis with osteoarthritis (joint location of OA, date of primary diagnosis, age of individual as of primary diagnosis), knee history (current symptoms, any major knee injury, meniscectomy, knee replacement surgery, age of surgery), HRT history, osteoporosis diagnosis.

[0017] Based in part upon selection criteria set forth above, individuals having osteoarthritis can be selected for genetic studies. Also, individuals having no history of osteoarthritis often are selected for genetic studies, as described hereafter.

Polymorphic Variants Associated with Osteoarthritis

[0018] A genetic analysis provided herein linked osteoarthritis with polymorphic variant nucleic acid sequences in the human genome. As used herein, the term “polymorphic site” refers to a region in a nucleic acid at which two or more alternative nucleotide sequences are observed in a significant number of nucleic acid samples from a population of individuals. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. A polymorphic site is often one nucleotide in length, which is referred to herein as a “single nucleotide polymorphism” or a “SNP.”

[0019] Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a “polymorphic variant” or “nucleic acid variant.” Where two polymorphic variants exist, for example, the polymorphic variant represented in a minority of samples from a population is sometimes referred to as a “minor allele” and the polymorphic variant that is more prevalently represented is sometimes referred to as a “major allele.” Many organisms possess a copy of each chromosome (*e.g.*, humans), and those individuals who possess two major alleles or two minor alleles are often referred to as being “homozygous” with respect to the polymorphism, and those individuals who possess one major allele and one minor allele are normally referred to as being “heterozygous” with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

[0020] In genetic analysis that associate polymorphic variants with osteoarthritis, samples from individuals having osteoarthritis and individuals not having osteoarthritis often are allelotyped and/or genotyped. The term “allelotype” as used herein refers to a process for determining the allele frequency for a polymorphic variant in pooled DNA samples from cases and controls. By pooling DNA from each group, an allele frequency for each SNP in each group is calculated. These allele frequencies are then compared to one another. The term “genotyped” as used herein refers to a process for determining a genotype of one or more individuals, where a “genotype” is a representation of one or more polymorphic variants in a population.

[0021] A genotype or polymorphic variant may be expressed in terms of a "haplotype," which as used herein refers to two or more polymorphic variants occurring within genomic DNA in a group of individuals within a population. For example, two SNPs may exist within a gene where each SNP position includes a cytosine variation and an adenine variation. Certain individuals in a population may carry one allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

[0022] As used herein, the term "phenotype" refers to a trait which can be compared between individuals, such as presence or absence of a condition, a visually observable difference in appearance between individuals, metabolic variations, physiological variations, variations in the function of biological molecules, and the like. An example of a phenotype is occurrence of osteoarthritis.

[0023] Researchers sometimes report a polymorphic variant in a database without determining whether the variant is represented in a significant fraction of a population. Because a subset of these reported polymorphic variants are not represented in a statistically significant portion of the population, some of them are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined. Methods for detecting a polymorphic variant in a population are described herein, specifically in Example 2. A polymorphic variant is statistically significant and often biologically relevant if it is represented in 5% or more of a population, sometimes 10% or more, 15% or more, or 20% or more of a population, and often 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more of a population.

[0024] A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5' untranslated region (UTR), a 3' UTR, and in DNA (e.g., genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (e.g., mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

[0025] It was determined that polymorphic variations associated with an increased risk of osteoarthritis existed in a *APOL3* region in SEQ ID NO: 1. In certain embodiments, a polymorphic variant at position rs132659 in the human genome was associated with an increased risk of osteoarthritis, and in a specific embodiment, a cytosine at position rs132659 was associated with an increased risk of osteoarthritis.

[0026] Polymorphic variants in and around the *APOL3* locus were tested for association with osteoarthritis. These include polymorphic variants at positions in SEQ ID NO: 1 selected from the group

consisting of 201, 425, 1095, 2201, 7879, 8395, 8461, 9503, 10304, 10695, 16300, 16444, 17591, 17988, 19116, 19358, 20300, 20669, 20891, 21451, 21978, 22785, 24248, 24770, 24844, 25066, 25096, 25309, 25344, 25529, 25537, 25554, 27963, 28134, 28356, 29648, 29986, 30217, 30267, 30315, 30585, 30724, 30897, 30931, 31080, 31246, 31373, 31463, 31467, 32188, 32288, 32520, 32594, 32657, 32677, 32764, 32784, 32830, 32872, 33121, 33348, 33952, 34184, 34361, 35026, 35192, 35600, 36033, 36289, 38869, 39629, 40530, 41621, 42379, 42802, 42865, 43644, 45051, 45828, 45829, 46257, 47286, 47427, 47963, 48013, 48229, 48282, 48376, 48404, 49900, 52699, 52897, 53414, 53487, 54112, 55492, 59766, 60307, 60701, 60952, 61401, 62379, 62870, 62879, 63499, 64284, 64408, 64760, 65230, 66127, , 6634, 66686, 66694, 67113, 67257, 67403, 67609, 68418, 68610, 69629, 70024, 70848, 71428, 71553, 71633, 71768, , 71769, 73039, 73325, 73412, 73547, 73769, 73806, 74467, 74472, 74473, 74482, 74494, 74592, 74670, 74672, 74714, 74723, 74749, 74861, 74892, 74893, 75176, 75705, 75989, 76027, 77949, 77974, 78167, 78310, 78415, 78575, 78590, 78709, 78875, 79864, 81316, 81320, 81409, 81737, 81843, 82102, 82833, 83461, 83624, 83660, 83701, 83708, 83782, 85707, 85717, 86486, 86833, 87115, 87234, 87479, 87561, 87604, 87674, 87958, 87992, 88019, 88074, 88079, 88115, 88118, 88120, 88135, 88142, 88143, 88149, 88340, 88344, 88512, 88521, 88650, 88827, 89230, 89236, 90754, 90984, 91110, 92026, 92954, 93375, 93794, 94937, 95068, 96188, 97092 and 98812. Polymorphic variants at the following positions in SEQ ID NO: 1 in particular were associated with an increased risk of osteoarthritis: 20300, 46257, 87958, 89236, 30267, 32657, 36289, 38869, 45051, 54112, 60307, 63499, 20891, 52699, 71768, with specific embodiments directed to position 46257. In particular, the following polymorphic variants in SEQ ID NO: 1 were associated with risk of osteoarthritis: an adenine at position 20300, a thymine at position 46257, an adenine at position 89236, a guanine at position 30267, an adenine at position 32657, a cytosine at position 36289, a guanine at position 38869, a thymine at position 45051, a guanine at position 54112, an adenine at position 60307, a thymine at position 63499, a guanine at position 20891, a guanine at position 52699, and a cytosine at position 71768.

[0027] Based in part upon analyses summarized in Figure 1, a region with significant association has been identified in a locus associated with osteoarthritis. Any polymorphic variants associated with osteoarthritis in a region of significant association can be utilized for embodiments described herein. For example, polymorphic variants in a region approximately 5000 nucleotides in length and spanning chromosome positions 34828750 and 34833750 in a APOL3 locus have significant association (chromosome positions are within NCBI's Genome build 34)

Additional Polymorphic Variants Associated with Osteoarthritis

[0028] Also provided is a method for identifying polymorphic variants proximal to an incident, founder polymorphic variant associated with osteoarthritis. Thus, featured herein are methods for identifying a polymorphic variation associated with osteoarthritis that is proximal to an incident

polymorphic variation associated with osteoarthritis, which comprises identifying a polymorphic variant proximal to the incident polymorphic variant associated with osteoarthritis, where the incident polymorphic variant is in a *APOL3* nucleotide sequence. The nucleotide sequence often comprises a polynucleotide sequence selected from the group consisting of (a) a polynucleotide sequence of SEQ ID NO: 1-7; (b) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1-7; and (c) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7 or a polynucleotide sequence 90% or more identical to the polynucleotide sequence of SEQ ID NO: 1-7. The presence or absence of an association of the proximal polymorphic variant with osteoarthritis then is determined using a known association method, such as a method described in the Examples hereafter. In an embodiment, the incident polymorphic variant is a polymorphic variant associated with osteoarthritis described herein. In another embodiment, the proximal polymorphic variant identified sometimes is a publicly disclosed polymorphic variant, which for example, sometimes is published in a publicly available database. In other embodiments, the polymorphic variant identified is not publicly disclosed and is discovered using a known method, including, but not limited to, sequencing a region surrounding the incident polymorphic variant in a group of nucleic samples. Thus, multiple polymorphic variants proximal to an incident polymorphic variant are associated with osteoarthritis using this method.

[0029] The proximal polymorphic variant often is identified in a region surrounding the incident polymorphic variant. In certain embodiments, this surrounding region is about 50 kb flanking the first polymorphic variant (e.g. about 50 kb 5' of the first polymorphic variant and about 50 kb 3' of the first polymorphic variant), and the region sometimes is composed of shorter flanking sequences, such as flanking sequences of about 40 kb, about 30 kb, about 25 kb, about 20 kb, about 15 kb, about 10 kb, about 7 kb, about 5 kb, or about 2 kb 5' and 3' of the incident polymorphic variant. In other embodiments, the region is composed of longer flanking sequences, such as flanking sequences of about 55 kb, about 60 kb, about 65 kb, about 70 kb, about 75 kb, about 80 kb, about 85 kb, about 90 kb, about 95 kb, or about 100 kb 5' and 3' of the incident polymorphic variant.

[0030] In certain embodiments, polymorphic variants associated with osteoarthritis are identified iteratively. For example, a first proximal polymorphic variant is associated with osteoarthritis using the methods described above and then another polymorphic variant proximal to the first proximal polymorphic variant is identified (e.g., publicly disclosed or discovered) and the presence or absence of an association of one or more other polymorphic variants proximal to the first proximal polymorphic variant with osteoarthritis is determined.

[0031] The methods described herein are useful for identifying or discovering additional polymorphic variants that may be used to further characterize a gene, region or loci associated with a

condition, a disease (*e.g.*, osteoarthritis), or a disorder. For example, allelotyping or genotyping data from the additional polymorphic variants may be used to identify a functional mutation or a region of linkage disequilibrium. In certain embodiments, polymorphic variants identified or discovered within a region comprising the first polymorphic variant associated with osteoarthritis are genotyped using the genetic methods and sample selection techniques described herein, and it can be determined whether those polymorphic variants are in linkage disequilibrium with the first polymorphic variant. The size of the region in linkage disequilibrium with the first polymorphic variant also can be assessed using these genotyping methods. Thus, provided herein are methods for determining whether a polymorphic variant is in linkage disequilibrium with a first polymorphic variant associated with osteoarthritis, and such information can be used in prognosis/diagnosis methods described herein.

Isolated Nucleic Acids

[0032] Featured herein are isolated *APOL3* nucleic acid variants depicted in SEQ ID NO: 1-7, and substantially identical nucleic acids thereof. A nucleic acid variant may be represented on one or both strands in a double-stranded nucleic acid or on one chromosomal complement (heterozygous) or both chromosomal complements (homozygous).

[0033] As used herein, the term “nucleic acid” includes DNA molecules (*e.g.*, a complementary DNA (cDNA) and genomic DNA (gDNA)) and RNA molecules (*e.g.*, mRNA, rRNA, siRNA and tRNA) and analogs of DNA or RNA, for example, by use of nucleotide analogs. The nucleic acid molecule can be single-stranded and it is often double-stranded. The term “isolated or purified nucleic acid” refers to nucleic acids that are separated from other nucleic acids present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term “isolated” includes nucleic acids which are separated from the chromosome with which the genomic DNA is naturally associated. An “isolated” nucleic acid is often free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term “gene” refers to a nucleotide sequence that encodes a polypeptide.

[0034] Also included herein are nucleic acid fragments. These fragments often have a nucleotide sequence identical to a nucleotide sequence of SEQ ID NO: 1-7, a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence that is complementary to

the foregoing. The nucleic acid fragment may be identical, substantially identical or homologous to a nucleotide sequence in an exon or an intron in a nucleotide sequence of SEQ ID NO: 1-7, and may encode a domain or part of a domain of a polypeptide. Sometimes, the fragment will comprises one or more of the polymorphic variations described herein as being associated with osteoarthritis. The nucleic acid fragment is often 50, 100, or 200 or fewer base pairs in length, and is sometimes about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 3000, 4000, 5000, 10000, 15000, or 20000 base pairs in length. A nucleic acid fragment that is complementary to a nucleotide sequence identical or substantially identical to a nucleotide sequence in SEQ ID NO: 1-7 and hybridizes to such a nucleotide sequence under stringent conditions is often referred to as a “probe.” Nucleic acid fragments often include one or more polymorphic sites, or sometimes have an end that is adjacent to a polymorphic site as described hereafter.

[0035] An example of a nucleic acid fragment is an oligonucleotide. As used herein, the term “oligonucleotide” refers to a nucleic acid comprising about 8 to about 50 covalently linked nucleotides, often comprising from about 8 to about 35 nucleotides, and more often from about 10 to about 25 nucleotides. The backbone and nucleotides within an oligonucleotide may be the same as those of naturally occurring nucleic acids, or analogs or derivatives of naturally occurring nucleic acids, provided that oligonucleotides having such analogs or derivatives retain the ability to hybridize specifically to a nucleic acid comprising a targeted polymorphism. Oligonucleotides described herein may be used as hybridization probes or as components of prognostic or diagnostic assays, for example, as described herein.

[0036] Oligonucleotides are typically synthesized using standard methods and equipment, such as the ABITM3900 High Throughput DNA Synthesizer and the EXPEDITETM 8909 Nucleic Acid Synthesizer, both of which are available from Applied Biosystems (Foster City, CA). Analogs and derivatives are exemplified in U.S. Pat. Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WO 00/56746; WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above and in U.S. Pat. Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; in WO 00/75372; and in related publications.

[0037] Oligonucleotides may also be linked to a second moiety. The second moiety may be an additional nucleotide sequence such as a tail sequence (e.g., a polyadenosine tail), an adapter sequence (e.g., phage M13 universal tail sequence), and others. Alternatively, the second moiety may be a non-nucleotide moiety such as a moiety which facilitates linkage to a solid support or a label to facilitate detection of the oligonucleotide. Such labels include, without limitation, a radioactive label, a

fluorescent label, a chemiluminescent label, a paramagnetic label, and the like. The second moiety may be attached to any position of the oligonucleotide, provided the oligonucleotide can hybridize to the nucleic acid comprising the polymorphism.

Uses for Nucleic Acid Sequence

[0038] Nucleic acid coding sequences may be used for diagnostic purposes for detection and control of polypeptide expression. Also, included herein are oligonucleotide sequences such as antisense RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to inhibit translation of a polypeptide. Antisense techniques and RNA interference techniques are known in the art and are described herein.

[0039] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ribozyme molecules may be engineered that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences corresponding to or complementary to *APOL3* nucleotide sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0040] Antisense RNA and DNA molecules, siRNA and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0041] DNA encoding a polypeptide also may have a number of uses for the diagnosis of diseases, including osteoarthritis, resulting from aberrant expression of a target gene described herein. For example, the nucleic acid sequence may be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (*e.g.*, Southern or Northern blot analysis, *in situ* hybridization assays).

[0042] In addition, the expression of a polypeptide during embryonic development may also be determined using nucleic acid encoding the polypeptide. As addressed, *infra*, production of functionally impaired polypeptide is the cause of various disease states, such as osteoarthritis. *In situ* hybridizations using polypeptide as a probe may be employed to predict problems related to osteoarthritis. Further, as indicated, *infra*, administration of human active polypeptide, recombinantly produced as described herein, may be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with dysfunctional polypeptide.

Expression Vectors, Host Cells, and Genetically Engineered Cells

[0043] Provided herein are nucleic acid vectors, often expression vectors, which contain a *APOL3* nucleotide sequence, or a substantially identical sequence thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

[0044] A vector can include a *APOL3* nucleotide sequence in a form suitable for expression of an encoded target polypeptide or target nucleic acid in a host cell. A "target polypeptide" is a polypeptide encoded by a *APOL3* nucleotide sequence, or a substantially identical nucleotide sequence thereof. The recombinant expression vector typically includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. Expression vectors can be introduced into host cells to produce target polypeptides, including fusion polypeptides.

[0045] Recombinant expression vectors can be designed for expression of target polypeptides in prokaryotic or eukaryotic cells. For example, target polypeptides can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

[0046] Expression of polypeptides in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion

polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant polypeptide; 2) to increase the solubility of the recombinant polypeptide; and 3) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith & Johnson, *Gene* 67: 31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRITS (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0047] Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for target polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector is used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).

[0048] Expressing the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide is often used to maximize recombinant polypeptide expression (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California 185: 119-128 (1990)). Another strategy is to alter the nucleotide sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, *Nucleic Acids Res.* 20: 2111-2118 (1992)). Such alteration of nucleotide sequences can be carried out by standard DNA synthesis techniques.

[0049] When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors are often capable of directing expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include an albumin promoter (liver-specific; Pinkert *et al.*, *Genes Dev.* 1: 268-277 (1987)), lymphoid-specific promoters (Calame & Eaton, *Adv. Immunol.* 43: 235-275 (1988)), promoters of T cell receptors (Winoto & Baltimore, *EMBO J.* 8: 729-733 (1989)) promoters of immunoglobulins (Banerji *et al.*, *Cell* 33: 729-740 (1983); Queen & Baltimore, *Cell* 33: 741-748 (1983)), neuron-specific promoters (e.g., the neurofilament promoter; Byrne & Ruddle, *Proc. Natl. Acad. Sci. USA* 86: 5473-5477 (1989)), pancreas-specific promoters (Edlund *et al.*, *Science* 230: 912-916 (1985)), and mammary

gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel & Gruss, *Science* 249: 374-379 (1990)) and the α -fetoprotein promoter (Campes & Tilghman, *Genes Dev.* 3: 537-546 (1989)).

[0050] A *APOL3* nucleic acid also may be cloned into an expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a *APOL3* nucleic acid cloned in the antisense orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) (1986).

[0051] Also provided herein are host cells that include a *APOL3* nucleotide sequence within a recombinant expression vector or a fragment of such a nucleotide sequence which facilitate homologous recombination into a specific site of the host cell genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. Such terms refer not only to the particular subject cell but rather also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a target polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0052] Vectors can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DEAE-dextran-mediated transfection, lipofection, or electroporation.

[0053] A host cell provided herein can be used to produce (*i.e.*, express) a target polypeptide or a substantially identical polypeptide thereof. Accordingly, further provided are methods for producing a target polypeptide using host cells described herein. In one embodiment, the method includes culturing host cells into which a recombinant expression vector encoding a target polypeptide has been introduced in a suitable medium such that a target polypeptide is produced. In another embodiment, the method further includes isolating a target polypeptide from the medium or the host cell.

[0054] Also provided are cells or purified preparations of cells which include a *APOL3* transgene, or which otherwise misexpress target polypeptide. Cell preparations can consist of human or non-human

cells, *e.g.*, rodent cells, *e.g.*, mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a *APOL3* transgene (*e.g.*, a heterologous form of a *APOL3* gene, such as a human gene expressed in non-human cells). The transgene can be misexpressed, *e.g.*, overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpress an endogenous target polypeptide (*e.g.*, expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or mis-expressed alleles or for use in drug screening. Also provided are human cells (*e.g.*, a hematopoietic stem cells) transfected with a *APOL3* nucleic acid.

[0055] Also provided are cells or a purified preparation thereof (*e.g.*, human cells) in which an endogenous *APOL3* nucleic acid is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene. The expression characteristics of an endogenous gene within a cell (*e.g.*, a cell line or microorganism) can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (*e.g.*, a gene which is “transcriptionally silent,” not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, *e.g.*, Chappel, US 5,272,071; WO 91/06667, published on May 16, 1991.

Transgenic Animals

[0056] Non-human transgenic animals that express a heterologous target polypeptide (*e.g.*, expressed from a *APOL3* nucleic acid or substantially identical sequence thereof) can be generated. Such animals are useful for studying the function and/or activity of a target polypeptide and for identifying and/or evaluating modulators of the activity of *APOL3* nucleic acids and encoded polypeptides. As used herein, a “transgenic animal” is a non-human animal such as a mammal (*e.g.*, a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (*e.g.*, a chicken or a turkey), an amphibian (*e.g.*, a frog, salamander, or newt), or an insect (*e.g.*, *Drosophila melanogaster*), in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (*e.g.*, a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, and other transgenes can reduce expression (*e.g.*, a knockout). Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a *APOL3* nucleic acid has been altered by homologous recombination between the endogenous gene and an

exogenous DNA molecule introduced into a cell of the animal (e.g., an embryonic cell of the animal) prior to development of the animal.

[0057] Intrinsic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a *APOL3* nucleotide sequence to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of a *APOL3* nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a *APOL3* nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

[0058] Target polypeptides can be expressed in transgenic animals or plants by introducing, for example, a *APOL3* nucleic acid into the genome of an animal that encodes the target polypeptide. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, e.g., a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

Target Polypeptides

[0059] Also featured herein are isolated target polypeptides, which are encoded by a *APOL3* nucleotide sequence (e.g., SEQ ID NO: 1-7), or a substantially identical nucleotide sequence thereof. Examples of *APOL3* polypeptides are set forth in SEQ ID NO: 8-10. The term “polypeptide” as used herein includes proteins and peptides. An “isolated” or “purified” polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, the language “substantially free” means preparation of a target polypeptide having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-target polypeptide (also referred to herein as a “contaminating protein”), or of chemical precursors or non-target chemicals. When the target polypeptide or a biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, specifically, where culture medium represents less than about 20%, sometimes less than about 10%, and often less than about 5% of the volume of the polypeptide preparation. Isolated or purified target polypeptide preparations are sometimes 0.01 milligrams or more or 0.1 milligrams or more, and often 1.0 milligrams or more and 10 milligrams or more in dry weight. In certain embodiments, the *APOL3* polypeptide or polypeptide fragment has *APOL3* biological activity, for example, apolipoprotein activity.

[0060] Further included herein are target polypeptide fragments. The polypeptide fragment may be a domain or part of a domain of a target polypeptide. The polypeptide fragment may have increased,

decreased or unexpected biological activity. The polypeptide fragment is often 50 or fewer, 100 or fewer, or 200 or fewer amino acids in length, and is sometimes 300, 400, 500, 600, 700, or 900 or fewer amino acids in length. The polypeptide fragment sometimes is amino acids 90-396; amino acids 19-325; or amino acids 1-196.

[0061] Substantially identical target polypeptides may depart from the amino acid sequences of target polypeptides in different manners. For example, conservative amino acid modifications may be introduced at one or more positions in the amino acid sequences of target polypeptides. A “conservative amino acid substitution” is one in which the amino acid is replaced by another amino acid having a similar structure and/or chemical function. Families of amino acid residues having similar structures and functions are well known. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Also, essential and non-essential amino acids may be replaced. A “non-essential” amino acid is one that can be altered without abolishing or substantially altering the biological function of a target polypeptide, whereas altering an “essential” amino acid abolishes or substantially alters the biological function of a target polypeptide. Amino acids that are conserved among target polypeptides are typically essential amino acids. In certain embodiments, the polypeptide includes one or more non-synonymous polymorphic variants associated with osteoarthritis.

[0062] Also, target polypeptides may exist as chimeric or fusion polypeptides. As used herein, a target “chimeric polypeptide” or target “fusion polypeptide” includes a target polypeptide linked to a non-target polypeptide. A “non-target polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to the target polypeptide, which includes, for example, a polypeptide that is different from the target polypeptide and derived from the same or a different organism. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire target polypeptide or a fragment thereof. The non-target polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

[0063] Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide), and a nucleotide sequence in SEQ ID NO: 1-7, or a substantially identical nucleotide sequence thereof, can be cloned into an

expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (*e.g.*, an IgG constant region or human serum albumin).

[0064] Target polypeptides can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Administration of these target polypeptides can be used to affect the bioavailability of a substrate of the target polypeptide and may effectively increase target polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a target polypeptide; (ii) mis-regulation of the gene encoding the target polypeptide; and (iii) aberrant post-translational modification of a target polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify target polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a target polypeptide with a substrate.

[0065] In addition, polypeptides can be chemically synthesized using techniques known in the art (See, *e.g.*, Creighton, 1983 *Proteins*. New York, N.Y.: W. H. Freeman and Company; and Hunkapiller et al., (1984) *Nature* July 12 -18;310(5973):105-11). For example, a relative short fragment can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotatory).

[0066] Polypeptides and polypeptide fragments sometimes are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; and the like. Additional post-translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical

moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

[0067] Also provided are chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (*see e.g.*, U.S. Pat. No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0068] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (*e.g.*, the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0069] The polymers should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (*e.g.*, EP 0 401 384 (coupling PEG to G-CSF) and Malik et al. (1992) Exp Hematol. September;20(8):1028-35 (pegylation of GM-CSF using tresyl chloride)). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

[0070] Proteins can be chemically modified at the N-terminus. Using polyethylene glycol as an illustration of such a composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (*i.e.*, separating this moiety from other monopegylated moieties if

necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

Substantially Identical Nucleic Acids and Polypeptides

[0071] Nucleotide sequences and polypeptide sequences that are substantially identical to a *APOL3* nucleotide sequence and the target polypeptide sequences encoded by those nucleotide sequences, respectively, are included herein. The term "substantially identical" as used herein refers to two or more nucleic acids or polypeptides sharing one or more identical nucleotide sequences or polypeptide sequences, respectively. Included are nucleotide sequences or polypeptide sequences that are 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (each often within a 1%, 2%, 3% or 4% variability) identical to a *APOL3* nucleotide sequence or the encoded target polypeptide amino acid sequences. One test for determining whether two nucleic acids are substantially identical is to determine the percent of identical nucleotide sequences or polypeptide sequences shared between the nucleic acids or polypeptides.

[0072] Calculations of sequence identity are often performed as follows. Sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is sometimes 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70% or more, 80% or more, 90% or more, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or polypeptide positions, respectively, are then compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the nucleotides or amino acids are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

[0073] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS 4:* 11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Also, percent identity between two amino acid

sequences can be determined using the Needleman & Wunsch, *J. Mol. Biol.* 48: 444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at the http address www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blosum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0074] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As use herein, the term "stringent conditions" refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y., 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. More often, stringency conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0075] An example of a substantially identical nucleotide sequence to a nucleotide sequence in SEQ ID NO: 1-7 is one that has a different nucleotide sequence but still encodes the same polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO: 1-7. Another example is a nucleotide sequence that encodes a polypeptide having a polypeptide sequence that is more than 70% or more identical to, sometimes more than 75% or more, 80% or more, or 85% or more identical to, and often more than 90% or more and 95% or more identical to a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7.

[0076] Nucleotide sequences in SEQ ID NO: 1-7 and amino acid sequences of encoded polypeptides can be used as "query sequences" to perform a search against public databases to identify other family members or related sequences, for example. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.*, *J. Mol. Biol.* 215: 403-10 (1990). BLAST nucleotide

searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleotide sequences in SEQ ID NO: 1-7. BLAST polypeptide searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to polypeptides encoded by the nucleotide sequences of SEQ ID NO: 1-7. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, *Nucleic Acids Res.* 25(17): 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see* the *http* address www.ncbi.nlm.nih.gov).

[0077] A nucleic acid that is substantially identical to a nucleotide sequence in SEQ ID NO: 1-7 may include polymorphic sites at positions equivalent to those described herein when the sequences are aligned. For example, using the alignment procedures described herein, SNPs in a sequence substantially identical to a sequence in SEQ ID NO: 1-7 can be identified at nucleotide positions that match (*i.e.*, align) with nucleotides at SNP positions in each nucleotide sequence in SEQ ID NO: 1-7. Also, where a polymorphic variation results in an insertion or deletion, insertion or deletion of a nucleotide sequence from a reference sequence can change the relative positions of other polymorphic sites in the nucleotide sequence.

[0078] Substantially identical nucleotide and polypeptide sequences include those that are naturally occurring, such as allelic variants (same locus), splice variants, homologs (different locus), and orthologs (different organism) or can be non-naturally occurring. Non-naturally occurring variants can be generated by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product). Orthologs, homologs, allelic variants, and splice variants can be identified using methods known in the art. These variants normally comprise a nucleotide sequence encoding a polypeptide that is 50% or more, about 55% or more, often about 70-75% or more or about 80-85% or more, and sometimes about 90-95% or more identical to the amino acid sequences of target polypeptides or a fragment thereof. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions to a nucleotide sequence in SEQ ID NO: 1 or a fragment of this sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of a nucleotide sequence in SEQ ID NO: 1-7 can further be identified by mapping the sequence to the same chromosome or locus as the nucleotide sequence in SEQ ID NO: 1-7.

[0079] Also, substantially identical nucleotide sequences may include codons that are altered with respect to the naturally occurring sequence for enhancing expression of a target polypeptide in a particular expression system. For example, the nucleic acid can be one in which one or more codons are

altered, and often 10% or more or 20% or more of the codons are altered for optimized expression in bacteria (e.g., *E. coli*), yeast (e.g., *S. cerevisiae*), human (e.g., 293 cells), insect, or rodent (e.g., hamster) cells.

Methods for Identifying Risk of osteoarthritis

[0080] Methods for prognosing and diagnosing osteoarthritis are included herein. These methods include detecting the presence or absence of one or more polymorphic variations in a nucleotide sequence associated with osteoarthritis, such as variants in or around the loci set forth herein, or a substantially identical sequence thereof, in a sample from a subject, where the presence of a polymorphic variant described herein is indicative of a risk of osteoarthritis. Determining a risk of osteoarthritis sometimes refers to determining whether an individual is at an increased risk of osteoarthritis (e.g., intermediate risk or higher risk).

[0081] Thus, featured herein is a method for identifying a subject who is at risk of osteoarthritis, which comprises detecting an aberration associated with osteoarthritis in a nucleic acid sample from the subject. An embodiment is a method for detecting a risk of osteoarthritis in a subject, which comprises detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-7; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising the polymorphic site; whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject. In certain embodiments, polymorphic variants at the positions described herein are detected for determining a risk of osteoarthritis, and polymorphic variants at positions in linkage disequilibrium with these positions are detected for determining a risk of osteoarthritis. As used herein, "SEQ ID NO: 1-7" refers to individual sequences in SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, each sequence being separately applicable to embodiments described herein.

[0082] Risk of osteoarthritis sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. Risk often is based upon the presence or absence of one or more polymorphic variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (see, e.g., Agresti, *Categorical Data Analysis*, 2nd Ed. 2002. Wiley). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic

method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations.

[0083] In certain embodiments, determining the presence of a combination of two or more polymorphic variants associated with osteoarthritis in one or more genetic loci (e.g., one or more genes) of the sample is determined to identify, quantify and/or estimate, risk of osteoarthritis. The risk often is the probability of having or developing osteoarthritis. The risk sometimes is expressed as a relative risk with respect to a population average risk of osteoarthritis, and sometimes is expressed as a relative risk with respect to the lowest risk group. Such relative risk assessments often are based upon penetrance values determined by statistical methods, and are particularly useful to clinicians and insurance companies for assessing risk of osteoarthritis (e.g., a clinician can target appropriate detection, prevention and therapeutic regimens to a patient after determining the patient's risk of osteoarthritis, and an insurance company can fine tune actuarial tables based upon population genotype assessments of osteoarthritis risk). Risk of osteoarthritis sometimes is expressed as an odds ratio, which is the odds of a particular person having a genotype has or will develop osteoarthritis with respect to another genotype group (e.g., the most disease protective genotype or population average). In related embodiments, the determination is utilized to identify a subject at risk of osteoarthritis. In an embodiment, two or more polymorphic variations are detected in two or more regions in human genomic DNA associated with increased risk of osteoarthritis, such as a locus containing a *APOL3*, for example. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected in the sample. In specific embodiments, polymorphic variants are detected in a *APOL3* region, for example. In certain embodiments, polymorphic variants are detected at other genetic loci (e.g., the polymorphic variants can be detected in *APOL3* in addition to other loci or only in other loci), where the other loci include but are not limited to those described in concurrently-filed patent applications having attorney docket number 524593008700, 524593008800, 524593008900, 524593009000 or 524593009100, each of which is incorporated herein by reference in its entirety.

[0084] Results from prognostic tests may be combined with other test results to diagnose osteoarthritis. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to osteoarthritis, the patient sample is analyzed, and the results of the analysis may be utilized to diagnose osteoarthritis. Also osteoarthritis diagnostic method can be developed from studies used to generate prognostic methods in which populations are stratified into subpopulations having different progressions of osteoarthritis. In another embodiment, prognostic results may be gathered, a patient's risk factors for developing osteoarthritis (e.g., age, weight, race, diet) analyzed, and a patient sample may be ordered based on a determined predisposition to osteoarthritis.

[0085] The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and

biopsy tissue. The nucleic acid sample can be isolated from a biological sample using standard techniques, such as the technique described in Example 2. As used herein, the term “subject” refers primarily to humans but also refers to other mammals such as dogs, cats, and ungulates (*e.g.*, cattle, sheep, and swine). Subjects also include avians (*e.g.*, chickens and turkeys), reptiles, and fish (*e.g.*, salmon), as embodiments described herein can be adapted to nucleic acid samples isolated from any of these organisms. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (*e.g.*, frozen) for a period of time before being subjected to analysis.

[0086] The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample from a subject having a copy of each chromosome is useful for determining the zygosity of an individual for the polymorphic variant (*i.e.*, whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (*e.g.*, U.S. Pat. Nos. 5,891,625 and 6,013,499), PCR-based assays (*e.g.*, TAQMAN® PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used.

[0087] Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP® Systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon a *APOL3* nucleotide sequence using knowledge available in the art.

[0088] Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. As used herein, the term “adjacent” refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic

acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144, and a method often utilized is described herein in Example 2.

[0089] A microarray can be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330; 5,695,940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microarray may comprise one or more oligonucleotides complementary to a polymorphic site set forth herein.

[0090] A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit often comprises one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of SEQ ID NO: 1-7 or a substantially identical sequence thereof, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to a *APOL3* nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it also often comprises chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dITP, provided that such analogs are substrates for a thermostable nucleic acid polymerase and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP, and the like. In an embodiment, the kit comprises one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

[0091] An individual identified as being at risk of osteoarthritis may be heterozygous or homozygous with respect to the allele associated with a higher risk of osteoarthritis. A subject homozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively high risk of osteoarthritis, a subject heterozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively intermediate risk of osteoarthritis, and a subject homozygous for an allele associated with a decreased risk of osteoarthritis is at a comparatively low risk of osteoarthritis. A genotype may be assessed for a complementary strand, such that the complementary nucleotide at a particular position is detected.

[0092] Also featured are methods for determining risk of osteoarthritis and/or identifying a subject at risk of osteoarthritis by contacting a polypeptide or protein encoded by a *APOL3* nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with increased risk of osteoarthritis in the polypeptide.

Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

[0093] Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype as a particular treatment regimen may exert a differential effect depending upon the subject's genotype. For example, based upon the outcome of a prognostic test described herein, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (e.g., the treatment has no therapeutic effect and/or the subject experiences adverse side effects).

[0094] The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant interaction with a major allele and a comparatively weak interaction with a minor allele (e.g., an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the minor allele, and sometimes not administered to a subject genotyped as being heterozygous for the minor allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a major allele but is comparatively toxic when administered to subjects heterozygous or homozygous for a minor allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the minor allele.

[0095] The methods described herein are applicable to pharmacogenomic methods for preventing, alleviating or treating osteoarthritis. For example, a nucleic acid sample from an individual may be subjected to a prognostic test described herein. Where one or more polymorphic variations associated

with increased risk of osteoarthritis are identified in a subject, information for preventing or treating osteoarthritis and/or one or more osteoarthritis treatment regimens then may be prescribed to that subject.

[0096] In certain embodiments, a treatment or preventative regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing osteoarthritis assessed by the methods described herein. Thus, provided are methods for identifying a subject predisposed to osteoarthritis and then prescribing a therapeutic or preventative regimen to individuals identified as having a predisposition. Thus, certain embodiments are directed to a method for reducing osteoarthritis in a subject, which comprises: detecting the presence or absence of a polymorphic variant associated with osteoarthritis in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-7; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (d) a fragment of a polynucleotide sequence of (a), (b), or (c); and prescribing or administering a treatment regimen to a subject from whom the sample originated where the presence of a polymorphic variation associated with osteoarthritis is detected in the nucleotide sequence. In these methods, predisposition results may be utilized in combination with other test results to diagnose osteoarthritis.

[0097] Certain preventative treatments often are prescribed to subjects having a predisposition to osteoarthritis and where the subject is diagnosed with osteoarthritis or is diagnosed as having symptoms indicative of an early stage of osteoarthritis. The treatment sometimes is preventative (e.g., is prescribed or administered to reduce the probability that osteoarthritis arises or progresses), sometimes is therapeutic, and sometimes delays, alleviates or halts the progression of osteoarthritis. Any known preventative or therapeutic treatment for alleviating or preventing the occurrence of osteoarthritis is prescribed and/or administered. For example, the treatment often is directed to decreasing pain and improving joint movement. Examples of OA treatments include exercises to keep joints flexible and improve muscle strength. Different medications to control pain, including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., Voltaren); cyclooxygenase-2 (COX-2) inhibitors (e.g., Celebrex, Vioxx, Mobic, and Bextra); monoclonal antibodies (e.g., Remicade); tumor necrosis factor inhibitors (e.g., Enbrel); or injections of glucocorticoids, hyaluronic acid or chondroitin sulfate into joints that are inflamed and not responsive to NSAIDs. Orally administered chondroitin sulfate also may be used as a therapeutic, as it may increase hyaluronic acid levels and viscosity of synovial fluid, and decrease collagenase levels in synovial fluid. Also, glucosamine can serve as an OA therapeutic as delivering it into joints may inhibit enzymes involved in cartilage degradation and enhance the

production of hyaluronic acid. For mild pain without inflammation, acetaminophen may be used. Other treatments include: heat/cold therapy for temporary pain relief; joint protection to prevent strain or stress on painful joints; surgery to relieve chronic pain in damaged joints; and weight control to prevent extra stress on weight-bearing joints.

[0098] As therapeutic approaches for treating osteoarthritis continue to evolve and improve, the goal of treatments for osteoarthritis related disorders is to intervene even before clinical signs first manifest. Thus, genetic markers associated with susceptibility to osteoarthritis prove useful for early diagnosis, prevention and treatment of osteoarthritis.

[0099] As osteoarthritis preventative and treatment information can be specifically targeted to subjects in need thereof (e.g., those at risk of developing osteoarthritis or those in an early stage of osteoarthritis), provided herein is a method for preventing or reducing the risk of developing osteoarthritis in a subject, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying a subject with a predisposition to osteoarthritis, whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject; and (c) if such a predisposition is identified, providing the subject with information about methods or products to prevent or reduce osteoarthritis or to delay the onset of osteoarthritis. Also provided is a method of targeting information or advertising to a subpopulation of a human population based on the subpopulation being genetically predisposed to a disease or condition, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; and (c) providing information only to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition.

[0100] Pharmacogenomics methods also may be used to analyze and predict a response to osteoarthritis treatment or a drug. For example, if pharmacogenomics analysis indicates a likelihood that an individual will respond positively to osteoarthritis treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regimen (e.g., exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based

upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

[0101] The tests described herein also are applicable to clinical drug trials. One or more polymorphic variants indicative of response to an agent for treating osteoarthritis or to side effects to an agent for treating osteoarthritis may be identified using the methods described herein. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

[0102] Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variation which is associated with a positive response to the treatment or the drug, or at least one polymorphic variation which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains said polymorphic variation associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said polymorphic variation associated with a negative response to the treatment or the drug. In addition, the methods described herein for selecting an individual for inclusion in a clinical trial of a treatment or drug encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination. The polymorphic variation may be in a sequence selected individually or in any combination from the group consisting of (i) a nucleotide sequence of SEQ ID NO: 1-7; (ii) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (iv) a fragment of a polynucleotide sequence of (i), (ii), or (iii) comprising the polymorphic site. The including step (c) optionally comprises administering the drug or the treatment to the individual if the nucleic acid sample contains the polymorphic variation associated with a positive response to the treatment or the drug and the nucleic acid sample lacks said biallelic marker associated with a negative response to the treatment or the drug.

[0103] Also provided herein is a method of partnering between a diagnostic/prognostic testing provider and a provider of a consumable product, which comprises: (a) the diagnostic/prognostic testing provider detects the presence or absence of a polymorphic variation associated with osteoarthritis at a

polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) the diagnostic/prognostic testing provider identifies the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; (c) the diagnostic/prognostic testing provider forwards information to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition; and (d) the provider of a consumable product forwards to the diagnostic test provider a fee every time the diagnostic/prognostic test provider forwards information to the subject as set forth in step (c) above.

Compositions Comprising Osteoarthritis-Directed Molecules

[0104] Featured herein is a composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and one or more molecules specifically directed and targeted to a nucleic acid comprising a *APOL3* nucleotide sequence or amino acid sequence. Such directed molecules include, but are not limited to, a compound that binds to a *APOL3* nucleotide sequence or amino acid sequence referenced herein; a RNAi or siRNA molecule having a strand complementary or substantially complementary to a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); an antisense nucleic acid complementary or substantially complementary to an RNA encoded by a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); a ribozyme that hybridizes to a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); a nucleic acid aptamer that specifically binds a polypeptide encoded by *APOL3* nucleotide sequence; and an antibody that specifically binds to a polypeptide encoded by *APOL3* nucleotide sequence or binds to a nucleic acid having such a nucleotide sequence. In specific embodiments, the osteoarthritis directed molecule interacts with a nucleic acid or polypeptide variant associated with osteoarthritis, such as variants referenced herein. In other embodiments, the osteoarthritis directed molecule interacts with a polypeptide involved in a signal pathway of a polypeptide encoded by a *APOL3* nucleotide sequence, or a nucleic acid comprising such a nucleotide sequence.

[0105] Compositions sometimes include an adjuvant known to stimulate an immune response, and in certain embodiments, an adjuvant that stimulates a T-cell lymphocyte response. Adjuvants are known, including but not limited to an aluminum adjuvant (e.g., aluminum hydroxide); a cytokine adjuvant or adjuvant that stimulates a cytokine response (e.g., interleukin (IL)-12 and/or gamma-interferon cytokines); a Freund-type mineral oil adjuvant emulsion (e.g., Freund's complete or incomplete adjuvant); a synthetic lipid compound; a copolymer adjuvant (e.g., TitreMax); a saponin; Quil A; a liposome; an oil-in-water emulsion (e.g., an emulsion stabilized by Tween 80 and pluronic polyoxyethylene/polyoxypropylene block copolymer (Syntex Adjuvant Formulation); TitreMax; detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) in 2% squalene (Ribi

Adjuvant System)); a muramyl dipeptide; an immune-stimulating complex (ISCOM, e.g., an Ag-modified saponin/cholesterol micelle that forms stable cage-like structure); an aqueous phase adjuvant that does not have a depot effect (e.g., Gerbu adjuvant); a carbohydrate polymer (e.g., AdjuPrime); L-tyrosine; a manide-oleate compound (e.g., Montanide); an ethylene-vinyl acetate copolymer (e.g., Elvax 40W1,2); or lipid A, for example. Such compositions are useful for generating an immune response against osteoarthritis directed molecule (e.g., an HLA-binding subsequence within a polypeptide encoded by a *APOL3* nucleotide sequence). In such methods, a peptide having an amino acid subsequence of a polypeptide encoded by a *APOL3* nucleotide sequence is delivered to a subject, where the subsequence binds to an HLA molecule and induces a CTL lymphocyte response. The peptide sometimes is delivered to the subject as an isolated peptide or as a minigene in a plasmid that encodes the peptide. Methods for identifying HLA-binding subsequences in such polypeptides are known (see e.g., publication WO02/20616 and PCT application US98/01373 for methods of identifying such sequences).

[0106] The cell may be in a group of cells cultured *in vitro* or in a tissue maintained *in vitro* or present in an animal *in vivo* (e.g., a rat, mouse, ape or human). In certain embodiments, a composition comprises a component from a cell such as a nucleic acid molecule (e.g., genomic DNA), a protein mixture or isolated protein, for example. The aforementioned compositions have utility in diagnostic, prognostic and pharmacogenomic methods described previously and in therapeutics described hereafter. Certain osteoarthritis directed molecules are described in greater detail below.

Compounds

[0107] Compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (see, e.g., Zuckermann et al., J. Med. Chem. 37: 2678-85 (1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; "one-bead one-compound" library methods; and synthetic library methods using affinity chromatography selection. Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, (1997)). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90: 6909 (1993); Erb et al., Proc. Natl. Acad. Sci. USA 91: 11422 (1994); Zuckermann et al., J. Med. Chem. 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2059 (1994); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2061 (1994); and in Gallop et al., J. Med. Chem. 37: 1233 (1994).

[0108] Libraries of compounds may be presented in solution (e.g., Houghten, *Biotechniques* 13: 412-421 (1992)), or on beads (Lam, *Nature* 354: 82-84 (1991)), chips (Fodor, *Nature* 364: 555-556 (1993)), bacteria or spores (Ladner, United States Patent No. 5,223,409), plasmids (Cull et al., *Proc. Natl. Acad. Sci. USA* 89: 1865-1869 (1992)) or on phage (Scott and Smith, *Science* 249: 386-390 (1990); Devlin, *Science* 249: 404-406 (1990); Cwirla et al., *Proc. Natl. Acad. Sci.* 87: 6378-6382 (1990); Felici, *J. Mol. Biol.* 222: 301-310 (1991); Ladner supra.).

[0109] A compound sometimes alters expression and sometimes alters activity of a polypeptide target and may be a small molecule. Small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

Antisense Nucleic Acid Molecules, Ribozymes, RNAi, siRNA and Modified Nucleic Acid Molecules

[0110] An "antisense" nucleic acid refers to a nucleotide sequence complementary to a "sense" nucleic acid encoding a polypeptide, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand, or to a portion thereof or a substantially identical sequence thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence (e.g., 5' and 3' untranslated regions in SEQ ID NO: 1).

[0111] An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence (e.g., SEQ ID NO: 1), and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or noncoding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described hereafter, can be designed to target a *APOL3* nucleotide sequence, often a variant associated with osteoarthritis, or a substantially identical sequence thereof. Among the variants, minor alleles and major alleles can be targeted, and those associated with a higher risk of osteoarthritis are often designed, tested, and administered to subjects.

[0112] An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0113] When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

[0114] Antisense nucleic acid molecules sometimes are alpha-anomeric nucleic acid molecules. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15: 6625-6641 (1987)). Antisense nucleic acid molecules can also comprise a 2'-o-methylribonucleotide (Inoue et al., Nucleic Acids Res. 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215: 327-330 (1987)). Antisense nucleic acids sometimes are composed of DNA or PNA or any other nucleic acid derivatives described previously.

[0115] In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a *APOL3* nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach, Nature 334: 585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA is sometimes utilized in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Also, target mRNA sequences

can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see e.g., Bartel & Szostak, *Science* 261: 1411-1418 (1993)).

[0116] Osteoarthritis directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a *APOL3* nucleotide sequence, or a substantially identical sequence thereof, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a nucleotide sequence referenced herein or a substantially identical sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (see e.g., Helene, *Anticancer Drug Des.* 6(6): 569-84 (1991); Helene et al., *Ann. N.Y. Acad. Sci.* 660: 27-36 (1992); and Maher, *Bioassays* 14(12): 807-15 (1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0117] Osteoarthritis directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al., US Patent Number 6,506,559; Tuschl et al. PCT International Publication No. WO 01/75164; Kay et al. PCT International Publication No. WO 03/010180A1; or Bosher JM, Labouesse, *Nat Cell Biol* 2000 Feb;2(2):E31-6. This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that "switched off" genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (see, e.g., Caplen et al. *Proc Natl Acad Sci U S A.* 2001 Aug 14;98(17):9742-7 and Elbashir et al. *Methods* 2002 Feb;26(2):199-213). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. Patent Application No. US2001000993183; Caplen et al. *Proc Natl Acad Sci U S A;* and Abderrahmani et al. *Mol Cell Biol* 2001 Nov;21(21):7256-67).

[0118] An "siRNA" or "RNAi" refers to a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is delivered to or expressed in the same cell as the gene or target gene. "siRNA" refers to short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In

one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

[0119] When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al., Methods 26:199-213 (2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA(N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C-content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA(N21). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence-specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR(N17)YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters often is efficient when the first transcribed nucleotide is a purine.

[0120] The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, sometimes about 20-30 nucleotides in length or about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are well known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

[0121] Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al., Bioorganic & Medicinal Chemistry 4 (1): 5-23 (1996)). As used herein, the terms "peptide

nucleic acid" or "PNA" refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al., (1996) *supra* and Perry-O'Keefe et al., Proc. Natl. Acad. Sci. 93: 14670-675 (1996).

[0122] PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as antisense or antigenic agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as "artificial restriction enzymes" when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup et al., (1996) *supra*; Perry-O'Keefe *supra*).

[0123] In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across cell membranes (see e.g., Letsinger et al., Proc. Natl. Acad. Sci. USA 86: 6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci. USA 84: 648-652 (1987); PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., Bio-Techniques 6: 958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res. 5: 539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

[0124] Also included herein are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a *APOL3* nucleotide sequence, or a substantially identical sequence thereof, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al., U.S. Patent No. 5,854,033; Nazarenko et al., U.S. Patent No. 5,866,336, and Livak et al., U.S. Patent 5,876,930.

Antibodies

[0125] The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody sometimes is a polyclonal, monoclonal, recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g.,

murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

[0126] A full-length polypeptide or antigenic peptide fragment encoded by a nucleotide sequence referenced herein can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence referenced herein, or substantially identical sequence thereof, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

[0127] Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides described herein.

[0128] Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al International Application No. PCT/US86/02269; Akira, et al European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al European Patent Application 173,494; Neuberger et al PCT International Publication No. WO 86/01533; Cabilly et al U.S. Patent No. 4,816,567; Cabilly et al European Patent Application 125,023; Better et al., Science 240: 1041-1043 (1988); Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443 (1987); Liu et al., J. Immunol. 139: 3521-3526 (1987); Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218 (1987); Nishimura et al., Canc. Res. 47: 999-1005 (1987); Wood et al., Nature 314: 446-449 (1985); and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559 (1988); Morrison, S. L., Science 229: 1202-1207 (1985); Oi et al., BioTechniques 4: 214 (1986); Winter U.S. Patent 5,225,539; Jones et al., Nature 321: 552-525 (1986); Verhoeyan et al., Science 239: 1534; and Beidler et al., J. Immunol. 141: 4053-4060 (1988).

[0129] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar, Int. Rev. Immunol. 13: 65-93 (1995); and U.S.

Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, CA) and Medarex, Inc. (Princeton, NJ), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al., Bio/Technology 12: 899-903 (1994).

[0130] An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al., Ann. N Y Acad. Sci. 880: 263-80 (1999); and Reiter, Clin. Cancer Res. 2: 245-52 (1996)). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

[0131] Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region).

[0132] Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0133] Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, gamma-interferon, alpha-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or

other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, for example.

[0134] An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferon, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H . Also, an antibody can be utilized as a test molecule for determining whether it can treat osteoarthritis, and as a therapeutic for administration to a subject for treating osteoarthritis.

[0135] An antibody can be made by immunizing with a purified antigen, or a fragment thereof, e.g., a fragment described herein, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

[0136] Included herein are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with osteoarthritis.

Methods for Identifying Candidate Therapeutics for Treating Osteoarthritis

[0137] Current therapies for the treatment of osteoarthritis have limited efficacy, limited tolerability and significant mechanism-based side effects, and few of the available therapies adequately address underlying defects. Current therapeutic approaches were largely developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Therefore, provided are methods of identifying candidate therapeutics that target biochemical pathways related to the development of osteoarthritis.

[0138] Thus, featured herein are methods for identifying a candidate therapeutic for treating osteoarthritis. The methods comprise contacting a test molecule with a target molecule in a system. A “target molecule” as used herein refers to a *APOL3* nucleic acid, a substantially identical nucleic acid thereof, or a fragment thereof, and an encoded polypeptide of the foregoing. The methods also comprise determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate osteoarthritis therapeutic. The interaction between the test molecule and the target molecule may be quantified.

[0139] Test molecules and candidate therapeutics include, but are not limited to, compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by a *APOL3* nucleotide sequence, or a substantially identical sequence or fragment thereof, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A “modulator” may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post-translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro-polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (e.g., effecting progression of osteoarthritis).

[0140] As used herein, the term “system” refers to a cell free *in vitro* environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism. A system is “contacted” with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. As used herein, the term “interaction” refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

[0141] There are many standard methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrimetric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.

[0142] Test molecule/target molecule interactions can be detected and/or quantified using assays known in the art. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as ^{125}I , ^{131}I , ^{35}S or ^3H , which can be detected by direct counting of radioemission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product. In addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell, H. M. *et al.*, *Science* 257: 1906-1912 (1992)).

[0143] In cell-based systems, cells typically include a *APOL3* nucleic acid, an encoded polypeptide, or substantially identical nucleic acid or polypeptide thereof, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (*e.g.*, cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)_n, 3-[$(3\text{-cholamidopropyl})\text{dimethylamminio}$]-1-propane sulfonate (CHAPS), 3-[$(3\text{-cholamidopropyl})\text{dimethylamminio}$]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0144] An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (*see, e.g.*, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos *et al.* U.S. Patent No. 4,868,103). A fluorophore label on a first, "donor" molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, "acceptor" molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the "donor" polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the "acceptor" molecule label may be differentiated from that of the "donor". Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the

"acceptor" molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

[0145] In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (*see, e.g.*, Sjolander & Urbaniczka, *Anal. Chem.* 63: 2338-2345 (1991) and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5: 699-705 (1995)). "Surface plasmon resonance" or "biomolecular interaction analysis (BIA)" can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (e.g., BIACore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0146] In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In an embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels discussed herein.

[0147] It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non-covalent (*see, e.g.*, U.S. Patent No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a bead (*see, e.g.*, Lam, *Nature* 354: 82-84 (1991)) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are well known (*see, e.g.*, U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0148] In an embodiment, target molecule may be immobilized to surfaces via biotin and streptavidin. For example, biotinylated target polypeptide can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/target polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivitized microtiter plates, which are then combined with a test molecule

under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

[0149] In an embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, *e.g.*, by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.*, a labeled anti-Ig antibody.

[0150] In another embodiment, an assay is performed utilizing antibodies that specifically bind target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be derivitized to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0151] Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (*see, e.g.*, Rivas, G., and Minton, *Trends Biochem Sci Aug;18(8):284-7* (1993)); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (*see, e.g.*, Ausubel *et al.*, eds. *Current Protocols in Molecular Biology*, J. Wiley: New York (1999)); and immunoprecipitation (*see, e.g.*, Ausubel *et al.*, eds., *supra*). Media and chromatographic techniques are known to one skilled in the art (*see, e.g.*, Heegaard, *J Mol. Recognit. Winter; 11(1-6): 141-8* (1998); Hage & Tweed, *J. Chromatogr. B Biomed. Sci. Appl. Oct 10; 699 (1-2): 499-525* (1997)). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

[0152] In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or target polypeptide is evaluated relative to the level of expression of target mRNA or target

polypeptide in the absence of the candidate compound. When expression of target mRNA or target polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or target polypeptide expression. Alternatively, when expression of target mRNA or target polypeptide is less (e.g., less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or target polypeptide expression. The level of target mRNA or target polypeptide expression can be determined by methods described herein.

[0153] In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extracellular macromolecules, such as polypeptides *in vivo*, and these interacting molecules are referred to herein as "binding partners." Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity *in vivo* and thereby treat osteoarthritis.

[0154] Binding partners of target molecules can be identified by methods known in the art. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.*, *Cell* 72:223-232 (1993); Madura *et al.*, *J. Biol. Chem.* 268: 12046-12054 (1993); Bartel *et al.*, *Biotechniques* 14: 920-924 (1993); Iwabuchi *et al.*, *Oncogene* 8: 1693-1696 (1993); and Brent WO94/10300). A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a *APOL3* nucleic acid (sometimes referred to as the "bait") is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner (sometimes referred to as the "prey") is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a *APOL3* nucleic acid can be fused to the activation domain. If the "bait" and the "prey" molecules interact *in vivo*, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

[0155] In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The

test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo. Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule agonizes target molecule/binding partner complex formation. In another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (*e.g.*, amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

[0156] The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, *e.g.*, molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

[0157] In a heterogeneous assay embodiment, the target molecule or the binding partner is anchored onto a solid surface (*e.g.*, a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; *e.g.*, by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

[0158] In another embodiment, the reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

[0159] In an alternate embodiment, a homogenous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (e.g., U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target molecule/binding partner complexes can be identified.

[0160] Candidate therapeutics for treating osteoarthritis are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (e.g., agonize or antagonize) a function associated with the target molecule (e.g., DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information described herein can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

Therapeutic Formulations

[0161] Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method described above. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may comprise a target polypeptide or fragment thereof in combination with a pharmaceutically acceptable carrier, where the polypeptide or fragment sometimes has an *APOL3* biological activity (e.g., apolipoprotein activity), and sometimes includes all or part of an apolipoprotein domain.

[0162] As used herein, the term “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be

incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0163] A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0164] Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0165] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens,

chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0166] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0167] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0168] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0169] In one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0170] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete

units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0171] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Molecules which exhibit high therapeutic indices are preferred. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0172] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0173] As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

[0174] With regard to polypeptide formulations, featured herein is a method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject with a first polypeptide, where the subject comprises a second polypeptide having one or more polymorphic

variations associated with cancer, and where the first polypeptide comprises fewer polymorphic variations associated with cancer than the second polypeptide. The first and second polypeptides are encoded by a nucleic acid which comprises a nucleotide sequence in SEQ ID NO: 1-7; a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence referenced in SEQ ID NO: 1-7; a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7 and a nucleotide sequence 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-7. The subject often is a human.

[0175] For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank *et al.*, *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193 (1997).

[0176] Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0177] For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is

understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0178] With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent 5,328,470) or by stereotactic injection (*see e.g.*, Chen *et al.*, (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057).

Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.

Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (*e.g.*, retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

Therapeutic Methods

[0179] A therapeutic formulation described above can be administered to a subject in need of a therapeutic for inducing a desired biological response.. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

[0180] As used herein, the term "treatment" is defined as the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect osteoarthritis, symptoms of osteoarthritis or a predisposition towards osteoarthritis. A therapeutic formulation includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of osteoarthritis, such that osteoarthritis is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

[0181] As discussed, successful treatment of osteoarthritis can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

[0182] Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

[0183] Another method by which nucleic acid molecules may be utilized in treating or preventing osteoarthritis is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (*see, e.g., Osborne, et al., Curr. Opin. Chem. Biol.* 1(1): 5-9 (1997); and Patel, D. J., *Curr. Opin. Chem. Biol.* Jun; 1(1): 32-46 (1997)).

[0184] Yet another method of utilizing nucleic acid molecules for osteoarthritis treatment is gene therapy, which can also be referred to as allele therapy. Provided herein is a gene therapy method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-7). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allele therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes polymorphic variants associated with osteoarthritis.

[0185] In another allele therapy embodiment, provided herein is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-7). Genomic DNA in the subject comprises a

second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleic acid has a nucleotide sequence identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human.

[0186] For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of osteoarthritis.

[0187] In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (*see, e.g., Herlyn, Ann. Med.; 31(1): 66-78 (1999); and Bhattacharya-Chatterjee & Foon, Cancer Treat. Res.; 94: 51-68 (1998)*). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to osteoarthritis also may be generated in this fashion.

[0188] In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (*see, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA 90: 7889-7893 (1993)*).

[0189] Modulators can be administered to a patient at therapeutically effective doses to treat osteoarthritis. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of osteoarthritis. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Modulators that exhibit large therapeutic indices are preferred. While modulators that exhibit toxic side effects can be used, care

should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0190] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0191] Another example of effective dose determination for an individual is the ability to directly assay levels of "free" and "bound" compound in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell *et al.*, *Current Opinion in Biotechnology* 7: 89-94 (1996) and in Shea, *Trends in Polymer Science* 2: 166-173 (1994). Such "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, *et al.*, *Nature* 361: 645-647 (1993). Through the use of isotope-labeling, the "free" concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of IC₅₀. Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC₅₀. An example of such a "biosensor" is discussed in Kriz *et al.*, *Analytical Chemistry* 67: 2142-2144 (1995).

[0192] The examples set forth below are intended to illustrate but not limit the invention.

Examples

[0193] In the following studies a group of subjects was selected according to specific parameters relating to osteoarthritis (OA). Nucleic acid samples obtained from individuals in the study group were subjected to genetic analysis, which identified associations between osteoarthritis and a polymorphism in the *APOL3* gene on chromosome twenty-two. The polymorphism was genotyped again in two replication cohorts consisting of individuals selected for OA. In addition, SNPs proximal to the incident polymorphism were identified and allelotyped in OA case and control pools. Methods are described for producing *APOL3* polypeptide and *APOL3* polypeptide variants *in vitro* or *in vivo*. *APOL3* nucleic acids or polypeptides and variants thereof are utilized for screening test molecules for those that interact with *APOL3* molecules. Test molecules identified as interactors with *APOL3* molecules and *APOL3* variants are further screened *in vivo* to determine whether they treat osteoarthritis.

Example 1

Samples and Pooling Strategies

Sample Selection

[0194] Blood samples were collected from individuals diagnosed with knee osteoarthritis, which were referred to as case samples. Also, blood samples were collected from individuals not diagnosed with knee osteoarthritis as gender and age-matched controls. A database was created that listed all phenotypic trait information gathered from individuals for each case and control sample. Genomic DNA was extracted from each of the blood samples for genetic analyses.

DNA Extraction from Blood Samples

[0195] Six to ten milliliters of whole blood was transferred to a 50 ml tube containing 27 ml of red cell lysis solution (RCL). The tube was inverted until the contents were mixed. Each tube was incubated for 10 minutes at room temperature and inverted once during the incubation. The tubes were then centrifuged for 20 minutes at 3000 x g and the supernatant was carefully poured off. 100-200 µl of residual liquid was left in the tube and was pipetted repeatedly to resuspend the pellet in the residual supernatant. White cell lysis solution (WCL) was added to the tube and pipetted repeatedly until completely mixed. While no incubation was normally required, the solution was incubated at 37°C or room temperature if cell clumps were visible after mixing until the solution was homogeneous. 2 ml of protein precipitation was added to the cell lysate. The mixtures were vortexed vigorously at high speed for 20 sec to mix the protein precipitation solution uniformly with the cell lysate, and then centrifuged for 10 minutes at 3000 x g. The supernatant containing the DNA was then poured into a clean 15 ml tube, which contained 7 ml of 100% isopropanol. The samples were mixed by inverting the tubes gently until

white threads of DNA were visible. Samples were centrifuged for 3 minutes at 2000 x g and the DNA was visible as a small white pellet. The supernatant was decanted and 5 ml of 70% ethanol was added to each tube. Each tube was inverted several times to wash the DNA pellet, and then centrifuged for 1 minute at 2000 x g. The ethanol was decanted and each tube was drained on clean absorbent paper. The DNA was dried in the tube by inversion for 10 minutes, and then 1000 µl of 1X TE was added. The size of each sample was estimated, and less TE buffer was added during the following DNA hydration step if the sample was smaller. The DNA was allowed to rehydrate overnight at room temperature, and DNA samples were stored at 2-8°C.

[0196] DNA was quantified by placing samples on a hematology mixer for at least 1 hour. DNA was serially diluted (typically 1:80, 1:160, 1:320, and 1:640 dilutions) so that it would be within the measurable range of standards. 125 µl of diluted DNA was transferred to a clear U-bottom microtitre plate, and 125 µl of 1X TE buffer was transferred into each well using a multichannel pipette. The DNA and 1X TE were mixed by repeated pipetting at least 15 times, and then the plates were sealed. 50 µl of diluted DNA was added to wells A5-H12 of a black flat bottom microtitre plate. Standards were inverted six times to mix them, and then 50 µl of 1X TE buffer was pipetted into well A1, 1000 ng/ml of standard was pipetted into well A2, 500 ng/ml of standard was pipetted into well A3, and 250 ng/ml of standard was pipetted into well A4. PicoGreen (Molecular Probes, Eugene, Oregon) was thawed and freshly diluted 1:200 according to the number of plates that were being measured. PicoGreen was vortexed and then 50µl was pipetted into all wells of the black plate with the diluted DNA. DNA and PicoGreen were mixed by pipetting repeatedly at least 10 times with the multichannel pipette. The plate was placed into a Fluoroskan Ascent Machine (microplate fluorometer produced by Labsystems) and the samples were allowed to incubate for 3 minutes before the machine was run using filter pairs 485 nm excitation and 538 nm emission wavelengths. Samples having measured DNA concentrations of greater than 450 ng/µl were re-measured for conformation. Samples having measured DNA concentrations of 20 ng/µl or less were re-measured for confirmation.

Pooling Strategies – Discovery Cohort

[0197] Samples were derived from the Nottingham knee OA family study (UK) where index cases were identified through a knee replacement registry. Siblings were approached and assessed with knee x-rays and assigned status as affected or unaffected. In all 1,157 individuals were available. In order to create same-sex pools of appropriate sizes, 335 unrelated female individuals with OA from the Nottingham OA sample were selected for the case pool. The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St.

Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The female case samples and female control samples are described further in Table 1 below.

[0198] A select set of samples from each group were utilized to generate pools, and one pool was created for each group. Each individual sample in a pool was represented by an equal amount of genomic DNA. For example, where 25 ng of genomic DNA was utilized in each PCR reaction and there were 200 individuals in each pool, each individual would provide 125 pg of genomic DNA. Inclusion or exclusion of samples for a pool was based upon the following criteria: the sample was derived from an individual characterized as Caucasian; the sample was derived from an individual of British paternal and maternal descent; case samples were derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic. Control samples were derived from individuals free of OA, family history of OA, and rheumatoid arthritis. Also, sufficient genomic DNA was extracted from each blood sample for all allelotyping and genotyping reactions performed during the study. Phenotype information from each individual was collected and included age of the individual, gender, family history of OA, general medical information (e.g., height, weight, thyroid disease, diabetes, psoriasis, hysterectomy), joint history (previous and current symptoms, joint-related operations, age at onset of symptoms, date of primary diagnosis, age of individual as of primary diagnosis and order of involvement), and knee-related findings (crepitus, restricted passive movement, bony swelling/deformity). Additional knee information included knee history, current symptoms, any major knee injury, meniscectomy, knee replacement surgery, age of surgery, and treatment history (including hormone replace therapy (HRT)). Samples that met these criteria were added to appropriate pools based on disease status.

[0199] The selection process yielded the pools set forth in Table 1, which were used in the studies that follow:

TABLE 1

	Female case	Female control
Pool size (Number)	335	335
Pool Criteria (ex: case/control)	control	case
Mean Age (ex: years)	57.21	69.95

Example 2

Association of Polymorphic Variants with Osteoarthritis

[0200] A whole-genome screen was performed to identify particular SNPs associated with occurrence of osteoarthritis. As described in Example 1, two sets of samples were utilized, which included samples from female individuals having knee osteoarthritis (osteoarthritis cases), and samples from female individuals not having knee osteoarthritis (female controls). The initial screen of each pool was performed in an alleotyping study, in which certain samples in each group were pooled. By pooling DNA from each group, an allele frequency for each SNP in each group was calculated. These allele frequencies were then compared to one another. Particular SNPs were considered as being associated with osteoarthritis when allele frequency differences calculated between case and control pools were statistically significant. SNP disease association results obtained from the alleotyping study were then validated by genotyping each associated SNP across all samples from each pool. The results of the genotyping then were analyzed, allele frequencies for each group were calculated from the individual genotyping results, and a p-value was calculated to determine whether the case and control groups had statistically significant differences in allele frequencies for a particular SNP. When the genotyping results agreed with the original alleotyping results, the SNP disease association was considered validated at the genetic level.

SNP Panel Used for Genetic Analyses

[0201] A whole-genome SNP screen began with an initial screen of approximately 25,000 SNPs over each set of disease and control samples using a pooling approach. The pools studied in the screen are described in Example 1. The SNPs analyzed in this study were part of a set of 25,488 SNPs confirmed as being statistically polymorphic as each is characterized as having a minor allele frequency of greater than 10%. The SNPs in the set reside in genes or in close proximity to genes, and many reside in gene exons. Specifically, SNPs in the set are located in exons, introns, and within 5,000 base-pairs upstream of a transcription start site of a gene. In addition, SNPs were selected according to the following criteria: they are located in ESTs; they are located in Locuslink or Ensembl genes; and they are located in Genomatix promoter predictions. SNPs in the set were also selected on the basis of even spacing across the genome, as depicted in Table 2.

[0202] A case-control study design using a whole genome association strategy involving approximately 28,000 single nucleotide polymorphisms (SNPs) was employed. Approximately 25,000 SNPs were evenly spaced in gene-based regions of the human genome with a median inter-marker distance of about 40,000 base pairs. Additionally, approximately 3,000 SNPs causing amino acid substitutions in genes described in the literature as candidates for various diseases were used. The case-

control study samples were of female Caucasian origin (British paternal and maternal descent) 670 individuals were equally distributed in two groups: female controls and female cases. The whole genome association approach was first conducted on 2 DNA pools representing the 2 groups. Significant markers were confirmed by individual genotyping.

TABLE 2

General Statistics		Spacing Statistics	
Total # of SNPs	25,488	Median	37,058 bp
# of Exonic SNPs	>4,335 (17%)	Minimum*	1,000 bp
# SNPs with refSNP ID	20,776 (81%)	Maximum*	3,000,000 bp
Gene Coverage	>10,000	Mean	122,412 bp
Chromosome Coverage	All	Std Deviation	373,325 bp

*Excludes outliers

Allelotyping and Genotyping Results

[0203] The genetic studies summarized above and described in more detail below identified an allelic variant in the APOL3 gene that is associated with osteoarthritis.

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0204] A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hMET™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0205] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which where used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension primers used for analyzing polymorphisms. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl₂ (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

TABLE 3: PCR Primers

SNP Reference	Forward PCR primer	Reverse PCR primer
rs132659	ACGTTGGATGGGCCCATAGTGGGTCAAAAC	ACGTTGGATGGTGGGGTGAGTGCCCCAAAG

[0206] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0207] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 4, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

TABLE 4: Extension Primers

SNP Reference	Extend Probe	Termination Mix
rs132659	AGAACTCCCCAAATCGTCCT	ACG

[0208] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0209] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and

SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0210] Minor allelic frequencies for the polymorphisms set forth in Table A were verified as being 10% or greater using the extension assay described above in a group of samples isolated from 92 individuals originating from the state of Utah in the United States, Venezuela and France (Coriell cell repositories).

[0211] Genotyping results are shown for female pools in Table 5. In Table 5, "AF" refers to allelic frequency; and "F case" and "F control" refer to female case and female control groups, respectively.

TABLE 5: Genotyping Results

SNP Reference	AF F case	AF F control	p-value
rs132659	C = 0.675 T = 0.325	C = 0.589 T = 0.411	0.0015

[0212] The single marker alleles set forth in Table A were considered validated, since the genotyping data agreed with the allelotyping data and each SNP significantly associated with osteoarthritis. Particularly significant associations with osteoarthritis are indicated by a calculated p-value of less than 0.05 for genotype results.

Example 3

Association of Polymorphic Variants with Osteoarthritis in Replication Cohorts

[0213] The single marker polymorphism set forth in Table A was genotyped again in two replication cohorts consisting of individuals selected for OA.

Sample Selection and Pooling Strategies – Replication Sample 1

[0214] A second case control sample (replication sample #1) was created by using 100 Caucasian female cases from Chingford, UK, and 148 unrelated female cases from the St. Thomas twin study. Cases were defined as having Kellgren-Lawrence (KL) scores of at least 2 in at least one knee x-ray. In addition, 199 male knee replacement cases from Nottingham were included. (For a cohort description, see the Nottingham description provided in Example 1). The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age.

The replication sample 1 cohort was used to replicate the initial results. Table 6 below summarizes the selected phenotype data collected from the case and control individuals.

TABLE 6

Phenotype	Female cases (n=248): median (range)/ (n,%)	Male cases (n=199): median (range)/ (n,%)	Female controls (n=313): mean (range)/ (n,%)
Age	59 (39- 73)	66 (45- 73)	55 (50- 72)
Height (cm)	162 (141- 178)	175 (152- 198)	162 (141- 176)
Weight (kg)	68 (51- 123)	86 (62- 127)	64 (40- 111)
Body mass index (kg/m ²)	26 (18- 44)	29 (21- 41)	24 (18- 46)
Kellgren- Lawrence* left knee	0 (63, 26%), 1 (20, 8%), 2 (105, 43%), 3 (58, 23%), 4 (1, 0%)	NA	NA
Kellgren- Lawrence* right knee	0 (43, 7%), 1 (18, 7%), 2 (127, 52%), 3 (57, 23%), 4 (1, 0%)	NA	NA
KL* >2 both knees	No (145, 59%), Yes (101, 41%)	NA	NA
KL* >2 either knee	No (0, 0%), Yes (248, 100%)	NA	NA

* 0: normal, 1: doubtful, 2: definite osteophyte (bony protuberance), 3: joint space narrowing (with or without osteophyte), 4: joint deformity

Sample Selection and Pooling Strategies – Replication Sample 2

[0215] A third case control sample (replication sample #2) was created by using individuals with symptoms of OA from Newfoundland, Canada. These individuals were recruited and examined by rheumatologists. Affected joints were x-rayed and a final diagnosis of definite or probable OA was made according to American College of Rheumatology criteria by a single rheumatologist to avoid any inter-examiner diagnosis variability. Controls were recruited from volunteers without any symptoms from the musculoskeletal system based on a normal joint exam performed by a rheumatologist. Only cases with a diagnosis of definite OA were included in the study. Only individuals of Caucasian origin were included. The cases consisted of 228 individuals with definite knee OA, 106 individuals with definite hip OA, and 74 individuals with hip OA.

TABLE 7

Phenotype	Case	Control
Age at Visit	62.7	52.5
Sex (Female/Male)	227/119	174/101
Knee OA Xray: No	35% (120)	80% (16)

Unknown	1% (4)	0% (0)
Yes	64% (221)	20% (4)
Hip OA Xray: No	63% (215)	80% (16)
Unknown	2% (7)	0% (0)
Yes	35% (121)	20% (4)

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0216] Genotyping of the replication cohorts described in Tables 6 and 7 was performed using the same methods used for the original genotyping, as described herein. A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0217] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which were used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension probes used for analyzing (e.g., genotyping) polymorphisms in the replication cohorts. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl₂ (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

[0218] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0219] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs)

used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 7, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

[0220] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0221] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0222] Genotyping results for replication cohorts #1 and #2 are provided in Tables 8 and 9, respectively.

TABLE 8

rsID	Replication #1 (Mixed Male/Female cases and Female controls)				Meta-analysis Disc. + Rep #1 P-value				
	AF	OA	Con	AF	OA	Cas	Delta	P-value	
rs132659	0.38			0.34			0.04	0.128	0.0077

TABLE 9

rsID	Replication #2 (Newfoundland) (Male/Female cases and controls)				Meta-analysis Disc. + Rep #2 Not Done				
	AF	OA	Con	AF	OA	Cas	Delta	P-value	
rs132659	0.36			0.36			-0.001	0.973	

[0223] To combine the evidence for association from multiple sample collections, a meta-analysis procedure was employed. The allele frequencies were compared between cases and controls within the discovery sample, as well as within the replication cohort #1 using the DerSimonian-Laird approach
(DerSimonian, R. and N. Laird. 1986. Meta-analysis in clinical trials. *Control Clin Trials* 7: 177-188.)

[0224] The absence of a statistically significant association in one or more of the replication cohorts should not be interpreted as minimizing the value of the original finding. There are many reasons why a biologically derived association identified in a sample from one population would not replicate in a sample from another population. The most important reason is differences in population history. Due to bottlenecks and founder effects, there may be common disease predisposing alleles present in one population that are relatively rare in another, leading to a lack of association in the candidate region. Also, because common diseases such as arthritis-related disorders are the result of susceptibilities in many genes and many environmental risk factors, differences in population-specific genetic and environmental backgrounds could mask the effects of a biologically relevant allele. For these and other reasons, statistically strong results in the original, discovery sample that did not replicate in one or more of the replication samples may be further evaluated in additional replication cohorts and experimental systems.

Example 4

APOL3 Region Proximal SNPs

[0225] It has been discovered that SNP rs132659 in *APOL3* is associated with occurrence of osteoarthritis in subjects. *APOL3* belongs to the high density lipoprotein family that plays a central role in cholesterol transport. The cholesterol content of membranes is important in cellular processes such as modulating gene transcription and signal transduction both in the adult brain and during neurodevelopment. It has been shown that the APOL1-APOL4 gene cluster on chromosome 22 exists only in primates (humans and African green monkeys) and not in dogs, pigs, or rodents, suggesting that this gene cluster has arisen recently in evolution (Monajemi et. al., *Genomics* 79: 539-546, 2002). Six transcript variants encoding three different isoforms have been identified.

[0226] Expression of this gene is upregulated by tumor necrosis factor-alpha in endothelial cells lining the normal and atherosclerotic iliac artery and aorta (Horrevoets et. al., *Blood* 93: 3418-3431, 1999). *APOL3* is genetically linked to OA and may play a role in the pathophysiology of OA brought about by inflammation. *APOL3* is likely inhibited by a small molecule inhibitor or by specific antibodies. *APOL3* activity may be increased in a subject by administering *APOL3* recombinant protein or a functional fragment thereof.

[0227] Two hundred-nineteen additional allelic variants proximal to rs132659 were identified and subsequently allelotyped in osteoarthritis case and control sample sets as described in Examples 1 and 2.

The polymorphic variants are set forth in Table 10. The chromosome positions provided in column four of Table 10 are based on Genome “Build 34” of NCBI’s GenBank.

TABLE 10

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs3888818	22	201	34781551	c/t
rs2010605	22	425	34781775	a/g
rs743919	22	1095	34782445	g/t
rs1008134	22	2201	34783551	a/c
rs132607	22	7879	34789229	a/g
rs1476029	22	8395	34789745	c/t
rs1476030	22	8461	34789811	c/t
rs2413380	22	9503	34790853	c/t
rs2051609	22	10304	34791654	g/t
rs2413381	22	10695	34792045	c/t
rs1894604	22	16300	34797650	a/g
rs1894605	22	16444	34797794	g/t
rs132609	22	17591	34798941	c/t
rs132610	22	17988	34799338	-/a
rs132611	22	19116	34800466	-/t
rs132612	22	19358	34800708	c/t
rs1008790	22	20300	34801650	a/g
rs23085	22	20669	34802019	a/t
rs105161	22	20891	34802241	a/g
rs132613	22	21451	34802801	c/t
rs132614	22	21978	34803328	c/t
rs132615	22	22785	34804135	c/g
rs132617	22	24248	34805598	c/t
rs3865724	22	24770	34806120	c/t
rs2019657	22	24844	34806194	a/g
rs3865725	22	25066	34806416	g/t
rs2019364	22	25096	34806446	c/t
rs2008383	22	25309	34806659	a/g
rs3986002	22	25344	34806694	a/c
rs3888942	22	25529	34806879	a/t
rs3888943	22	25537	34806887	a/g
rs3888944	22	25554	34806904	a/c
rs132618	22	27963	34809313	a/t
rs132619	22	28134	34809484	g/t
rs3827346	22	28356	34809706	a/g
rs132620	22	29648	34810998	-/a
rs132621	22	29986	34811336	a/g
rs80575	22	30217	34811567	g/t
rs80576	22	30267	34811617	a/g
rs80577	22	30315	34811665	a/g
rs80578	22	30585	34811935	c/t
rs80579	22	30724	34812074	a/c
rs80580	22	30897	34812247	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132622	22	30931	34812281	c/t
rs132623	22	31080	34812430	g/t
rs132624	22	31246	34812596	c/t
rs132625	22	31373	34812723	a/t
rs132626	22	31463	34812813	a/g
rs132627	22	31467	34812817	a/g
rs1807672	22	32188	34813538	g/t
rs132628	22	32288	34813638	c/t
rs132629	22	32520	34813870	a/t
rs132630	22	32594	34813944	a/c
rs132631	22	32657	34814007	a/c
rs132632	22	32677	34814027	a/g
rs132633	22	32764	34814114	c/t
rs132634	22	32784	34814134	a/g
rs132635	22	32830	34814180	c/t
rs132636	22	32872	34814222	c/t
rs129603	22	33121	34814471	a/c
rs132637	22	33348	34814698	g/t
rs3788518	22	33952	34815302	c/g
rs132638	22	34184	34815534	c/g
rs132639	22	34361	34815711	a/t
rs132640	22	35026	34816376	a/g
rs132641	22	35192	34816542	a/g
rs132642	22	35600	34816950	a/t
rs132643	22	36033	34817383	c/t
rs132644	22	36289	34817639	c/t
rs132645	22	38869	34820219	a/g
rs2017329	22	39629	34820979	a/t
rs739198	22	40530	34821880	c/t
rs132647	22	41621	34822971	c/t
rs2097465	22	42379	34823729	c/t
rs2105915	22	42802	34824152	c/t
rs132648	22	42865	34824215	t/c
rs132649	22	43644	34824994	a/g
rs132650	22	45051	34826401	c/t
rs132651	22	45828	34827178	a/c
rs132652	22	45829	34827179	a/t
rs80584	22	46257	34827607	c/t
rs132653	22	47286	34828636	a/c
rs916334	22	47427	34828777	c/t
rs132654	22	47963	34829313	c/t
rs132655	22	48013	34829363	c/t
rs132656	22	48229	34829579	c/t
rs3834684	22	48282	34829632	-a
rs132657	22	48376	34829726	-g
rs916335	22	48404	34829754	a/g
rs132659	22	49900	34831250	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132660	22	52699	34834049	g/t
rs132661	22	52897	34834247	a/g
rs132662	22	53414	34834764	a/g
rs132663	22	53487	34834837	a/t
rs132664	22	54112	34835462	g/t
rs132667	22	55492	34836842	a/g
rs132670	22	59766	34841116	c/t
rs132671	22	60307	34841657	a/g
rs132672	22	60701	34842051	a/g
rs132673	22	60952	34842302	a/g
rs132674	22	61401	34842751	c/t
rs132675	22	62379	34843729	c/t
rs80585	22	62870	34844220	c/t
rs80586	22	62879	34844229	a/g
rs132676	22	63499	34844849	a/t
rs132677	22	64284	34845634	-/a
rs132678	22	64408	34845758	a/g
rs132680	22	64760	34846110	a/g
rs132681	22	65230	34846580	a/g
rs132683	22	66127	34847477	a/g
rs2269594	22	66634	34847984	c/t
rs132684	22	66686	34848036	a/g
rs132685	22	66694	34848044	c/g
rs132686	22	67113	34848463	a/g
rs132687	22	67257	34848607	a/g
rs132688	22	67403	34848753	a/g
rs132689	22	67609	34848959	a/g
rs132690	22	68418	34849768	-/a
rs132691	22	68610	34849960	c/g
rs132692	22	69629	34850979	c/t
rs132693	22	70024	34851374	a/g
rs132694	22	70848	34852198	a/g
rs132695	22	71428	34852778	c/g
rs1966266	22	71553	34852903	c/t
rs1966267	22	71633	34852983	a/g
rs106808	22	71768	34853118	a/c
rs132696	22	71769	34853119	a/g
rs2239829	22	73039	34854389	a/g
rs2285154	22	73325	34854675	a/g
rs2239830	22	73412	34854762	a/c
rs2239831	22	73547	34854897	c/t
rs3865722	22	73769	34855119	a/t
rs3865723	22	73806	34855156	a/g
rs3985996	22	74467	34855817	c/t
rs3985997	22	74472	34855822	c/t
rs3985998	22	74473	34855823	a/g
rs3985999	22	74482	34855832	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs3986000	22	74494	34855944	a/c
rs2413382	22	74592	34855942	a/g
rs2413383	22	74670	34856020	g/t
rs2413384	22	74672	34856022	g/t
rs2413385	22	74714	34856064	g/t
rs2413386	22	74723	34856073	a/t
rs1894606	22	74749	34856099	a/g
rs916336	22	74861	34856211	c/g
rs916337	22	74892	34856242	c/t
rs916338	22	74893	34856243	c/t
rs132697	22	75176	34856526	a/g
rs12781	22	75705	34857055	a/g
rs1053983	22	75989	34857339	a/g
rs1053982	22	76027	34857377	a/g
rs2227167	22	77949	34859299	a/g
rs2227168	22	77974	34859324	c/t
rs132700	22	78167	34859517	c/t
rs3075364	22	78310	34859660	-/ct
rs2227169	22	78415	34859765	c/t
rs2097466	22	78575	34859925	c/t
rs2097467	22	78590	34859940	c/t
rs2413387	22	78709	34860059	c/t
rs132701	22	78875	34860225	c/t
rs132702	22	79864	34861214	c/t
rs132703	22	81316	34862666	c/t
rs2269595	22	81320	34862670	a/g
rs2269596	22	81409	34862759	c/t
rs132704	22	81737	34863087	c/t
rs2007468	22	81843	34863193	a/g
rs132705	22	82102	34863452	c/t
rs2007706	22	82833	34864183	c/t
rs132706	22	83461	34864811	c/t
rs132707	22	83624	34864974	c/t
rs132708	22	83660	34865010	c/g
rs132709	22	83701	34865051	a/t
rs132710	22	83708	34865058	a/g
rs132711	22	83782	34865132	c/t
rs132712	22	85707	34867057	a/g
rs132713	22	85717	34867067	a/g
rs132714	22	86486	34867836	c/t
rs132716	22	86833	34868183	a/g
rs132717	22	87115	34868465	c/t
rs132718	22	87234	34868584	a/g
rs132719	22	87479	34868829	g/t
rs132720	22	87561	34868911	a/g
rs132721	22	87604	34868954	a/g
rs132722	22	87674	34869024	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132723	22	87958	34869308	a/g
rs132724	22	87992	34869342	-/g
rs132725	22	88019	34869369	a/g
rs132726	22	88074	34869424	c/g
rs132727	22	88079	34869429	c/g
rs132728	22	88115	34869465	a/g
rs132729	22	88118	34869468	c/g
rs132730	22	88120	34869470	a/g
rs132731	22	88135	34869485	-/ctcat
rs132732	22	88142	34869492	g/t
rs132733	22	88143	34869493	g/t
rs140575	22	88149	34869499	aca/tg
rs132734	22	88340	34869690	a/g
rs132735	22	88344	34869694	g/t
rs80587	22	88512	34869862	c/g
rs132736	22	88521	34869871	c/t
rs132737	22	88650	34870000	c/g
rs132738	22	88827	34870177	c/t
rs1807673	22	89230	34870580	a/g
rs2014700	22	89236	34870586	a/g
rs132739	22	90754	34872104	g/a
rs1812023	22	90984	34872334	a/g
rs1812024	22	91110	34872460	a/g
rs2005590	22	92026	34873376	c/t
rs132740	22	92954	34874304	c/t
rs3986001	22	93375	34874725	-/ttgc
rs2413390	22	93794	34875144	c/t
rs132743	22	94937	34876287	c/g
rs132744	22	95068	34876418	c/t
rs2413391	22	96188	34877538	a/g
rs132749	22	97092	34878442	c/t
rs132750	22	98812	34880162	c/t
rs132741	22	not mapped	not mapped	a/c
rs2413388	22	not mapped	not mapped	a/t
rs2413389	22	not mapped	not mapped	c/g

Assay for Verifying and Allelotyping SNPs

[0228] The methods used to verify and allelotype the 219 proximal SNPs of Table 10 are the same methods described in Examples 1 and 2 herein. The primers and probes used in these assays are provided in Table 11 and Table 12, respectively.

TABLE 11

dbSNP rs#	Forward PCR primer	Reverse PCR primer
--------------	-----------------------	-----------------------

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3888818	ACGTTGGATGTGAGGTCAAGGAGTTTGAGAC	ACGTTGGATGCCATGCCCATGCCCTAATTTCG
rs2010605	ACGTTGGATGTGCTTCTTATGCTTAGG	ACGTTGGATGGACTTTAGAAAGAAAAGTAC
rs743919	ACGTTGGATGTTCTCACCAAGCCCTTC	ACGTTGGATGCCAACACACACAAAGATGG
rs1008134	ACGTTGGATGACATATCGGGGATCTTTTC	ACGTTGGATGCATCCACAGGATGCCAATTC
rs132607	ACGTTGGATGTAGTTGCAGGTCAACAAGGG	ACGTTGGATGGGAAGGAAGGCCAACACG
rs1476029	ACGTTGGATGTGGGTACAGAGATCCTTC	ACGTTGGATGAAACTCAGGGAAACCGACTC
rs1476030	ACGTTGGATGATCCTAGCACTGGGATTG	ACGTTGGATGCGTTCCCTGAGTTTCACTG
rs2413380	ACGTTGGATGTGATGACTGAGTCCAGGAGG	ACGTTGGATGAAAGGCTACTTCTGCTCAC
rs2051609	ACGTTGGATGTAATCCAGCACTTGGGAG	ACGTTGGATGACAGAGGGGTTTCTCATATG
rs2413381	ACGTTGGATGAGGGCTGCAAGTAGAAAAGCG	ACGTTGGATGACGATCGTGTGCCAGAC
rs1894604	ACGTTGGATGAAGTGTGCTGTCAAAGAG	ACGTTGGATGTCTCCACTCCATTCTGTG
rs1894605	ACGTTGGATGTGAGAGATGCGAGATCGC	ACGTTGGATGTATTCAAGAAATTAGCCCTGCG
rs132609	ACGTTGGATGGCATTTGAAAGGTCCTGATC	ACGTTGGATGCCAAATCTGCTTTTACCC
rs132610	ACGTTGGATGTTCTACAAGAGCTAGGGACC	ACGTTGGATGGATCTTGTGCTTAGGCC
rs132611	ACGTTGGATGGCTCTTCTACTCTGCTCTC	ACGTTGGATGGTTTCTTCAGGTCCTCC
rs132612	ACGTTGGATGAAAAATCTCCCGCTACCTC	ACGTTGGATGTCTGTGAGCTTCTCTGT
rs1008790	ACGTTGGATGGTGGAGGTCCTTTATGATG	ACGTTGGATGATAACAGCCCCCTGACAGATG
rs23085	ACGTTGGATGAAACCGTGCAGCTGAGGAT	ACGTTGGATGGTCGGCAAGGAAGGAGGAATC
rs105161	ACGTTGGATGAAAGGAGGGGAAATCTTTC	ACGTTGGATGTGAGGAGGCTGAAATGCTAG
rs132613	ACGTTGGATGATGAAAACCAATGGCCCTC	ACGTTGGATGAAAGCTTCAGATTGTCACCC
rs132614	ACGTTGGATGCAAGGCCCCCTGTTTGAG	ACGTTGGATGTCCTGCCACCGAGAGATGA
rs132615	ACGTTGGATGAAATCTGGAGGCTTGGTGC	ACGTTGGATGTGAGCATTACATGGGACAG
rs132617	ACGTTGGATGGAGAAGAAGTGTGTTG	ACGTTGGATGACAGGGCTCTGAATTGTC
rs3865724	ACGTTGGATGTTCTGTGATAATTCCCATC	ACGTTGGATGGCTGGATCAGAAAGAGTA
rs2019657	ACGTTGGATGACGCCAGAACATTGTTTC	ACGTTGGATGGTGCCAGAAACATTCAAAC
rs3865725	ACGTTGGATGAATATAGAACCTGCTGGCGC	ACGTTGGATGTGACTTAGGAGAGGTTCTGG
rs2019364	ACGTTGGATGTGACTTGGAGGAGGTTCTGG	ACGTTGGATGAAATATAGAACCTGCTGGCGC
rs2008383	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGACATGGTGACCCATCAAG
rs3986002	ACGTTGGATGCTCTGCTCTCTGTGTC	ACGTTGGATGCAGGCAGAGGTTTGG
rs3888942	ACGTTGGATGCTGGGCTTTGTGCTAAGAG	ACGTTGGATGGGGCCAATTGCCCCATAAA
rs3888943	ACGTTGGATGCTGGGCTTTGTGCTAAGAG	ACGTTGGATGTTGGGCCAATTGCCCCATA
rs3888944	ACGTTGGATGATACGCCCTGCCACATATG	ACGTTGGATGTTGAAGACATGGAAAGCAGGG
rs132618	ACGTTGGATGAAATCCGTGCCATCAGGCAAG	ACGTTGGATGCCCTGCAATCGTCTCTG
rs132619	ACGTTGGATGTCACTAGCAGAAGCTGAAGC	ACGTTGGATGGGTGATGTCACGCATAAC
rs3827346	ACGTTGGATGAAAGGTCACAGGAGCTG	ACGTTGGATGAAAAGACGCCAGAAGGGA
rs132620	ACGTTGGATGTCACATTAGATCAGGAAGCC	ACGTTGGATGTTAGGCCAGTTAGCAAGAAA
rs132621	ACGTTGGATGCTCAAATCTGCAACTGGTG	ACGTTGGATGGATAGCTTAAAGGACTCAGAG
rs80575	ACGTTGGATGGCTGCACTGAACTCTCAAG	ACGTTGGATGTGACATGTGACAGTGGAGACC
rs80576	ACGTTGGATGTGAAAGCTGTCACCTGCTAAG	ACGTTGGATGAACTCTCAACGCCACTTGAC
rs80577	ACGTTGGATGAGTCATAAGAGGTTCCATG	ACGTTGGATGAACTAATGCCCTAGCAGGTG
rs80578	ACGTTGGATGACTGTTCCCTGACAGCATG	ACGTTGGATGTGAGAACAGAAGAGGGTCC
rs80579	ACGTTGGATGTGGAGTAGGGTGTGAGAAGAG	ACGTTGGATGACTCACTGTCCTCTGCCAAG
rs80580	ACGTTGGATGTCAATCAGATGGCGTGTG	ACGTTGGATGGATGGCATCTGACTTCTGG
rs132622	ACGTTGGATGTATGCTTGGAGACTGGGAC	ACGTTGGATGACCTGCTGTCATTCTCAGG
rs132623	ACGTTGGATGAGCTGTCCAACTCCATTG	ACGTTGGATGCTGAGGAAACTGCACAAACAC
rs132624	ACGTTGGATGTGCTGGATTACAGGCGATGA	ACGTTGGATGTCAAAGAAAGTCTCTGCTGG
rs132625	ACGTTGGATGTTTACGCCATTCTCTGCC	ACGTTGGATGCGATGAAACCCCGTGTAC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132626	ACGTTGGATGTGGAGTCAGTGGCATGATC	ACGTTGGATGGCAGGAGAATGGCGTGAAC
rs132627	ACGTTGGATGAGGAGAACCTGGCTGAAACCG	ACGTTGGATGAGACAGACTTGCTTGTG
rs1807672	ACGTTGGATGGTGTGCTACAGCTAAATGG	ACGTTGGATGAATAACCCATGTGACAGCTG
rs132628	ACGTTGGATGTATAAGCTGAGTTGTGCCC	ACGTTGGATGTGCTTAAAGGCTCAATCTCC
rs132629	ACGTTGGATGCTCTCCCTGCTCTCTT	ACGTTGGATGTGCTCTCACATGGCTT
rs132630	ACGTTGGATGTTCAAAAGTGAAAGGTGCCAG	ACGTTGGATGAAGGCCATGTGAGGACACAG
rs132631	ACGTTGGATGGGTGGCTCCAACAACGTATG	ACGTTGGATGATCAACCCCTGTGGCACCTT
rs132632	ACGTTGGATGCTTGGAAATTCGGCTTCCAG	ACGTTGGATGTCCTTGGCTTAGTAAAAC
rs132633	ACGTTGGATGAAAGATGATTACCAAGGG	ACGTTGGATGGAAAGCTCATTCTGTG
rs132634	ACGTTGGATGAAGTGCATGGTGTCTTG	ACGTTGGATGGAAAGCATGGTGGAAAGCTC
rs132635	ACGTTGGATGAATAGGCACATGGCAGAAGG	ACGTTGGATGCACCAAGAAAGTGGCTTCC
rs132636	ACGTTGGATGAAGGCTTGGACATAGGCAC	ACGTTGGATGAAAGTGGCTTCCACCATG
rs129603	ACGTTGGATGTGTCATATTGACACAGATTG	ACGTTGGATGAGGGTGTATATATATACCC
rs132637	ACGTTGGATGGCATCTTAGTACACAGCAGG	ACGTTGGATGTTCCAAATCCCTGCAAACCC
rs3788518	ACGTTGGATGAATCCCTCAAGAAGGGCTTGG	ACGTTGGATGGCCGCGTTATAAACACAG
rs132638	ACGTTGGATGCATCCTTCAGTGAAGGAGG	ACGTTGGATGTTGCCAAGGCAACTCAGTGA
rs132639	ACGTTGGATGACACCCTGGCAAAACAAAGG	ACGTTGGATGAAGTCCCATAGTGGCAG
rs132640	ACGTTGGATGTAAGAAGCTCCAGGTGACAC	ACGTTGGATGAAAAGAGTGACTCAGCGTCC
rs132641	ACGTTGGATGAGGGCTCAGCTGGAGGAGCA	ACGTTGGATGAGGGCTGAGAGGAGGAGGTTG
rs132642	ACGTTGGATGAGAACAGCAAGCCTACCTGAG	ACGTTGGATGAAACGAACCCCTTCAGTCAG
rs132643	ACGTTGGATGATCACAGACACCCAGTACAC	ACGTTGGATGACGTTCTGACAAATGACCTGG
rs132644	ACGTTGGATGGCATAGATGCAAGACACAG	ACGTTGGATGGGGCTCCTACCTCTTAAATA
rs132645	ACGTTGGATGTGAAGGCAACAGTACAAGA	ACGTTGGATGAAAGTTAACCAAGTGTTC
rs2017329	ACGTTGGATGCCCTTCCCAATAAAAGCAGC	ACGTTGGATGGGGCAACAAAGTGTGAAATT
rs739198	ACGTTGGATGAAACCTTGGCTCCACAAACC	ACGTTGGATGTGAGTTGTCTAAAGGACGG
rs132647	ACGTTGGATGCCCTCACTACAGAAACCATGG	ACGTTGGATGAACTCACTGTTCAACAC
rs2097465	ACGTTGGATGGAATTGACCAAACTGCAGGG	ACGTTGGATGAGGGTGTGAACTGTTGACATG
rs2105915	ACGTTGGATGACACCACAGGAGTTCAGGACAA	ACGTTGGATGGGAACATACAAGTCATCAC
rs132648	ACGTTGGATGGTGGCTCAGGGCTGTAATT	ACGTTGGATGTGCTCTGAACCTCTGGGTT
rs132649	ACGTTGGATGGTCTCCCTCCAGTCCTTATTAC	ACGTTGGATGATTCAAGGGTTAGCTGGCTC
rs132650	ACGTTGGATGAAAGTGTGGGATTACAGGC	ACGTTGGATGCTAAATCTCTGGCCTAGGG
rs132651	ACGTTGGATGAGGTGCTGGTGTGACCTTC	ACGTTGGATGAGCAAGGGTAGGGCTACCTAA
rs132652	ACGTTGGATGAGCAGGGTAGGGCATCTAAC	ACGTTGGATGAGGTAGGGTGTGACCTTCC
rs80584	ACGTTGGATGATGGAGTCCTGTCATCAC	ACGTTGGATGAAACTGAGGCCATGGAGAT
rs132653	ACGTTGGATGCGAGCTGCTACCTGCATAAT	ACGTTGGATGCGATCTCCCTTTGGGTT
rs916334	ACGTTGGATGAAACAGATGCTTCCAGGC	ACGTTGGATGCTGCTCTGGGATCAGCAGGA
rs132654	ACGTTGGATGTAAGGAAAGTGTCCAGAACGCC	ACGTTGGATGAAATGATCTCCCTGCTCAG
rs132655	ACGTTGGATGACTTTCCAGGTGAAGGTAG	ACGTTGGATGTTGCGAACGCCATACCTGT
rs132656	ACGTTGGATGACTAACAGAACAGAACCC	ACGTTGGATGCCCCAGGTTGACTGAACAAAG
rs3834684	ACGTTGGATGAGCCCTGTTACTAGAACG	ACGTTGGATGGGTGATGTGGAGTAAAAG
rs132657	ACGTTGGATGGGCTGACTGACAATTACCTG	ACGTTGGATGAGGGCTCTGAGCTTTCAG
rs916335	ACGTTGGATGATGAGCAGAAAAAGGTGG	ACGTTGGATGATTGAAAGGATGCACTGTG
rs132659	ACGTTGGATGGGCCCATAGTGGGTCAATAAC	ACGTTGGATGGTGGGGTAGTGGCCAAAAG
rs132660	ACGTTGGATGTCATCTGGTGTACCTCC	ACGTTGGATGCTGGCATGGTTTACCCATC
rs132661	ACGTTGGATGCTCGAGAACATCCGC	ACGTTGGATGCAAAATGCAAGCTCAAGGC
rs132662	ACGTTGGATGATCTCTTAAATGGGCCAGG	ACGTTGGATGTTGAAAGGCCACGCCATGT
rs132663	ACGTTGGATGCCACTAACAGGATTGAGATC	ACGTTGGATGTGGCTTCAACCAGCAACTC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132664	ACGTTGGATGTCATGCCACTGCAATCCAG	ACGTTGGATGGCATATGTGACTGCTTCCTC
rs132667	ACGTTGGATCTGGAGAAATCTAAATAGAGAG	ACGTTGGATGTGTCAGCTTTGACAGTTG
rs132670	ACGTTGGATGAAGGCGGGAGTTCAAGAC	ACGTTGGATGACGCCGGCTGATTGTAT
rs132671	ACGTTGGATGGTGAGGCCATACCCATCACATC	ACGTTGGATGCTGTAGTAAGGCTGGTGC
rs132672	ACGTTGGATGCTCCCCAATAAGCTAACAC	ACGTTGGATGCTGTAGGCAATGAAGGC
rs132673	ACGTTGGATGTGAGTAGTGTGGTAGTGG	ACGTTGGATGCAATGGATGAAGCTGATCCC
rs132674	ACGTTGGATGAACTGTAGTCCAGCTACTC	ACGTTGGATGTAGCTATCACTCATGCTG
rs132675	ACGTTGGATGGTAGACGACTGTGCAATGG	ACGTTGGATGTGCTAACCATCTGCTTGTG
rs80585	ACGTTGGATGTGCTTGTTCACACCTTCAC	ACGTTGGATGGGTCTGCTACTAGAATTCA
rs80586	ACGTTGGATGTTAAGTGTAAAGAAGGCTGC	ACGTTGGATGCAAGGCATAATATTCTGACC
rs132676	ACGTTGGATGCAAACATTCTGCAAGAACGG	ACGTTGGATGAAGCGTGTGCTGAGAAAATG
rs132677	ACGTTGGATGCTCTGTTAAATGAAGGG	ACGTTGGATGGCTATCTAGGCTAAACATCC
rs132678	ACGTTGGATGAAAGGCTACTGAAATGCTAG	ACGTTGGATGGGAATCCAGATGCTTACATG
rs132680	ACGTTGGATGGCCTTAGCTATCATGTTCTC	ACGTTGGATGGCGTGTAAAGGCAATTCTC
rs132681	ACGTTGGATGTACTGAAGGCTGAGACTAGC	ACGTTGGATGCTAGCAGAAACATACCGAGC
rs132683	ACGTTGGATGTTACCCATGGTAAATGGCAG	ACGTTGGATGACTGATTAGTACAGGAAGGG
rs2269594	ACGTTGGATGTGGCATGGCTAAAGGACAG	ACGTTGGATGGATTGTTCTGATGCCAGTG
rs132684	ACGTTGGATGCCTTCTAGCCATGCCATTG	ACGTTGGATGTCACTGTAACCGTGCACC
rs132685	ACGTTGGATGTCAGTGAAACGTCGCCACC	ACGTTGGATGCCCTTACGGCATGCCATTG
rs132686	ACGTTGGATGCAGAAATTCACAGTCAGGTG	ACGTTGGATGGACAGCTTAGGACTATGTGC
rs132687	ACGTTGGATGCAACTGTAAACGCCATTG	ACGTTGGATGCTGACGGTCAATGGATAC
rs132688	ACGTTGGATGAGTACTACAGGACGTGCTTG	ACGTTGGATGGGTGCGCTATATGGTAG
rs132689	ACGTTGGATGGTACTGGGACAGTCTGCTTC	ACGTTGGATGACTTACAGTGTGGAGCAG
rs132690	ACGTTGGATGTGTTGCTTGCCTCTCC	ACGTTGGATGCTGTCACCCACTTGGGG
rs132691	ACGTTGGATGTCAGGCAACGCCATTGTC	ACGTTGGATGCTGTCATCTGGAAAGGG
rs132692	ACGTTGGATGGAATCTAACCGAGCTGTTGG	ACGTTGGATGGGAGCATCATGGATTCT
rs132693	ACGTTGGATGCCAGAAGGAAAGAGTGTGG	ACGTTGGATGATTCTGCTGTGAAACGTCC
rs132694	ACGTTGGATGATAGAGACTGAGAGCTGCAG	ACGTTGGATGCAGAACAAAGCAGGAAGCTC
rs132695	ACGTTGGATGGCCTCTCTATGACTACAC	ACGTTGGATGTTACAGCAGGGACTCTTC
rs1966266	ACGTTGGATGTGATTGTAACAGGAGACCC	ACGTTGGATGTGTAAGCACCTGCTTAC
rs1966267	ACGTTGGATGTAACCTACAGGACCATGAGGG	ACGTTGGATGGGAGGAAAAGCACAGCAGAAAT
rs108808	ACGTTGGATGAAACAGGCCAGATCTCCCG	ACGTTGGATGATGGTTCTGAAAGGCACTG
rs132696	ACGTTGGATGATGGTCTCTGAAGAGCAGTG	ACGTTGGATGAACAAGGCAGATCTTCCCG
rs2239829	ACGTTGGATGTGCTCTGCTGGATGG	ACGTTGGATGAAAGAGCAGAACACTCGCTC
rs2285154	ACGTTGGATGTGAAACTGATGCCGCC	ACGTTGGATGAAAGAACCTTCTGACTGGG
rs2239830	ACGTTGGATGAAACCTTAATGGGAAGGCTC	ACGTTGGATGTTGTTGAGCAAGCAGTGTAC
rs2239831	ACGTTGGATGAGAACAGTCAGTACGCCAG	ACGTTGGATGGCTCACACACTTGTATTC
rs3865722	ACGTTGGATGCCACTGTACTGCTAGTATTG	ACGTTGGATGACCTGCTCTAGTTTCTC
rs3865723	ACGTTGGATGCCCTGCTTGTGCAATTCC	ACGTTGGATGTTCTGTTCTGCTGCTTGC
rs3985996	ACGTTGGATGACATGGCTGACCTATCAAG	ACGTTGGATGTGATTCTAGGAGCAGGACTG
rs3985997	ACGTTGGATGCAAGAAATTCTCCCGGCATC	ACGTTGGATGTGATTCTAGGAGCAGGACTG
rs3985998	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGCAAGAAATTCTCCCGGCATC
rs3985999	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGCAAGAAATTCTCCCGGCATC
rs3986000	ACGTTGGATGCCACTGTACTGCTGTTGG	ACGTTGGATGCTTCTGCTTCTCTGTGTC
rs2413382	ACGTTGGATGAAACAAATCTCTGCCTGGG	ACGTTGGATGAAAAGGCCAGAGCCCTTCATG
rs2413383	ACGTTGGATGCTGGGCTTGTGCTAAGAG	ACGTTGGATGGGCAAGTTGACCCATAAA
rs2413384	ACGTTGGATGCTGGGCTTGTGCTAAGAG	ACGTTGGATGGGCAAGTTGACCCATAAA

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs2413385	ACGTTGGATGAATGGCTTCGCTGATAACAC	ACGTTGGATGTGGAAAGCCGGTGTGATG
rs2413386	ACGTTGGATGTTTATGGGTCACCTGGCC	ACGTTGGATGTCACCGGGCTTCGCTG
rs1894606	ACGTTGGATTTATGGGTCACCTGGCC	ACGTTGGATGAGACTCTGCACAAAGCTCC
rs916336	ACGTTGGATGGGATGAGGGTATTGCTGTC	ACGTTGGATGGGCTGTATGAGGTTGAAG
rs916337	ACGTTGGATGAGATCAGAACGGCCTGTATG	ACGTTGGATGATTGCTGTGGCTGTCTC
rs916338	ACGTTGGATGATTGCTGTGGCTGTCTC	ACGTTGGATGAGATCAGAACGGCCTGTATG
rs132697	ACGTTGGATGCATGAGGAAGAGAAGTCAGG	ACGTTGGATGCACTGACTGTGACTGAGC
rs12781	ACGTTGGATGTTACACACAGGGCACTCAGC	ACGTTGGATGGAGGCCAGAAAATTACTGAAAA GC
rs1053983	ACGTTGGATGCCATCATCAAAGGCACTC	ACGTTGGATGTCCTACAGCACCTCCACTC
rs1053982	ACGTTGGATGGGAGGTGGATGCTGGTAAG	ACGTTGGATGCGGTTGAATGTCCTCCAAAG
rs2227167	ACGTTGGATGCTCTGGATGTAGGACATC	ACGTTGGATGGCATTAAAGGACATCTGC
rs2227168	ACGTTGGATGCCAATTGGAGGCATTAAAGGG	ACGTTGGATGCTCTGAGGTATGGACATC
rs132700	ACGTTGGATGAATGTTGCTGTGGCTCCAC	ACGTTGGATGCTCAGCCCTGCTGTAATGG
rs3075364	ACGTTGGATGGAACAGCCTTAGGGAGTG	ACGTTGGATGCGAACGGCTCTTATGGACTC
rs2227169	ACGTTGGATGAGGTAAAGTGTGCCCTTC	ACGTTGGATGTTCAAGGCTCATAGAGAGC
rs2097466	ACGTTGGATGCTGGGATTACAAGCATGAGC	ACGTTGGATGTCGATTAACACAGAGCTG
rs2097467	ACGTTGGATGATCTCTGCACCTTGTGATCC	ACGTTGGATGATTCTTCAGGCCGGCG
rs2413387	ACGTTGGATGAAAGTAGGGACTACAGGC	ACGTTGGATGTAACACGGTAAACCCCGTC
rs132701	ACGTTGGATGGTGGCATATCTGTGTC	ACGTTGGATGGCAGACTTCATCTCAAAA
rs132702	ACGTTGGATGGAAGCTCACCGATTAAGGA	ACGTTGGATGCCCTGTAACAACAATCTG
rs132703	ACGTTGGATGCTGGACTGATCAATGTG	ACGTTGGATGTTGTGCAAGTCTCAGAAAG
rs2269595	ACGTTGGATGAAAGTCAGGAAAGGGCC	ACGTTGGATGCCAGGACTCTCTGGGA
rs2269596	ACGTTGGATGAGGTGCTCAAGTAGCGTTC	ACGTTGGATGTCACAGGGCTCTGCTG
rs132704	ACGTTGGATGATATTCTCTGCACTGCTG	ACGTTGGATGATCTCCCCGGCTAGTTTC
rs2007468	ACGTTGGATGAGGTACCTGGCAATTCC	ACGTTGGATGAGGAAATCTCTGCTGACTGG
rs132705	ACGTTGGATGTTTGATGGGACCACTG	ACGTTGGATGTCACATGGCTACTGG
rs2007706	ACGTTGGATGCCCAAGGAAATTACATAAGGG	ACGTTGGATGTTGAACATAGCAAGAGTGAG
rs132706	ACGTTGGATGAAAGGTCAGTGTGAGGGTC	ACGTTGGATGATTCTCCCTGCTGGTACGG
rs132707	ACGTTGGATGAACTCTTGGAAAGGGCTGG	ACGTTGGATGAGCTGGCCCGTGTAGAAAC
rs132708	ACGTTGGATGCTTGTTCAGAGGGAGAGC	ACGTTGGATGTCAGCCAATCCCGAAATC
rs132709	ACGTTGGATGTGAGTCCTGTCCAAGATGAG	ACGTTGGATGAGGCCCTCTAAGGATTCTG
rs132710	ACGTTGGATGTGAGTCCTGTCCAAGATGAG	ACGTTGGATGCCCCTAAAGGATTCTGGGATTGG
rs132711	ACGTTGGATGTCATCTGGACAGGACTCG	ACGTTGGATGTTGCCATGGCAACCAAGTC
rs132712	ACGTTGGATGGCTTCAGGCTGAGTGAGC	ACGTTGGATGACTCCACGTGGCCTCTTGG
rs132713	ACGTTGGATGAAAGGCTGAGTGAGCCCCAAC	ACGTTGGATGACTCCACGTGGCCTCTT
rs132714	ACGTTGGATGACACGGTAAACCCCTTCTC	ACGTTGGATGAGTAGCTGGACTACAGGTG
rs132716	ACGTTGGATGTGGGATTGCAATGAGGAGTC	ACGTTGGATGTCAAATGACTGTGCTTACTC
rs132717	ACGTTGGATGAATGTTGGCAGTTACGTC	ACGTTGGATGGATGCCCTAGGGTTTTG
rs132718	ACGTTGGATGTCAGAGGGTATCACATCTC	ACGTTGGATGTCAGGGCTCTTCATATACGTC
rs132719	ACGTTGGATGATACTCTCACTGTTACCCAG	ACGTTGGATGCTGAACAAAGGAGAAAGGAGG
rs132720	ACGTTGGATGATACTGGTACAACGTGAGGG	ACGTTGGATGCCCTCTCCACCTTTCTCAAC
rs132721	ACGTTGGATCAGCTACAAGATGCTAAATGG	ACGTTGGATGTCATTTGTTACCCCTCCCTC
rs132722	ACGTTGGATGACAATGGTAATGCTGGAGC	ACGTTGGATGGGGAGGGTACAATAAGATG
rs132723	ACGTTGGATGACACAGATGCTGTCTCTG	ACGTTGGATGATACTCCCTGGTAAATGCT
rs132724	ACGTTGGATGCCCTATGCAACAGGGTAAA	ACGTTGGATGTTGCCCTACAGCAAGAAGC
rs132725	ACGTTGGATGCCCTATGCAACAGGGTAAA	ACGTTGGATGTCCTTACAGCAAGAAGC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132726	ACGTTGGATGGGTCAACAGTGAACAAAG	ACGTTGGATGTTCTTGCTTAAGGGACAGG
rs132727	ACGTTGGATGGGTCAACAGTGAACAAAG	ACGTTGGATGTTCTTGCTTAAGGGACAGG
rs132728	ACGTTGGATGAGTTCTACTGGCTCATGGT	ACGTTGGATGTTGCCCTTCCTGCCTT
rs132729	ACGTTGGATGAGTTCTACTGGCTCATGGT	ACGTTGGATGTTGCCCTTCCTGCCTT
rs132730	ACGTTGGATGTTGCCCTTCCTGCCTT	ACGTTGGATGAGTTCTACTGGCTCATGGT
rs132731	ACGTTGGATGTTGTCACTGTGTGACCCC	ACGTTGGATGTCCTGGCTCCAGTCTA
rs132732	ACGTTGGATGGCCAAGGCACCATCTAAC	ACGTTGGATGTCAGCTCATCACAGCGTC
rs132733	ACGTTGGATGGCCAAGGCACCATCTAAC	ACGTTGGATGTCAGCTCATCACAGCGTC
rs140575	ACGTTGGATGTCAGCTCATCACAGCGTC	ACGTTGGATGTCAGCTCATCACAGCGTC
rs132734	ACGTTGGATGGATACTGACTGTGACCTC	ACGTTGGATGCCGAATTGACCAACTGGTAG
rs132735	ACGTTGGATGGATACTGACTGTGACCTC	ACGTTGGATGCCGAATTGACCAACTGGTAG
rs80587	ACGTTGGATGTCGACCTGACCTGACCGA	ACGTTGGATGTTTCCCTGCCCAAGGGAGGAG
rs132736	ACGTTGGATGTTTCCCTGCCCAAGGGAGGAG	ACGTTGGATGAAAGCTCACAGATCAGACAG
rs132737	ACGTTGGATGTCAGGCAGCAATGAGCTAG	ACGTTGGATGTCCTCCCTGAGAAATCAC
rs132738	ACGTTGGATGTCAGGCAGCAATGAGCTAG	ACGTTGGATGTCCTCCCTGAGAAATCAC
rs1807673	ACGTTGGATGTTGCACTGAGCAGGATTG	ACGTTGGATGTTGAAATCTGAGTCGTGGTC
rs2014700	ACGTTGGATGTTGCACTGAGCAGAGATTG	ACGTTGGATGTTGAAATCTGAGTCGTGGTC
rs132739	ACGTTGGATGGGAATCAAAGAAGGTGGAGG	ACGTTGGATGTTGTTGCCCCAGACCATAA
rs1812023	ACGTTGGATGAGCAGGAGGGAGGGAGCAAT	ACGTTGGATGCCCTCCCTCCATCTCCCTTA
rs1812024	ACGTTGGATGTCAGGAGGAATGCTTCCAGT	ACGTTGGATGCTCATAGAGCATTCCTCG
rs2005590	ACGTTGGATGGAGGGCAATGCTGATTTC	ACGTTGGATGTTGCTTCCACCAACCTGGAAA
rs132740	ACGTTGGATGTTCATCTTGTGACAG	ACGTTGGATGCTTACTGGTACCTAACATG
rs3986001	ACGTTGGATGTTTCTGACTGGCATCACC	ACGTTGGATGCCAAAGTATCCACCTTCC
rs2413390	ACGTTGGATGATAAATTGTCGCTGAGCTC	ACGTTGGATGATCTGTGGCATAAGGAGTC
rs132743	ACGTTGGATGACAGGGAGAAAGTGGAGGA	ACGTTGGATGATCTGTGGCATAAGGAGTC
rs132744	ACGTTGGATGGGTCTTTCAGGAGCATG	ACGTTGGATGTCATGGCTATGGCCACAG
rs2413391	ACGTTGGATGGGCAAAAGCAGAAACTACTG	ACGTTGGATGCCCTCAAACCCCTGTTTCTG
rs132749	ACGTTGGATGGGCAAAAGCAGAAACTACTG	ACGTTGGATGTTGTCCTGGGAAATGAT
rs132750	ACGTTGGATGTCCTGTCCTGAGAAACTC	ACGTTGGATGGGTTCTCCAGTGGCAAAAG
rs132741	ACGTTGGATGCTACAATTATCCGACTAG	ACGTTGGATGCCAAAGTCAGAAAAATGAGAG
rs2413388	ACGTTGGATGTCAGAAATTGAGACCAACCC	ACGTTGGATGCCCTGAGATTGATTTTICC
rs2413389	ACGTTGGATGGCTAGAAATCTACACAGCG	ACGTTGGATGCCCTACTATGATTTGTC

TABLE 12

dbSNP rs#	Extend Primer	Term Mix
rs3888818	TGAGACCAGCCTAGCCAAC	ACT
rs2010605	TGGTCCAAGATATTCTATAGA	ACT
rs743919	CTCACCTAAGGACTGCCTCT	ACT
rs1008134	CCGGGCATCTTCTCCATC	ACT
rs132607	GCAGGCAGGACAGCATGTG	ACT
rs1476029	CTTAGAGGCTATATTAAGCCA	ACG
rs1476030	TTGGCAATACTGGCTATTG	ACT
rs2413380	TCCAGGAGGGAAAGACAACC	ACT
rs2051609	CGCTTGAGGTCAAGGACCG	CGT

dbSNP rs#	Extend Primer	Term Mix
rs2413381	GCGTGTGCCAACAGCCTC	ACT
rs1894604	AAATGGGAGGGATTTGGC	ACG
rs1894605	TGCAGATCGCAACTGAGCG	ACT
rs132609	GTTTCAGAGGATCAGGGA	ACT
rs132610	GGTGAGATTGGAGACTTT	ACG
rs132611	CTCTGTCCCTAGCCCCC	ACT
rs132612	ATCTTCCCGCTACCTCAAGAGT	ACT
rs1008790	CATAATCACAAGTCCATGATTA	ACT
rs23085	AGGATGACCATGGCAAGGAA	CGT
rs105161	GGCCCTGGCAGGAACAG	ACG
rs132613	CCAATGGCCTCCACTGGC	ACT
rs132614	CGGCCACAGCGCTGCC	ACG
rs132615	GCTTCAGAACACAGGTAGAA	ACT
rs132617	AAGAGTGTGTGAGTAGCAAG	ACG
rs3865724	TCACTTAAGCTTGAATGTTCTG	ACT
rs2019657	GCCAGAACATTGTGTTTCAATTGT	ACG
rs3865725	GGCAAGAGATAACAGATGCACA	CGT
rs2019364	GTATCTTGGCCCTGCTC	ACG
rs2008383	GAAGGACAGAAAGGCTGATGC	ACG
rs3986002	TCTTCTCTGTGTCACTCT	CGT
rs3888942	ACATGGAAGCAGGGTTGA	CGT
rs3888943	AGCAGGGGTTGATGAAATCT	ACT
rs3888944	CATCTCCACATTGGGCCAA	ACT
rs132618	AATCTCAGCTGGAAAGTGG	CGT
rs132619	TGCAACACGATTGACCG	CGT
rs3827346	GAGGCTGCACCATCTCCAA	ACG
rs132620	GGAAAGCCTTATTCAAGGATTGT	ACT
rs132621	TCAAATCTGCAACTGGTGTAGAA	ACT
rs80575	GAACCTCTAACGCCACTTGAC	ACT
rs80576	GCTAAAGCATTAGTTGGCTGG	ACG
rs80577	TGAAATTGACATGGCATTGG	ACG
rs80578	ATGCCCTGGGAACCTGGGGC	ACT
rs80579	GGGAGGGACTGAGGGCATGAAA	ACT
rs80580	CTGAGAAATGAACAGCAGGTCA	ACT
rs132622	ATAGTAGTTCAATCAGATGGGC	ACT
rs132623	ATTCAGCCCTCTGTGTTCTG	ACT
rs132624	ACAGGCATGAGCCGCTGC	ACT
rs132625	GGCCCACCGCATCCGGCTA	CGT
rs132626	AGTGGCATGATCTCGGCCCCAC	ACG
rs132627	GAGGCGGAGGGTGCCTGTG	ACT
rs1807672	CATTGAGAATAAGGTGGTTCGA	ACT
rs132628	CCTCCAAATTCAATACTGAGACC	ACG
rs132629	TCTCTCTCTCACACAC	CGT
rs132630	CTGCTCTGGCTTACAGAG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132631	TCACAGITCTGGAGGCAAAAA	ACT
rs132632	TGGAATTTCGCTCCAGAACCTGT	ACT
rs132633	AGT GATT CACCAGGGAGTCGA	ACG
rs132634	GGT GCT TTGAGGAACC	ACT
rs132635	ATTTCCCCTACATGGGGAGAAA	ACT
rs132636	TGACAATAGGCACATGGCAG	ACT
rs129603	GCTGCCATCTAAACACATCTA	ACT
rs132637	ACACAGCAGGATTACTGCCAGA	ACT
rs3788518	TGGGAGGCTAAGGAAGAACTCT	ACT
rs132638	GGAAAAATAAAAGCAAAATACCC	ACT
rs132639	AAAGCAAACAGGCCTTCAGAA	CGT
rs132640	GTTGACACAGAGAACGCTGGC	ACT
rs132641	GGGAGGTCAAGGGTCGGG	ACT
rs132642	GTC ACT TGAGAGACTTTCC	CGT
rs132643	GACACCCAGTACACACTGGCT	ACT
rs132644	TTTGGAAATGAGGAGTCATTACA	ACT
rs132645	CTCAACAGTAAGCAAGATTAAA	ACT
rs2017329	TGATGTTCA GATTTCTTTTTT	CGT
rs739198	TGGTCTCCACAA CCTCTTATC	ACT
rs132647	AAACCATGGAAAGTCTAGAGTC	ACT
rs2097465	CAAAC TCGAGGCTTCCCCAG	ACT
rs2105915	CAAGCCTGGCAGCATAGCAC	ACT
rs132648	AATTCCCGTGCTTAATGCACG	ACT
rs132649	CAGTCTTATTACTTTGTACGAGG	ACT
rs132650	CATGAGCCACCGTCCAG	ACT
rs132651	CCTCAGGGTTTCACCTGCCT	ACT
rs132652	AGGGCATCTTAACCCCCCTA	CGT
rs80584	ATCTACCTGCTCAACTTCCCTGA	ACG
rs132653	AATAACCAGACACGTTCTCCAG	ACT
rs916334	GTC CAGCAGCACCCCTGGT	ACG
rs132654	CGACAAGAGCAGGTCTGGAC	ACT
rs132655	CAGAA GAACCCACATAAGGA	ACT
rs132656	TCTTGTCTTTACTCCCACATCC	ACT
rs3834684	CACTAGAAGCAAGGAACCCCC	ACT
rs132657	TACCTGACAATCACCCCCC	CGT
rs916335	TCAGGTAAATTGTCAGTCAGCC	ACT
rs132659	AGAACTCCCCAACATCGTCT	ACG
rs132660	CCCCAGAGTGGGCTTTCT	ACT
rs132661	CCGCTCTCCCTCTGAGAGT	ACT
rs132662	TGATCTGAGTTACAGGTGAG	ACT
rs132663	TGAGATCTGCTCAGACGCA	CGT
rs132664	CTGGGCTAGAGAGGGAGAC	ACT
rs132667	CTTTAACCTTGCTCACAAGAGT	ACT
rs132670	AGACCAAGCCTGATCAACATG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132671	ACATCAATAGGCCCTAAAAATCGTT	ACT
rs132672	GAAACTTGAATTCCCTTGAGAAAT	ACT
rs132673	GTGTGAGTGGGAAGCCCTCC	ACG
rs132674	GGAGTGGAGGCTGTAGTAA	ACT
rs132675	AGATGTCAATGGAAATTGGCAA	ACT
rs80585	AGGCATAATATTGACCATTAAAG	ACG
rs80586	GGTCTGCTACTAGAAITCAGAA	ACG
rs132676	ATCCCTTAATATTGATAGGAC	CGT
rs132677	GGGTTGAAGTACTATGCTAGT	CGT
rs132678	AGGGTAGTTCATGAACTCCCAT	ACT
rs132680	TTTATTTACCTTGAGCTTTCA	ACG
rs132681	CTAGCTCTAACATCACCTCTGC	ACG
rs132683	CAGGCCATACCCAAAATATGCT	ACT
rs2269594	TGGCTAAAGGACAGATAGAG	ACT
rs132684	GACACTAAGAGCGGTGAGAC	ACT
rs132685	CGTCCACCCAACGGAGA	ACT
rs132686	TGTGCATCTTATGGTGTACCA	ACG
rs132687	TCGTTACCCCCATTCTATCC	ACT
rs132688	ACAGGACGTCCTGAAAGAG	ACG
rs132689	TGGCGATGCCCTCTGCTC	ACT
rs132690	GCTCTCTTGCTTCAAAAAAAAA	CGT
rs132691	TGACCTATCCTGCTTCAGGT	ACT
rs132692	CGAAGTGTGTTAGCTCATGAC	ACT
rs132693	GAGTGTGGACCCAGGTCA	ACT
rs132694	CACCTTAGGAATGGCAGCTTC	ACG
rs132695	TATGACTACACATGCTGGAAAC	ACT
rs1966266	GCAGACCCCTAACCTCTAATTG	ACG
rs1966267	CACTGAGTTATGAGTACTAAC	ACT
rs106808	GATCCCTCCCGAGGACACC	ACT
rs132696	CAGGCTGCCTGAAAGGAGA	ACT
rs2239829	GATGGCTGGATTCTAACAGGTA	ACT
rs2285154	AGTGTGGGATTACAGGGCAT	ACT
rs2239830	CAGTCACCTGAAATTGTGCTTATT	ACT
rs2239831	GTCACTGACCCAAGCTATCC	ACG
rs3865722	CAATTGCAAGCAACAGAAAACAGAA	CGT
rs3865723	TCCACTGTACTGCTAGTATTG	ACG
rs3985996	AGAATTTCCTCCGGCATCAG	ACG
rs3985997	TCTCCCGGCATCAGCCCTTC	ACG
rs3985998	GGGAGGAGTGACACAGAGAAAGGA	ACG
rs3985999	GGGGTACTGGGAGGTGACAC	ACT
rs3986000	GCAGGACTGGGACTG	ACT
rs2413382	CAGGGGAACCTCAGGCCACA	ACT
rs2413383	AGCCATTGAAAGACATGGAAGCC	ACT
rs2413384	ATTGAAGACATGGAAGCCGG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2413385	GGCCAGCTCTCCCTCCAC	CGT
rs2413386	CTTGGCCCAATGTGGAGGA	CGT
rs1894606	CCTAGCGGCCAAGGGCTGT	ACT
rs916336	AGGGTATTGCTGTCTGGCTGTCT	ACT
rs916337	AAGGGCCTGTATGTAGGTTGAA	ACT
rs916338	CCCTCTATGTCATGGATTTCC	ACG
rs132697	CCTAGGGGAGCCCCATATATCA	ACT
rs12781	AGACAGCTCGAGAGATCC	ACT
rs1053983	GCTGACTCAGATACACCCCC	ACG
rs1053982	GATGCTGGTAAGACAGGG	ACG
rs2227167	CGTCAAAATCAAGTGCAA	ACT
rs2227168	CATTAAGGGACATTCTGC	ACT
rs132700	ATCCCTGTCGTGTCATTGGCGTT	ACT
rs3075364	GTTTAGGGAGGGTTTTGAAAG	CGT
rs2227169	TGTCCTTATTGGTACAGGGGAA	ACT
rs2097466	TACAAGCATGAGCCACCGC	ACT
rs2097467	TCCCAAAGTGCTGGGATTACA	ACT
rs2413387	TACAGGCACTCACCACAC	ACT
rs132701	TGTACAAAACATATTAAACCTGA	ACT
rs132702	CACCCAGTTAGGGAAAAATTCT	ACT
rs132703	GATCAATGTCGTGTCGGGA	ACT
rs2269595	GCCCCAGACAGCATCTCC	ACT
rs2269596	TTGCTGGCAAGAGACCAAGG	ACT
rs132704	GGGCTGCCTGGAGGAGG	ACG
rs2007468	TGGGCAATTCAGCCACACGCAC	ACT
rs132705	TATAGACTGAATTGTCGCC	ACG
rs2007706	GGAATTTACATAAGGGCTATAG	ACT
rs132706	GAACCCCCTCACTGCCC	ACT
rs132707	GCTCTCCCTCTGAAAACAAGATG	ACT
rs132708	GAGAGCTTCTCTGGCC	ACT
rs132709	CAGGGAAAGATTAGAACGCTGAGAC	CGT
rs132710	GGGCAAGGAAGATTAGAACG	ACG
rs132711	TTTGTGTCAGGGCGGC	ACG
rs132712	AACCCAGACGGAGGTGGC	ACG
rs132713	GCCCCAACGGAACCCAGA	ACG
rs132714	CCCCTTCTACTGAAAATACAAA	ACT
rs132716	TGAGGAGTCATTACCATGAG	ACG
rs132717	GCAGTTTACGTGAAGGGAGG	ACT
rs132718	GTTTTATACCTAGGCCACACT	ACT
rs132719	TACCCAGTATTCTTAACCTCC	CGT
rs132720	CAGCTACAAAGTTGCTAATGG	ACT
rs132721	ATGTTAGGAAAAGGTGGAGAG	ACT
rs132722	CCTAACTGGGATGGGCCTGAA	ACT
rs132723	TTCTGGGGCCCCCATGCA	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132724	ACCCAGTCCTGGGCAGCA	ACT
rs132725	GGGAGTATGCAGAGGGC	ACT
rs132726	CAGTGAACAAAGCAGGAAGAAGG	ACT
rs132727	GTCACACAGTGAAACAAAGCAGGAA	ACT
rs132728	CATGGTGTGAGATGGTTGCC	ACG
rs132729	GCTCATGGTGTGAGATGGTT	ACT
rs132730	GTGACCCCCTAGGCCAAGGCA	ACT
rs132731	GGCAACCATCTAACACCAT	ACT
rs132732	AACCATCTAACACCATGAGCCA	ACT
rs132733	ATCTCAACACCATGAGGCCAG	ACT
rs140575	GCTCTCTCTGGTCCTCC	ACG
rs132734	AGCCTCAACTAGGACACA	ACT
rs132735	TCAACTAGGACACAGTGC	ACT
rs80587	GCCAAAGCTCACCAAGATGCCAGA	ACT
rs132736	AGGGAGCTGCTTGTGAAA	ACT
rs132737	CCTGCAGCCTGGGTGACA	ACT
rs132738	GGCCAGGAGTTCAAGACAGCCTG	ACT
rs1807673	GGGCAACAGAGCGAGACTCC	ACT
rs2014700	GAGCGAGACTCCATCTCA	ACT
rs132739	GGGAGGTGACCTGGAGCC	ACG
rs1812023	GCAATCAGACTCAAGCCTGG	ACT
rs1812024	GGGATGGTGTGACCTCCC	ACG
rs2005590	CAATGCCCTGATTITGTCACTGAAAC	ACT
rs132740	GGCATATGTGCATTTGTCTGAG	ACG
rs3986001	TCCCTTTCTAAACCCCTGCAA	ACT
rs2413390	GGCTGAGCTCAAGGTTTAAA	ACT
rs132743	GGAGAAAGTGAGGAAGAAAATTA	ACT
rs132744	TGGGGTTTACAGTTGGTCATAACC	ACT
rs2413391	TGATATGTTCAGCGGTGCACT	ACT
rs132749	TCTTGATTTCTCCATATCCC	ACG
rs132750	CCTGTGAAAATCAGCAGC	ACG
rs132741	GCACTAGATATTGAATTCTTCC	ACT
rs2413388	CAACCCCGTGACTGGAGATTC	CGT
rs2413389	TTTCTCTCTAGTACTCTATT	ACT

Genetic Analysis

[0229] Allelotyping results from the discovery cohort are shown for cases and controls in Table 13. The allele frequency for the A2 allele is noted in the fifth and sixth columns for osteoarthritis case pools and control pools, respectively, where “AF” is allele frequency. The allele frequency for the A1 allele can be easily calculated by subtracting the A2 allele frequency from 1 (A1 AF = 1-A2 AF). For example, the SNP rs2010605 has the following case and control allele frequencies: case A1 (A) = 0.19; case A2

(G) = 0.81; control A1 (A) = 0.18; and control A2 (G) = 0.82, where the nucleotide is provided in parenthesis. Some SNPs are labeled “untyped” because of failed assays.

TABLE 13

dbSNP rs#	Position In SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.81	0.82	0.782
rs743919	1095	34782445	G/T	0.10	0.11	0.502
rs1008134	2201	34783551	A/C			
rs132807	7879	34789229	A/G	0.11	0.11	0.813
rs1476029	8395	34789745	C/T	0.15	0.15	0.983
rs1476030	8461	34789811	C/T	0.36	0.37	0.708
rs2413380	9503	34790853	C/T	0.29	0.29	0.900
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.08	0.08	0.759
rs1894605	16444	34797794	G/T	0.08	0.09	0.468
rs132609	17591	34798941	C/T	0.68	0.67	0.777
rs132610	17988	34799338	-A			
rs132611	19116	34800466	-T	0.14	0.15	0.863
rs132612	19358	34800708	C/T	0.23	0.23	0.951
rs1008790	20300	34801650	A/G	0.03	0.10	0.007
rs23085	20669	34802019	A/T	0.31	0.32	0.738
rs105161	20891	34802241	A/G	0.76	0.77	0.826
rs132613	21451	34802801	C/T	0.80	0.81	0.619
rs132614	21978	34803328	C/T	0.16	0.14	0.434
rs132615	22785	34804135	C/G	0.32	0.31	0.740
rs132617	24248	34805598	C/T	0.35	0.36	0.825
rs3865724	24770	34806120	C/T	0.65	0.65	0.940
rs2019657	24844	34806194	A/G	0.20	0.20	0.857
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.40	0.39	0.767
rs2008383	25309	34806659	A/G	0.18	0.17	0.665
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.43	0.43	0.934
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.84	0.84	0.976
rs132620	29648	34810998	-A	0.29	0.29	0.879
rs132621	29986	34811336	A/G	0.32	0.31	0.867
rs80575	30217	34811567	G/T	0.27	0.27	0.948
rs80576	30267	34811617	A/G	0.26	0.25	0.443
rs80577	30315	34811665	A/G	0.26	0.23	0.191
rs80578	30585	34811935	C/T	0.49	0.48	0.548
rs80579	30724	34812074	A/C	0.23	0.25	0.574
rs80580	30897	34812247	C/T	0.31	0.31	0.878
rs132622	30931	34812281	C/T	0.29	0.30	0.943
rs132623	31080	34812430	G/T	0.60	0.59	0.806
rs132624	31246	34812596	C/T	0.36	0.37	0.772
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.89	0.84	0.082
rs132627	31467	34812817	A/G	0.12	0.11	0.836
rs1807672	32188	34813538	G/T	0.30	0.30	0.974
rs132628	32288	34813638	C/T	0.25	0.24	0.691
rs132629	32520	34813870	A/T	0.04	0.06	0.250

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132630	32594	34813944	A/C	0.75	0.75	0.978
rs132631	32657	34814007	A/C	0.72	0.73	0.509
rs132632	32677	34814027	A/G	0.66	0.65	0.798
rs132633	32764	34814114	C/T	0.34	0.33	0.796
rs132634	32784	34814134	A/G	0.45	0.42	0.317
rs132635	32830	34814180	C/T	0.41	0.40	0.772
rs132636	32872	34814222	C/T	0.41	0.44	0.192
rs129603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.09	0.09	0.628
rs3788518	33952	34815302	C/G	0.17	0.19	0.297
rs132638	34184	34815534	C/G	0.56	0.56	0.509
rs132639	34361	34815711	A/T	0.13	0.12	0.561
rs132640	35026	34816376	A/G	0.32	0.30	0.388
rs132641	35192	34816542	A/G	0.48	0.51	0.287
rs132642	35600	34816950	A/T	0.15	0.14	0.732
rs132643	36033	34817383	C/T	0.44	0.46	0.360
rs132644	36289	34817639	C/T	0.53	0.58	0.075
rs132645	38869	34820219	A/G	0.19	0.18	0.572
rs2017329	39629	34820979	A/T	0.39	0.40	0.915
rs739198	40530	34821880	C/T	0.70	0.70	0.878
rs132647	41621	34822971	C/T	0.23	0.23	0.957
rs2097465	42379	34823729	C/T	0.54	0.51	0.344
rs2105915	42802	34824152	C/T	0.57	0.56	0.468
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.21	0.22	0.579
rs132650	45051	34826401	C/T	0.34	0.31	0.248
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs80584	46257	34827607	C/T	0.81	0.75	0.043
rs132653	47286	34828636	A/C	0.17	0.15	0.312
rs916334	47427	34828777	C/T	0.34	0.36	0.345
rs132654	47963	34829313	C/T	0.54	0.56	0.439
rs132655	48013	34829363	C/T	0.41	0.41	0.838
rs132656	48229	34829579	C/T	0.37	0.36	0.813
rs3834684	48282	34829632	-A	0.21	0.22	0.480
rs132657	48376	34829726	-G	0.49	0.50	0.719
rs916335	48404	34829754	A/G	0.38	0.36	0.509
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.37	0.38	0.754
rs132661	52897	34834247	A/G	0.27	0.29	0.291
rs132662	53414	34834764	A/G	0.61	0.58	0.186
rs132663	53487	34834837	A/T	0.26	0.29	0.167
rs132664	54112	34835462	G/T	0.25	0.29	0.098
rs132667	55492	34836842	A/G	0.35	0.36	0.559
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.49	0.53	0.145
rs132672	60701	34842051	A/G	0.23	0.22	0.716
rs132673	60952	34842302	A/G	0.41	0.37	0.184
rs132674	61401	34842751	C/T	0.32	0.31	0.476
rs132675	62379	34843729	C/T	0.38	0.35	0.188
rs80585	62870	34844220	C/T	0.28	0.27	0.525
rs80586	62879	34844229	A/G	0.66	0.66	0.966
rs132676	63499	34844849	A/T	0.26	0.23	0.177
rs132677	64284	34845634	-A	0.69	0.69	0.873
rs132678	64408	34845758	A/G	0.46	0.48	0.395
rs132680	64760	34846110	A/G	0.20	0.20	0.995
rs132681	65230	34846580	A/G	0.24	0.24	0.901

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132683	66127	34847477	A/G	0.19	0.19	0.851
rs2269594	66634	34847984	C/T	0.70	0.67	0.332
rs132684	66686	34848036	A/G	0.21	0.20	0.756
rs132685	66694	34848044	C/G	0.30	0.28	0.553
rs132686	67113	34848463	A/G	0.46	0.48	0.398
rs132687	67257	34848607	A/G	0.96	0.96	0.767
rs132688	67403	34848753	A/G	0.24	0.23	0.553
rs132689	67609	34848959	A/G	0.61	0.63	0.564
rs132690	68418	34849768	-A	0.16	0.17	0.672
rs132691	68610	34849960	C/G	0.52	0.52	0.976
rs132692	69629	34850979	C/T	0.63	0.62	0.800
rs132693	70024	34851374	A/G	0.58	0.58	0.868
rs132694	70848	34852198	A/G	0.17	0.16	0.583
rs132695	71428	34852778	C/G	0.23	0.22	0.616
rs1966266	71553	34852903	C/T	0.49	0.47	0.413
rs1966267	71633	34852983	A/G	0.40	0.41	0.773
rs106808	71768	34853118	A/C	0.68	0.67	0.617
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.34	0.36	0.510
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.49	0.50	0.841
rs2239831	73547	34854897	C/T	0.52	0.50	0.564
rs3865722	73769	34855119	A/T	0.57	0.56	0.861
rs3865723	73806	34855156	A/G	0.59	0.58	0.722
rs3985996	74467	34855817	C/T	0.30	0.29	0.861
rs3985997	74472	34855822	C/T	0.89	0.90	0.527
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.19	0.19	0.968
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.61	0.59	0.618
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.70	0.944
rs2413386	74723	34856073	A/T	0.70	0.71	0.816
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			
rs916338	74893	34856243	C/T	0.40	0.40	0.939
rs132697	75176	34856526	A/G	0.59	0.61	0.418
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.42	0.43	0.848
rs1053982	76027	34857377	A/G	0.69	0.69	0.981
rs2227167	77949	34859299	A/G	0.35	0.37	0.392
rs2227168	77974	34859324	C/T	0.38	0.38	0.797
rs132700	78167	34859517	C/T	0.25	0.25	0.729
rs3075364	78310	34859660	-C/T	0.42	0.42	0.879
rs2227169	78415	34859765	C/T	0.38	0.37	0.619
rs2097466	78575	34859925	C/T	0.52	0.52	0.962
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.23	0.951
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T	0.52	0.52	0.995
rs2269595	81320	34862670	A/G	0.19	0.18	0.464
rs2269596	81409	34862759	C/T	0.40	0.40	0.753
rs132704	81737	34863087	C/T	0.65	0.66	0.906
rs2007468	81843	34863193	A/G	0.40	0.40	0.987

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132705	82102	34863452	C/T	0.30	0.30	0.944
rs2007706	82833	34864183	C/T	0.32	0.32	0.944
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.26	0.28	0.540
rs132708	83660	34865010	C/G	0.30	0.29	0.506
rs132709	83701	34865051	A/T	0.45	0.46	0.538
rs132710	83708	34865058	A/G	0.62	0.60	0.310
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.84	0.84	0.693
rs132713	85717	34867067	A/G	0.29	0.30	0.911
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.48	0.49	0.647
rs132718	87234	34868584	A/G	0.68	0.69	0.453
rs132719	87479	34868829	G/T	0.59	0.54	0.078
rs132720	87561	34868911	A/G	0.12	0.13	0.607
rs132721	87604	34868954	A/G	0.73	0.73	0.919
rs132722	87674	34869024	C/T	0.22	0.22	0.985
rs132723	87958	34869308	A/G	0.03	NA	0.033
rs132724	87992	34869342	-/G	0.12	0.12	0.830
rs132725	88019	34869369	A/G	0.69	0.64	0.097
rs132726	88074	34869424	C/G	0.10	0.13	0.240
rs132727	88079	34869429	C/G	0.68	0.67	0.865
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.37	0.38	0.656
rs132734	88340	34869690	A/G	0.46	0.44	0.522
rs132735	88344	34869694	G/T	0.85	0.85	0.781
rs80587	88512	34869862	C/G	0.40	0.42	0.493
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.32	0.33	0.824
rs132738	88827	34870177	C/T	0.78	0.80	0.327
rs1807673	89230	34870580	A/G	0.28	0.28	0.969
rs2014700	89236	34870586	A/G	0.89	0.92	0.036
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.70	0.70	0.997
rs1812024	91110	34872460	A/G	0.68	0.69	0.755
rs2005590	92026	34873376	C/T	0.71	0.73	0.252
rs132740	92954	34874304	C/T	0.09	0.08	0.370
rs3986001	93375	34874725	-/TTGC	0.51	0.54	0.302
rs2413390	93794	34875144	C/T	0.37	0.41	0.103
rs132743	94937	34876287	C/G	0.07	0.07	0.985
rs132744	95068	34876418	C/T	0.73	0.78	0.078
rs2413391	96188	34877538	A/G	0.39	0.40	0.938
rs132749	97092	34878442	C/T	0.47	0.50	0.329
rs132750	98812	34880162	C/T	0.67	0.67	0.710
rs132741	not mapped	not mapped	A/C	0.29	0.30	0.608
rs2413388	not mapped	not mapped	A/T	0.31	0.31	0.967
rs2413389	not mapped	not mapped	C/G	0.30	0.28	0.393

[0230] The *APOL3* proximal SNPs were also allelotyped in the replication cohorts using the methods described herein and the primers provided in Tables 11 and 12. The replication allelotyping results for replication cohort #1 and replication cohort #2 are provided in Tables 14 and 15, respectively.

TABLE 14

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.79	0.80	0.664
rs743919	1095	34782445	G/T	0.11	0.11	0.982
rs1008134	2201	34783551	A/C			
rs132607	7879	34789229	A/G	0.10	0.11	0.589
rs1476029	8395	34789745	C/T	0.16	0.13	0.177
rs1476030	8461	34789811	C/T	0.33	0.38	0.149
rs2413380	9503	34790853	C/T	0.26	0.30	0.174
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.07	0.08	0.476
rs1894605	16444	34797794	G/T	0.07	0.09	0.269
rs132609	17591	34798941	C/T	0.68	0.67	0.687
rs132610	17988	34799338	-/A			
rs132611	19116	34800466	-/T	0.14	0.14	0.992
rs132612	19358	34800708	C/T	0.22	0.22	0.799
rs1008790	20300	34801650	A/G	0.03	0.06	0.358
rs23085	20669	34802019	A/T	0.31	0.30	0.868
rs105161	20891	34802241	A/G	0.75	0.80	0.058
rs132613	21451	34802801	C/T	0.82	0.81	0.725
rs132614	21978	34803328	C/T	0.15	0.15	0.914
rs132615	22785	34804135	C/G	0.32	0.32	0.885
rs132617	24248	34805598	C/T	0.36	0.37	0.706
rs3865724	24770	34806120	C/T	0.66	0.64	0.473
rs2019657	24844	34806194	A/G	0.21	0.21	0.898
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.41	0.39	0.480
rs2008383	25309	34806659	A/G	0.17	0.16	0.721
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.42	0.45	0.522
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.85	0.84	0.703
rs132620	29648	34810998	-/A	0.29	0.28	0.917
rs132621	29986	34811336	A/G	0.32	0.31	0.864
rs80575	30217	34811567	G/T	0.27	0.27	0.909
rs80576	30267	34811617	A/G	0.30	0.22	0.007
rs80577	30315	34811665	A/G	0.24	0.23	0.853
rs80578	30585	34811935	C/T	0.49	0.49	0.884
rs80579	30724	34812074	A/C	0.24	0.25	0.761
rs80580	30897	34812247	C/T	0.30	0.30	0.815
rs132622	30931	34812281	C/T	0.29	0.28	0.884
rs132623	31080	34812430	G/T	0.62	0.63	0.633
rs132624	31246	34812596	C/T	0.36	0.35	0.769
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.92	NA	NA
rs132627	31467	34812817	A/G	0.10	0.10	0.844
rs1807672	32188	34813538	G/T	0.29	0.29	0.954

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132628	32288	34813638	C/T	0.24	0.25	0.796
rs132629	32520	34813870	A/T	0.03	0.06	0.345
rs132630	32594	34813944	A/C	0.75	0.72	0.388
rs132631	32657	34814007	A/C	0.70	0.77	0.017
rs132632	32677	34814027	A/G	0.67	0.63	0.275
rs132633	32764	34814114	C/T	0.34	0.32	0.558
rs132634	32784	34814134	A/G	0.44	0.41	0.435
rs132635	32830	34814180	C/T	0.39	NA	0.409
rs132636	32872	34814222	C/T	0.42	0.46	0.179
rs129603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.08	0.10	0.462
rs3788518	33952	34815302	C/G	0.19	0.19	0.855
rs132638	34184	34815534	C/G	0.54	0.60	0.114
rs132639	34361	34815711	A/T	0.13	0.09	0.153
rs132640	35026	34816376	A/G	0.31	0.32	0.767
rs132641	35192	34816542	A/G	0.46	0.53	0.074
rs132642	35600	34816950	A/T	0.16	0.12	0.101
rs132643	36033	34817383	C/T	0.42	0.48	0.081
rs132644	36289	34817639	C/T	0.50	0.62	-0.0001
rs132645	38869	34820219	A/G	0.21	0.15	0.027
rs2017329	39629	34820979	A/T	0.40	0.38	0.737
rs739198	40530	34821880	C/T	0.74	NA	0.697
rs132647	41621	34822971	C/T	0.21	0.24	0.430
rs2097465	42379	34823729	C/T	0.54	0.52	0.670
rs2105915	42802	34824152	C/T	0.57	0.55	0.582
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.20	0.23	0.213
rs132650	45051	34826401	C/T	0.36	0.29	0.033
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs80584	46257	34827607	C/T	0.81	0.75	0.043
rs132653	47286	34828636	A/C	0.18	0.13	0.060
rs916334	47427	34828777	C/T	0.32	0.38	0.064
rs132654	47963	34829313	C/T	0.55	0.54	0.769
rs132655	48013	34829363	C/T	0.42	0.39	0.390
rs132656	48229	34829579	C/T	0.38	0.35	0.429
rs3834684	48282	34829632	-A	0.21	0.23	0.416
rs132657	48376	34829726	-G	0.47	0.53	0.089
rs916335	48404	34829754	A/G	0.39	0.33	0.153
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.39	0.36	0.227
rs132661	52897	34834247	A/G	0.25	0.31	0.086
rs132662	53414	34834764	A/G	0.63	0.57	0.083
rs132663	53487	34834837	A/T	0.25	0.31	0.051
rs132664	54112	34835462	G/T	0.23	0.29	0.037
rs132667	55492	34836842	A/G	0.34	0.32	0.546
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.49	0.55	0.041
rs132672	60701	34842051	A/G	0.24	0.20	0.211
rs132673	60952	34842302	A/G	0.40	0.36	0.284
rs132674	61401	34842751	C/T	0.32	0.29	0.453
rs132675	62379	34843729	C/T	0.38	0.33	0.178
rs80585	62870	34844220	C/T	0.29	0.24	0.164
rs80586	62879	34844229	A/G	0.65	0.69	0.212
rs132676	63499	34844849	A/T	0.26	0.20	0.034
rs132677	64284	34845634	-A	0.69	0.72	0.438
rs132678	64408	34845758	A/G	0.48	0.50	0.572

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132680	64760	34846110	A/G	0.20	0.18	0.429
rs132681	65230	34846580	A/G	0.25	0.22	0.362
rs132683	66127	34847477	A/G	0.19	0.17	0.449
rs2269594	66634	34847984	C/T	0.70	0.65	0.234
rs132684	66686	34848036	A/G	0.21	0.18	0.349
rs132685	66694	34848044	C/G	0.30	0.28	0.528
rs132686	67113	34848463	A/G	0.46	0.50	0.207
rs132687	67257	34848607	A/G	0.95	0.98	0.217
rs132688	67403	34848753	A/G	0.26	0.23	0.367
rs132689	67609	34848959	A/G	0.60	0.63	0.353
rs132690	68418	34849768	-A	0.16	0.15	0.901
rs132691	68610	34849960	C/G	0.51	0.53	0.573
rs132692	69629	34850979	C/T	0.62	0.64	0.566
rs132693	70024	34851374	A/G	0.58	0.62	0.227
rs132694	70848	34852198	A/G	0.17	0.14	0.195
rs132695	71428	34852778	C/G	0.24	0.22	0.560
rs1966266	71553	34852903	C/T	0.49	0.46	0.389
rs1966267	71633	34852983	A/G	0.40	0.43	0.304
rs1066808	71768	34853118	A/C	0.66	0.70	0.243
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.34	0.38	0.264
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.49	NA	0.490
rs2239831	73547	34854897	C/T	0.52	0.48	0.254
rs3865722	73769	34855119	A/T	0.57	0.56	0.739
rs3865723	73806	34855156	A/G	0.58	0.57	0.819
rs3985996	74467	34855817	C/T	0.30	0.31	0.799
rs3985997	74472	34855822	C/T	0.88	0.89	0.941
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.20	0.20	0.871
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.61	0.58	0.311
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.68	0.509
rs2413386	74723	34856073	A/T	0.71	0.70	0.807
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			
rs916338	74893	34856243	C/T	0.41	0.39	0.465
rs132697	75176	34856526	A/G	0.58	0.63	0.101
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.41	0.45	0.301
rs1053982	76027	34857377	A/G	0.66	0.66	0.959
rs2227167	77949	34859299	A/G	0.35	0.39	0.313
rs2227168	77974	34859324	C/T	0.39	0.35	0.234
rs132700	78167	34859517	C/T	0.26	0.24	0.652
rs3075364	78310	34859660	-CT	0.42	0.45	0.287
rs2227169	78415	34859765	C/T	0.40	0.36	0.293
rs2097466	78575	34859925	C/T	0.52	0.49	0.376
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.21	0.499
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T	0.52	0.52	0.995
rs2269595	81320	34862670	A/G	0.20	0.17	0.210
rs2269596	81409	34862759	C/T	0.42	0.37	0.172

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132704	81737	34863087	C/T	0.64	0.67	0.398
rs2007468	81843	34863193	A/G	0.39	0.42	0.354
rs132705	82102	34863452	C/T	0.29	0.28	0.834
rs2007706	82833	34864183	C/T	0.29	0.27	0.546
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.26	0.29	0.252
rs132708	83660	34865010	C/G	0.29	0.28	0.584
rs132709	83701	34865051	A/T	0.46	0.47	0.748
rs132710	83708	34865058	A/G	0.62	0.60	0.477
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.82	0.82	0.984
rs132713	85717	34867067	A/G	0.31	0.33	0.416
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.48	NA	NA
rs132718	87234	34868584	A/G	0.67	0.71	0.237
rs132719	87479	34868829	G/T	0.56	0.52	0.254
rs132720	87561	34868911	A/G	0.12	0.14	0.416
rs132721	87604	34868954	A/G	0.72	0.71	0.626
rs132722	87674	34869024	C/T	0.23	0.24	0.791
rs132723	87958	34869308	A/G	NA	NA	
rs132724	87992	34869342	-G	0.12	0.12	0.830
rs132725	88019	34869369	A/G	0.60	NA	0.691
rs132726	88074	34869424	C/G	0.09	0.15	0.103
rs132727	88079	34869429	C/G	0.68	0.66	0.536
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.43	0.44	0.792
rs132734	88340	34869690	A/G	0.45	0.41	0.263
rs132735	88344	34869694	G/T	0.83	0.82	0.629
rs80587	88512	34869862	C/G	0.42	0.47	0.152
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.33	0.35	0.631
rs132738	88827	34870177	C/T	0.74	0.79	0.131
rs1807673	89230	34870580	A/G	0.30	0.32	0.583
rs2014700	89236	34870586	A/G	0.85	0.90	0.043
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.70	NA	0.704
rs1812024	91110	34872460	A/G	0.66	0.68	0.563
rs2005590	92026	34873376	C/T	0.72	0.75	0.268
rs132740	92954	34874304	C/T	0.10	0.06	0.085
rs3986001	93375	34874725	-TTGC	0.49	0.53	0.341
rs2413390	93794	34875144	C/T	0.35	0.40	0.143
rs132743	94937	34876287	C/G	0.06	0.05	0.608
rs132744	95068	34876418	C/T	0.72	0.78	0.069
rs2413391	96188	34877538	A/G	0.37	0.39	0.544
rs132749	97092	34878442	C/T	0.48	0.51	0.311
rs132750	98812	34880162	C/T	0.65	0.67	0.678
rs132741	not mapped	not mapped	A/C	0.28	0.30	0.509
rs2413388	not mapped	not mapped	A/T	0.32	0.32	0.908
rs2413389	not mapped	not mapped	C/G	0.32	0.29	0.480

TABLE 15

dbSNP rs#	Position in SEQ ID NO: I	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.84	0.84	0.924
rs743919	1095	34782445	G/T	0.08	0.11	0.294
rs1008134	2201	34783551	A/C			
rs132607	7879	34789229	A/G	0.13	0.10	0.297
rs1476029	8395	34789745	C/T	0.13	0.18	0.126
rs1476030	8461	34789811	C/T	0.40	0.35	0.214
rs2413380	9503	34790853	C/T	0.33	0.28	0.163
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.09	0.08	0.726
rs1894605	16444	34797794	G/T	0.09	0.09	0.834
rs132609	17591	34798941	C/T	0.67	0.67	0.950
rs132610	17988	34799338	-A			
rs132611	19116	34800466	-T	0.14	0.15	0.749
rs132612	19358	34800708	C/T	0.23	0.24	0.780
rs1008790	20300	34801650	A/G	untyped	0.16	NA
rs23085	20669	34802019	A/T	0.32	0.35	0.395
rs105161	20891	34802241	A/G	0.78	0.71	0.037
rs132613	21451	34802801	C/T	0.78	0.82	0.245
rs132614	21978	34803328	C/T	0.17	0.13	0.167
rs132615	22785	34804135	C/G	0.31	0.30	0.691
rs132617	24248	34805598	C/T	0.35	0.35	0.862
rs3865724	24770	34806120	C/T	0.64	0.67	0.384
rs2019657	24844	34806194	A/G	0.17	0.18	0.745
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.38	0.39	0.702
rs2008383	25309	34806659	A/G	0.18	0.18	0.853
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.44	0.40	0.330
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.84	0.85	0.568
rs132620	29648	34810998	-A	0.30	0.31	0.665
rs132621	29986	34811336	A/G	0.32	0.32	0.955
rs80575	30217	34811567	G/T	0.26	0.27	0.812
rs80576	30267	34811617	A/G	0.22	0.29	0.024
rs80577	30315	34811665	A/G	0.27	0.21	0.072
rs80578	30585	34811935	C/T	0.50	0.46	0.263
rs80579	30724	34812074	A/C	0.22	0.24	0.639
rs80580	30897	34812247	C/T	0.32	0.32	0.976
rs132622	30931	34812281	C/T	0.30	0.32	0.701
rs132623	31080	34812430	G/T	0.57	0.52	0.224
rs132624	31246	34812596	C/T	0.36	0.39	0.393
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.86	0.84	0.723
rs132627	31467	34812817	A/G	0.14	0.12	0.672
rs1807672	32188	34813538	G/T	0.31	0.31	0.940
rs132628	32288	34813638	C/T	0.26	0.23	0.307
rs132629	32520	34813870	A/T	0.05	0.07	0.493
rs132630	32594	34813944	A/C	0.76	0.80	0.269
rs132631	32657	34814007	A/C	0.74	0.67	0.058
rs132632	32677	34814027	A/G	0.64	0.68	0.316
rs132633	32764	34814114	C/T	0.33	0.34	0.757

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132634	32784	34814134	A/G	0.45	0.43	0.574
rs132635	32830	34814180	C/T	0.42	-0.01	
rs132636	32872	34814222	C/T	0.40	0.40	0.856
rs132603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.09	0.09	0.882
rs3788518	33952	34815302	C/G	0.15	0.19	0.133
rs132638	34184	34815534	C/G	0.58	0.55	0.324
rs132639	34361	34815711	A/T	0.13	0.16	0.210
rs132640	35026	34816376	A/G	0.34	0.28	0.075
rs132641	35192	34816542	A/G	0.49	0.47	0.539
rs132642	35600	34816950	A/T	0.14	0.19	0.079
rs132643	36033	34817383	C/T	0.47	0.45	0.565
rs132644	36289	34817639	C/T	0.57	0.51	0.156
rs132645	38869	34820219	A/G	0.17	0.23	0.076
rs2017329	39629	34820979	A/T	0.39	0.42	0.531
rs739198	40530	34821880	C/T	0.64	0.05	
rs132647	41621	34822971	C/T	0.25	0.22	0.339
rs2097465	42379	34823729	C/T	0.54	0.50	0.311
rs2105915	42802	34824152	C/T	0.58	0.56	0.667
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.21	0.19	0.471
rs132650	45051	34826401	C/T	0.31	0.34	0.365
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs680584	46257	34827607	C/T			
rs132653	47286	34828636	A/C	0.15	0.18	0.404
rs916334	47427	34828777	C/T	0.36	0.33	0.383
rs132654	47963	34829313	C/T	0.53	0.60	0.090
rs132655	48013	34829363	C/T	0.39	0.44	0.150
rs132656	48229	34829579	C/T	0.36	0.39	0.507
rs3834684	48282	34829632	-A	0.21	0.21	0.956
rs132657	48376	34829726	-G	0.51	0.45	0.112
rs916335	48404	34829754	A/G	0.36	0.40	0.245
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.33	0.41	0.044
rs132661	52897	34834247	A/G	0.29	0.27	0.624
rs132662	53414	34834764	A/G	0.59	0.59	0.998
rs132663	53487	34834837	A/T	0.27	0.26	0.792
rs132664	54112	34835462	G/T	0.28	0.28	0.934
rs132667	55492	34836842	A/G	0.36	0.42	0.054
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.50	0.49	0.839
rs132672	60701	34842051	A/G	0.21	0.25	0.297
rs132673	60952	34842302	A/G	0.42	0.40	0.525
rs132674	61401	34842751	C/T	0.33	0.32	0.909
rs132675	62379	34843729	C/T	0.38	0.36	0.722
rs80585	62870	34844220	C/T	0.27	0.30	0.405
rs80586	62879	34844229	A/G	0.68	0.62	0.113
rs132676	63499	34844849	A/T	0.25	0.27	0.442
rs132677	64284	34845634	-A	0.69	0.64	0.147
rs132678	64408	34845758	A/G	0.43	0.45	0.620
rs132680	64760	34846110	A/G	0.19	0.23	0.258
rs132681	65230	34846580	A/G	0.23	0.28	0.201
rs132683	66127	34847477	A/G	0.19	0.21	0.493
rs2269594	66634	34847984	C/T	0.68	0.69	0.866
rs132684	66686	34848036	A/G	0.21	0.24	0.487
rs132685	66694	34848044	C/G	0.29	0.29	0.888

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132686	67113	34848463	A/G	0.45	0.44	0.708
rs132687	67257	34848607	A/G	0.96	0.93	0.210
rs132688	67403	34848753	A/G	0.22	0.23	0.917
rs132689	67609	34848959	A/G	0.63	0.62	0.839
rs132690	68418	34849768	-A	0.16	0.19	0.295
rs132691	68610	34849960	C/G	0.53	0.50	0.441
rs132692	69629	34850979	C/T	0.64	0.59	0.223
rs132693	70024	34851374	A/G	0.57	0.52	0.191
rs132694	70848	34852198	A/G	0.17	0.20	0.413
rs132695	71428	34852778	C/G	0.23	0.23	0.928
rs1966266	71553	34852903	C/T	0.49	0.49	0.881
rs1966267	71633	34852983	A/G	0.41	0.38	0.400
rs106808	71768	34853118	A/C	0.71	0.63	0.030
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.35	0.33	0.665
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.51	-0.02	
rs2239831	73547	34854897	C/T	0.51	0.53	0.577
rs3865722	73769	34855119	A/T	0.56	0.57	0.887
rs3865723	73806	34855156	A/G	0.61	0.60	0.837
rs3985996	74467	34855817	C/T	0.30	0.27	0.501
rs3985997	74472	34855822	C/T	0.89	0.92	0.287
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.18	0.17	0.691
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.60	0.62	0.642
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.72	0.433
rs2413386	74723	34856073	A/T	0.70	0.72	0.510
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			.
rs916338	74893	34856243	C/T	0.39	0.43	0.334
rs132697	75176	34856526	A/G	0.60	0.57	0.463
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.43	0.39	0.279
rs1053982	76027	34857377	A/G	0.74	0.74	0.852
rs2227167	77949	34859299	A/G	0.35	0.35	0.998
rs2227168	77974	34859324	C/T	0.38	0.42	0.226
rs132700	78167	34859517	C/T	0.25	0.25	0.989
rs3075364	78310	34859660	-C/T	0.41	0.37	0.252
rs2227169	78415	34859765	C/T	0.36	0.38	0.520
rs2097466	78575	34859925	C/T	0.52	0.57	0.255
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.27	0.255
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T			
rs2269595	81320	34862670	A/G	0.18	0.19	0.672
rs2269596	81409	34862759	C/T	0.39	0.43	0.258
rs132704	81737	34863087	C/T	0.67	0.64	0.391
rs2007468	81843	34863193	A/G	0.41	0.37	0.247
rs132705	82102	34863452	C/T	0.32	0.33	0.785
rs2007706	82833	34864183	C/T	0.36	0.41	0.226
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.27	0.26	0.598

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs132708	83660	34865010	C/G	0.31	0.30	0.754
rs132709	83701	34865051	A/T	0.43	0.45	0.627
rs132710	83708	34865058	A/G	0.63	0.60	0.482
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.87	0.86	0.667
rs132713	85717	34867067	A/G	0.28	0.24	0.293
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.47	0.49	0.533
rs132718	87234	34868584	A/G	0.68	0.66	0.705
rs132719	87479	34868829	G/T	0.62	0.57	0.223
rs132720	87561	34868911	A/G	0.12	0.11	0.727
rs132721	87604	34868954	A/G	0.75	0.77	0.495
rs132722	87674	34869024	C/T	0.21	0.20	0.630
rs132723	87958	34869308	A/G			
rs132724	87992	34869342	-/G			
rs132725	88019	34869369	A/G	0.69	0.00	
rs132726	88074	34869424	C/G	0.12	0.10	0.509
rs132727	88079	34869429	C/G	0.68	0.70	0.583
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.30	0.29	0.903
rs132734	88340	34869690	A/G	0.47	0.49	0.571
rs132735	88344	34869694	G/T	0.88	0.90	0.595
rs80587	88512	34869862	C/G	0.37	0.33	0.365
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.31	0.29	0.686
rs132738	88827	34870177	C/T	0.82	0.81	0.773
rs1807673	89230	34870580	A/G	0.26	0.23	0.356
rs2014700	89236	34870586	A/G	0.93	0.96	0.324
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.71	-0.01	
rs1812024	91110	34872460	A/G	0.70	0.70	0.888
rs2005590	92026	34873376	C/T	0.69	0.70	0.719
rs132740	92954	34874304	C/T	0.08	0.09	0.442
rs3986001	93375	34874725	-/TTGC	0.53	0.55	0.563
rs2413390	93794	34875144	C/T	0.40	0.43	0.365
rs132743	94937	34876287	C/G	0.07	0.09	0.436
rs132744	95068	34876418	C/T	0.74	untyped	
rs2413391	96188	34877538	A/G	0.43	0.41	0.611
rs132749	97092	34878442	C/T	0.47	0.48	0.858
rs132750	98812	34880162	C/T	0.70	0.67	0.285
rs132741	not mapped	not mapped	A/C	0.30	0.30	0.999
rs2413388	not mapped	not mapped	A/T	0.30	0.30	0.989
rs2413389	not mapped	not mapped	C/G	0.28	0.26	0.555

[0231] Allelotyping results were considered particularly significant with a calculated p-value of less than or equal to 0.05 for allelotype results. These values are indicated in bold. The allelotyping p-values were plotted in Figure 1 for the discovery cohort. The position of each SNP on the chromosome is presented on the x-axis. The y-axis provides the negative logarithm (base 10) of the p-value comparing

the estimated allele in the case group to that of the control group. The minor allele frequency of the control group for each SNP designated by an X or other symbol on the graph in Figure 1 can be determined by consulting Table 13. For example, the left-most X on the left graph is at position 34781551. By proceeding down the Table from top to bottom and across the graphs from left to right the allele frequency associated with each symbol shown can be determined.

[0232] To aid the interpretation, multiple lines have been added to the graph. The broken horizontal lines are drawn at two common significance levels, 0.05 and 0.01. The vertical broken lines are drawn every 20kb to assist in the interpretation of distances between SNPs. Two other lines are drawn to expose linear trends in the association of SNPs to the disease. The light gray line (or generally bottom-most curve) is a nonlinear smoother through the data points on the graph using a local polynomial regression method (W.S. Cleveland, E. Grosse and W.M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole.). The black line provides a local test for excess statistical significance to identify regions of association. This was created by use of a 10kb sliding window with 1kb step sizes. Within each window, a chi-square goodness of fit test was applied to compare the proportion of SNPs that were significant at a test wise level of 0.01, to the proportion that would be expected by chance alone (0.05 for the methods used here). Resulting p-values that were less than 10^{-8} were truncated at that value.

[0233] The exons and introns of the genes in the covered region are plotted below each graph at the appropriate chromosomal positions. The gene boundary is indicated by the broken horizontal line. The exon positions are shown as thick, unbroken bars. An arrow is placed at the 3' end of each gene to show the direction of transcription.

Example 5

In Vitro Production of Target Polypeptides

[0234] cDNA is cloned into a pIVEX 2.3-MCS vector (Roche Biochem) using a directional cloning method. A cDNA insert is prepared using PCR with forward and reverse primers having 5' restriction site tags (in frame) and 5-6 additional nucleotides in addition to 3' gene-specific portions, the latter of which is typically about twenty to about twenty-five base pairs in length. A Sal I restriction site is introduced by the forward primer and a Sma I restriction site is introduced by the reverse primer. The ends of PCR products are cut with the corresponding restriction enzymes (*i.e.*, Sal I and Sma I) and the products are gel-purified. The pIVEX 2.3-MCS vector is linearized using the same restriction enzymes, and the fragment with the correct sized fragment is isolated by gel-purification. Purified PCR product is ligated into the linearized pIVEX 2.3-MCS vector and *E. coli* cells transformed for plasmid amplification. The newly constructed expression vector is verified by restriction mapping and used for protein production.

[0235] *E. coli* lysate is reconstituted with 0.25 ml of Reconstitution Buffer, the Reaction Mix is reconstituted with 0.8 ml of Reconstitution Buffer; the Feeding Mix is reconstituted with 10.5 ml of Reconstitution Buffer; and the Energy Mix is reconstituted with 0.6 ml of Reconstitution Buffer. 0.5 ml of the Energy Mix was added to the Feeding Mix to obtain the Feeding Solution. 0.75 ml of Reaction Mix, 50 μ l of Energy Mix, and 10 μ g of the template DNA is added to the *E. coli* lysate.

[0236] Using the reaction device (Roche Biochem), 1 ml of the Reaction Solution is loaded into the reaction compartment. The reaction device is turned upside-down and 10 ml of the Feeding Solution is loaded into the feeding compartment. All lids are closed and the reaction device is loaded into the RTS500 instrument. The instrument is run at 30°C for 24 hours with a stir bar speed of 150 rpm. The pIVEX 2.3 MCS vector includes a nucleotide sequence that encodes six consecutive histidine amino acids on the C-terminal end of the target polypeptide for the purpose of protein purification. Target polypeptide is purified by contacting the contents of reaction device with resin modified with Ni²⁺ ions. Target polypeptide is eluted from the resin with a solution containing free Ni²⁺ ions.

Example 6

Cellular Production of Target Polypeptides

[0237] Nucleic acids are cloned into DNA plasmids having phage recombination sites and target polypeptides are expressed therefrom in a variety of host cells. Alpha phage genomic DNA contains short sequences known as attP sites, and *E. coli* genomic DNA contains unique, short sequences known as attB sites. These regions share homology, allowing for integration of phage DNA into *E. coli* via directional, site-specific recombination using the phage protein Int and the *E. coli* protein IHF. Integration produces two new att sites, L and R, which flank the inserted prophage DNA. Phage excision from *E. coli* genomic DNA can also be accomplished using these two proteins with the addition of a second phage protein, Xis. DNA vectors have been produced where the integration/excision process is modified to allow for the directional integration or excision of a target DNA fragment into a backbone vector in a rapid *in vitro* reaction (Gateway™ Technology (Invitrogen, Inc.)).

[0238] A first step is to transfer the nucleic acid insert into a shuttle vector that contains attL sites surrounding the negative selection gene, ccdB (e.g. pENTER vector, Invitrogen, Inc.). This transfer process is accomplished by digesting the nucleic acid from a DNA vector used for sequencing, and to ligate it into the multicloning site of the shuttle vector, which will place it between the two attL sites while removing the negative selection gene ccdB. A second method is to amplify the nucleic acid by the polymerase chain reaction (PCR) with primers containing attB sites. The amplified fragment then is integrated into the shuttle vector using Int and IHF. A third method is to utilize a topoisomerase-mediated process, in which the nucleic acid is amplified via PCR using gene-specific primers with the 5'

upstream primer containing an additional CACC sequence (e.g., TOPO® expression kit (Invitrogen, Inc.)). In conjunction with Topoisomerase I, the PCR amplified fragment can be cloned into the shuttle vector via the attL sites in the correct orientation.

[0239] Once the nucleic acid is transferred into the shuttle vector, it can be cloned into an expression vector having attR sites. Several vectors containing attR sites for expression of target polypeptide as a native polypeptide, N-fusion polypeptide, and C-fusion polypeptides are commercially available (e.g., pDEST (Invitrogen, Inc.)), and any vector can be converted into an expression vector for receiving a nucleic acid from the shuttle vector by introducing an insert having an attR site flanked by an antibiotic resistant gene for selection using the standard methods described above. Transfer of the nucleic acid from the shuttle vector is accomplished by directional recombination using Int, IHF, and Xis (LR clonase). Then the desired sequence can be transferred to an expression vector by carrying out a one hour incubation at room temperature with Int, IHF, and Xis, a ten minute incubation at 37°C with proteinase K, transforming bacteria and allowing expression for one hour, and then plating on selective media. Generally, 90% cloning efficiency is achieved by this method. Examples of expression vectors are pDEST 14 bacterial expression vector with att7 promoter, pDEST 15 bacterial expression vector with a T7 promoter and a N-terminal GST tag, pDEST 17 bacterial vector with a T7 promoter and a N-terminal polyhistidine affinity tag, and pDEST 12.2 mammalian expression vector with a CMV promoter and neo resistance gene. These expression vectors or others like them are transformed or transfected into cells for expression of the target polypeptide or polypeptide variants. These expression vectors are often transfected, for example, into murine-transformed an adipocyte cell line 3T3-L1, (ATCC), human embryonic kidney cell line 293, and rat cardiomyocyte cell line H9C2.

Nucleotide and Amino Acid Sequence Embodiments

[0240] Table A includes information pertaining to the incident polymorphic variant associated with osteoarthritis identified herein. Public information pertaining to the polymorphism and the genomic sequence that includes the polymorphism are indicated. The genomic sequences identified in Table A may be accessed at the http address www.ncbi.nih.gov/entrez/query.fcgi, for example, by using the publicly available SNP reference number (e.g., rs132659). The chromosome position refers to the position of the SNP within NCBI's Genome Build 34, which may be accessed at the following http address: www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr=hum_chr.inf&query=. The "Contig Position" provided in Table A corresponds to a nucleotide position set forth in the contig sequence (see "Contig Accession No."), and designates the polymorphic site corresponding to the SNP reference number. The sequence containing the polymorphisms also may be referenced by the "Nucleotide Accession No." set forth in Table A. The "Sequence Identification" corresponds to cDNA sequence that

encodes associated target polypeptides (e.g., APOL3) of the invention. The position of the SNP within the cDNA sequence is provided in the “Sequence Position” column of Table A. If the SNP falls within an exon, the corresponding amino acid position (and amino acid change, if applicable) is provided as well. Also, the allelic variation at the polymorphic site and the allelic variant identified as associated with osteoarthritis is specified in Table A. All nucleotide and polypeptide sequences referenced and accessed by the parameters set forth in Table A are incorporated herein by reference.

Table A

RS_ID	Chromosome	Chrom Position	Contig Accession No. [1]	Contig Position	Nucleotide Accession No. [2]	Sequence Position	Amino Acid Position	Locus	Locus ID	A [3]	Allelic Variability	OA Associate
rs132659	22	34831250	Hs22_11677_349	15897265	NM_014349	mma-utr		APOL3	80833	F	IC/TI	C

[1] Contig Accession Number which can be found in the NCBI Database:
http address: www.ncbi.nlm.nih.gov/entrez/query.fcgi

[2] Sequence Identification or Nucleotide Accession Number which can be found in the NCBI Database:
http address: www.ncbi.nlm.nih.gov/entrez/query.fcgi

[3] "A" column is the sequence orientation ("F" is forward, "R" is reverse).

[0241] The following is a genomic nucleotide sequence for an *APOL3* region. The following nucleotide representations are used throughout: "A" or "a" is adenosine, adenine, or adenylic acid; "C" or "c" is cytidine, cytosine, or cytidylic acid; "G" or "g" is guanosine, guanine, or guanylic acid; "T" or "t" is thymidine, thymine, or thymidylic acid; and "I" or "i" is inosine, hypoxanthine, or inosinic acid. Exons are indicated in italicized lower case type, introns are depicted in normal text lower case type, and polymorphic sites are depicted in bold upper case type. SNPs are designated by the following convention: "R" represents A or G, "M" represents A or C; "W" represents A or T; "Y" represents C or T; "S" represents C or G; "K" represents G or T; "V" represents A, C or G; "H" represents A, C, or T; "D" represents A, G, or T; "B" represents C, G, or T; and "N" represents A, G, C, or T.

APOE Genomic Sequence (SEQ ID NO: 1)

>22:34781351=34880400

4321 gggtgcattt agccaaatgc atgcatttcg actccagctt gggggata ggcgactct
4381 gtctaaaaaa acaaacaatc acaaaacaaa caatctataa ctatatatcat atctatcat
4441 ctatctatct atctatctat ctatctatct atctatataa agcagacagc atgtccacat
4501 ttcctcaagg tgacccttc ttcttaacat cagaacttc ttttttcta catggggat
4561 ttcccacact tttaaatcg aitgaagaca gagtaagctt tcctcttta cttggccacga
4621 gggccagggg ttgtctgtt ctcttcact acatccccgg caccctagacc catggccgg
4681 gtacccatc taggagcttc gtaatattt tgagggaaat caaatccca ctgttccaga
4741 atgaggcttc agactgcctt lgaacggcgc cagttttttc agtgggtttt acttcagttt
4801 gttcaaatat tcaatattt tttttttttt tttttttttt tttttttttt tttttttttt
4861 ccaggcttgc gtgcagtagc gtgatcttcg tcggctact gcaacactca cttccgttgg
4921 tcaggcgatt ctcttcgttc agcctccaa tgatgtggg tcataaagcat ggcacccac
4981 acctggctaa tattttttt tttttttttt atacagggtt tcaccatgtt ggtcaggctg
5041 gtctcaaat actgccttc aatgtatcc tcgtccatgtt ctccgaatgtt gctgggatca
5101 caggcggttg tcaccggcc tgccctccaga tttttttttt tcaacgatgtt tggttgaatgt
5161 tttttttttt agatataat gtgtatgtt tagaaaaaaag aattttttttt tttttttttt
5221 ccaagtagt ggcactacag tgccccacca ccatggcttg tttttttttt tttttttttt
5281 agagacaagg tttttacatc tgccggccgg tttttttttt tttttttttt tttttttttt
5341 acccttcgtt gctttccaaa tgctgtttttt tagaggatgtt agccacccaca ctggccaaaa
5401 ttattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
5461 ctatattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
5521 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
5581 gggtaaaaaa cataacatctt agatgtttt aattttttttt tttttttttt tttttttttt
5641 ctactgttat ctactttttt agatgtttt aactggggcc acagggtttt aatgttccatc
5701 tcaacccccc atgtatgtt agttttttt ccaggatgtt aacttcagag cttttttttt
5761 taatcacagc taatgtttttt ccaggatgtt tactttttt gcaatgtatc taatgttca
5821 caaggcaact gtgataaaaa aatgtatccaa gcctttttaa ggtttttttt taaggcagact
5881 gtgcacatc cacaatccatgg aacacatccaa acaacacgca cggaaatggacttattttt
5941 cacacatgg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6001 agatgtttt actctatgtt gttttttttt tttttttttt tttttttttt tttttttttt
6061 caccatgggtt gggatgtttt ccaggatgtt ccgtttttttt tttttttttt tttttttttt
6121 caggcgatt ttccgtttttt gttttttttt tttttttttt tttttttttt tttttttttt
6181 cccaggcttaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6241 tttttttttt gacccaaat gttttttttt tttttttttt tttttttttt tttttttttt
6301 gctgtttttt ccgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6361 gaaggccggaa agatgtttt aatgtttttt tttttttttt tttttttttt tttttttttt
6421 aacccggccat cttccgtttt gttttttttt tttttttttt tttttttttt tttttttttt
6481 atagatgtttt aatgtttttt aatgtttttt tttttttttt tttttttttt tttttttttt
6541 aatgtttttt ggtttttttt ggtttttttt tttttttttt tttttttttt tttttttttt
6601 tttttttttt atatgtttt aatgtttttt tttttttttt tttttttttt tttttttttt
6661 tttttttttt aatgtttttt tttttttttt tttttttttt tttttttttt tttttttttt
6721 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6781 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6841 ctctgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6901 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
6961 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7021 atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7081 atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7141 ctatctttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7201 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7261 atatgtttt gggatgtttt tttttttttt tttttttttt tttttttttt tttttttttt
7321 caacatggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7381 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7441 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7501 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7561 aatgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7621 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7681 aatctttttt gggccacccccc tttttttttt tttttttttt tttttttttt tttttttttt
7741 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7801 atatgtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7861 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7921 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
7981 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
8041 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
8101 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

8161 atctttcaca ttcaatttag aaaaatggca gatgttaatg tttttctgt taagagataa
8221 ttcttttta aaatgttgtt ttttttttc cccttactat gcctagtctc gctttttata
8281 tgataacaacg cttaggttg aaagaatgag agtttgggtg acagagatcc ttacatttga
8341 atctcaattt cacttagagg ctatgttcat gacttaggg ctatattaag accaYttaga
8401 ggctatggc atgacccgtg gtccgttcc ctgaggcttca ctgcctcaga ctaatcatac
8461 Ygaataggcc agtattgtcca aatcccagtg cttaggttgg gattaatgag aaaaacattt
8521 ccaaaaaacc tagtatacc tgttaatac ctgacacgtg gttaggttgc aataatgtat
8581 actatgtat tttttttt attttttt tttttttt ttgagacccg gtcttactt
8641 gtcacccagg cttaggtgca gaggcggtat ttgcacttac tgcacccctt accttctggg
8701 ttcaaatgt tctccgttcc gggcccccc agtagtggg ataaacaggcg tqtgcccacc
8761 cactggcta attttttat ttttagataa gacagggtt caccatgtg gccaggctgg
8821 ttctgaaactc ctgacccatcg gtatccggc ttccctcagcc tcccaaaatgt ctgagatatac
8881 agttgtgagc caccacccgt gtcaatcaat tgatgtatct tgtaataaac aatttgcattt
8941 cactaaaggd tttaaatgtg tgatccctt atagtgctt acaaacaatc tcttgcattt
9001 cagcacgtt gcttatatac gccaggatgt ttgcaggatgt gctgcataa aaaaacaaggcc
9061 cttaggtctg gcaaggccgg tcacgcgttgc atcccaacgaa ctttggaggg ccgaggccgg
9121 cgatccatcctt gaggatgttgc ttgttgcacca agctgttgcac acgttgtgaa cccctgttcc
9181 tttttttttt tcaaaatgtt cccggatgg ttgtgtatgc ctgtatgtt achtatgttgg
9241 gaggtgtggg caggagaatc gcttgcaccc gggagggtgg gcttgcgtg agccaaatgc
9301 gcccattgtc actccacgtt ggcttactat agggcaaccc tggctcaaa aaaaaaaacaa
9361 aactaaacaa aaaaaaaa caaaaaaaa aaaaaaaa aaaaaacccaa aaaaacccaa aaaaacaa
9421 cccgatctca ttgttgcacca acaggaaagg ctatctttt ctacgcgttac atgtccatca
9481 tggggcagggtt gctctctgc tcygggttgc ttccctcttgc gactcgtatc catggagca
9541 ccattttctt gaaatgttgc ttgttgcacca gtatggaaaa agggttctt atacgcattc
9601 atttgttgc tttagatgttgc acatatttca ttccatca aacttctt gtcagaatgt
9661 gtttacat tcccaacccaa ccataaaggag accaggaaaga ataatccca tttgttgcatt
9721 gaaggggaa aaggccacaa aatgttgcacca acaggccggc tgacttaccc cacagtgtt
9781 ttggaaaaaccctt ctggccagag ccagaaggat gggaggatc catggcgttgc ggaggaaagg
9841 agaaggccaa gggggatgttgc gaggccggc ggttgcgttgc atggaggggc atccatctt
9901 gttcaatgtt cagggttggg cccaggatggaa ggttgcgttgc tttttccatc ttgacccaga
9961 cccacacgaa ccccccggcc atttccgttgc tgccggaaac aaggccatgttcc ctttttttgc
10021 tgccgttgc acgggttccatc tgatggatgttgc ggttgcgttgc ggacgcgttgc tttttttt
10081 gttttttttt ttggagacggg gttttttttt gttttttttt gttttttttt gttttttttt
10141 ctgggttgcat tgccgttccgg cttttttttt gttttttttt gttttttttt gttttttttt
10201 ttctgttca gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
10261 ttctgttca tttagtacaga cttttttttt gttttttttt gttttttttt gttttttttt
10321 ggatccggcc cggccggcc tcccaaaatgttgc ttccatca gttttttttt gttttttttt
10381 ggccacggcc ttgttttttgc ttggacccatc ttccatgc gttttttttt gttttttttt
10441 ttcccttgc tccacccctc cggccgttgc gttttttttt gttttttttt
10501 gtgttccaa ctggccctt ctggccctt cttttttttt gttttttttt gttttttttt
10561 ggtttttgtt cttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
10621 caaggccggcc ggttgcgttgc gggccggcc gttttttttt gttttttttt gttttttttt
10681 ccccttgggtt ctggatgttgc ttgttgcacac gttttttttt gttttttttt gttttttttt
10741 atcgacggcc tcaaaatgttgc tgccggatgttgc ttgttgcgttgc gttttttttt
10801 ttgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
10861 ttcttccgg accttccctc cggccacaaatgttgc ttgttgcgttgc gttttttttt
10921 ccctcatccc cgtttttttt ccccaacccatc ttcatccatc ttgttgcgttgc gttttttttt
10981 tagccggggc aggccgttgc gttttttttt gttttttttt gttttttttt gttttttttt
11041 ggagacatca ctggaggatc gttttttttt gttttttttt gttttttttt gttttttttt
11101 ctcttactttaa aatccatccaa tttagtgcgttgc ttgttgcgttgc gttttttttt
11161 tgggggggtt ggggttgggg aatccgttgc acccggggatc gttttttttt gttttttttt
11221 gatgttgcgtt ctgcacttcc gttttttttt gttttttttt gttttttttt gttttttttt
11281 aaaaatgttgc tcaaaatgttgc ttgttgcgttgc gttttttttt gttttttttt
11341 tgatgttgc tcccttccgg ctggacgggtt gttttttttt gttttttttt gttttttttt
11401 cactcatgttcc tcaaggatc gttttttttt gttttttttt gttttttttt gttttttttt
11461 tcgttgcgttcc ttgttgcgttgc gttttttttt gttttttttt gttttttttt
11521 ggcttactttaa acacccgttgc ttgttgcgttgc gttttttttt gttttttttt
11581 taatgttgc tcaaggatc gttttttttt gttttttttt gttttttttt gttttttttt
11641 cttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
11701 aggttgcgttcc gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
11761 agtgcggccaa ggttgcgttgc tccatccatc ttgttgcgttgc gttttttttt
11821 gaaatgttgc gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
11881 tgcgttgcgttcc atacacccaa gttttttttt gttttttttt gttttttttt gttttttttt
11941 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt

23521 atgttaccc acaaataaacc actttcaaaa attttgttta tgatcatacc tcctaactca
23581 cagacttta ggtctggaa tttcagtatc taagggtgc aaaagtgtt tcagcagaaa
23641 ccatacgcc cttagtcatgc tccccatgtt agggtatgc atgacgtcac tgggttgat
23701 ataactcgtc atcatgttcc tccaggaaag ctcatgtgt tattacacag caggacagga
23761 ggaattgagg gatccccatg gattgtcctc tgaataactc taaaatgtt gatgtlal
23821 gtaaatgtt attagaaattt tcaccaactt actgaggccca gaccatcaag gagcttgcac
23881 accacgagaa tgacttgc cataaataag aggaacatctt atgtgaaatc ttcaagactt
23941 ctgtatgtt cagcaatgtt ctagatggc tttagccctt accgttaccc ttatatttt
24001 acaaataatac acacacaaaa attctgagac aagaatgtcc aatgtgaccaaa aaaaaaaaaatt
24061 gatctgtgc tgaggccctc ctccctgtac ataacttcg catgcagaaat gtggagatgc
24121 tggtgttgc ttcatctggg aaaggccat gtgcatttgc ttttttttt gggatgttgc
24181 gttcatatc agataaaggag agttttttt gtttgtatga gaagaagagt tggtgtcag
24241 tagcaaygg tgtagtgc aacaatgttcc caaatgggg tggctgttgg gcccaggatgt
24301 tcccatagg gttttgttgc ttgttacccccc tccccatcc ctataccata gcttcaactg
24361 ttatgttgc aagacttgc aacccaaatgttcc atttctgtca ctgtatgtt gaaactttt
24421 tcagagacat tggaaatca aatgttgc gtaaaatggc gtcaggccat gtgcaggccat gccccttggaa
24481 gggcaaaatc tatattccctt atgttgcgg tttgttgc tttgttgc tttgttgc
24541 gattttgttgc ttcttcat ctcttcgtt gttttttt tttttttt tttttttt
24601 ttgtttaaag acatgttgc ttgttgc tttttttt tttttttt tttttttt
24661 attcacggatc cagtttgc gttttttt tttttttt tttttttt tttttttt
24721 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
24781 caaacttgc ttgttgc gttttttt tttttttt tttttttt tttttttt
24841 acaaataatc aaaaatggc tttttttt tttttttt tttttttt tttttttt
24901 ctttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
24961 gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
25021 ctgggggtcc ttatcgtatc attttttt tttttttt tttttttt tttttttt
25081 ctgttgcggcc tttttttt tttttttt tttttttt tttttttt tttttttt
25141 aataatgttca aatattttttt tttttttt tttttttt tttttttt tttttttt
25201 ggcccccctt tttttttt tttttttt tttttttt tttttttt tttttttt
25261 ggagggttccctt atggcccccac tttttttt tttttttt tttttttt tttttttt
25321 ctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
25381 aaaaaatccatc tttttttt tttttttt tttttttt tttttttt tttttttt
25441 agcagccatc attttttttt tttttttt tttttttt tttttttt tttttttt
25501 ctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
25561 ctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
25621 aactttttt tttttttt tttttttt tttttttt tttttttt tttttttt
25681 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
25741 ctcttattttt tttttttt tttttttt tttttttt tttttttt tttttttt
25801 ctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
25861 gggccaaatcc agatgttcc tttttttt tttttttt tttttttt tttttttt
25921 gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
25981 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26041 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26101 aaaaatggccatc tttttttt tttttttt tttttttt tttttttt tttttttt
26161 acctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
26221 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26281 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26341 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26401 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26461 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26521 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26581 acctgttgc tttttttt tttttttt tttttttt tttttttt tttttttt
26641 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26701 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26761 aaaaatggccatc tttttttt tttttttt tttttttt tttttttt tttttttt
26821 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26881 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
26941 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
27001 gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
27061 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
27121 aaaaatggccatc tttttttt tttttttt tttttttt tttttttt tttttttt
27181 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
27241 gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
27301 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt

27361 tcagtcctt cttttccctgg cttttcattt gctgttgttt gcacacccttc cctcttattcc
27421 tcccccaat atattcgta gctaaaga aattttctt tcttattttt cacaactcc
27481 agtcctctt cttccctttt ccacggctt acgatcttcg cttttccctt ggtgcacttgt
27541 ccatacgat taacccttc ctgttgctc tgatctac agatggcca gtcataaca
27601 ctacgtcca taaaatctt ccgtccctt ttatccccctt aataaaatgc ctgcattttt
27661 tcgttgctc tgatgttgc acctccctt ctggctgtc tggtttttt gtcgttgtt
27721 tggcatgtt ctagacgtc atagatgttgc ctggatgttca tgatgtttt ctccaggatcc
27781 tgagtcgtcc gccttcgtc ctcacagat gcagactttt ccccttcatg caagtgttt
27841 gactctata caagggtac cacatccatg gcaaggaga tgccgttgaat ggctgcactt
27901 aggatccggg ctccctgt ctacggccc gtggccgtc ctgcgtttt ctctgttgta
27961 ccwccactt cagctgatg tgccgggtt gtcacaggta gtcggggcc ggtctgttgt
28021 tgcctgtt cagggatc accttcattt gttttgtttt ctgcgttata attataaaga
28081 agggaaaatg atgggtgtt gatgttcacg aataacttcc taaaatccctt caakcggtt
28141 atgtgtttt cagtcgttct gtcgttgc gttttgtgtt atgtgtttt tgagtgtcc
28201 acgtctgtt tgggtatccc agtcacacg gacgtgttc gggcccttc cccaggatgtca
28261 gtaaggccca gacttttttcc tgctgttataal gttggccaaa caacaggccc aagggtgtt
28321 atggccaggg caggcccaat gggctgtcc accacccatg gttttttttt gcttctgtgt
28381 acctttcaaa tacccatgg aaggggccatg acgttttttca tggttttttcc gatcccttcc
28441 ttgtatggg gaaatctt taaaacccat tcccttaaat gtcctttttt gtcgttccat
28501 tattctgtt caatagctgc atatgttta acgttttttca ggtttttttt gaggcttgc gagagcatc
28561 gcttcattt tgatccata aaggacatg gatagaagg ggcaggctat tttatctatg
28621 aatagctca aatagatctt ttccatataat atcacagac tttttttttt tttttttttt
28681 aaataaaggat ttaatittt aatggaaaaaa tttttttttt tttttttttt gttttttttt
28741 tttttttttat catatgtatcc cccacatgt tttttttttt tttttttttt gggataaaaaa aacttttttt
28801 catcttcga tgcttttttgg tgatgttttttcat gttatggaaa tgctgtttcc acgaagaggat
28861 gtcacatca tcccttttttcaat gttgttgg gaggggaaaat tttttttttt gttttttttt
28921 agtgggttccg gagaaaaaaag acctttatcc agaggatcat agaaacatgtt aggttttttt
28981 ttatagaaag agatgtttt cttttttttt gttttttttt gggggggggat cttttttttt
29041 ggaatgtttt cttttttttt gggggggggat cttttttttt tttttttttt gttttttttt
29101 tagcaatgtt atgggtgtt gtttttttttcat gtttttttttcat tttttttttt
29161 aactggggaa taagggtttt gtttttttttcat gtttttttttcat gttttttttt
29221 ggacatgtt tgatccatcc ccaggaaagat gtttttttttcat gtttttttttcat
29281 attttttttttcat gggccaaaat ctttttttttcat gtttttttttcat gttttttttt
29341 acettccatg cccatccatg gtttttttttcat gtttttttttcat gtttttttttcat
29401 ccaaggcaat tagggggggat ctttttttttcat gtttttttttcat gtttttttttcat
29461 cggtttttttcc ccccttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29521 aaaccccccaat ttcttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29581 gtttttttttcat attttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29641 ctgttacatca atcccttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29701 taacttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29761 gagaacacag ctttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29821 ctgttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29881 tcgtcaata acatgttttcat gtttttttttcat gtttttttttcat gtttttttttcat
29941 gtggggggat aagaacaaaccat ttttttttttcat gtttttttttcat gtttttttttcat
30001 gagatctgtt ttgttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30061 gagatccat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30121 tggatggccat tggggggccat gtttttttttcat gtttttttttcat gtttttttttcat
30181 agtttttttcat gcaatgttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30241 gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30301 ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30361 acttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30421 attagaaaaaaat ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30481 ttacccatgtt gggccatcat gtttttttttcat gtttttttttcat gtttttttttcat
30541 tacttttttcat agaaacaaaggat gtttttttttcat gtttttttttcat gtttttttttcat
30601 catgttttttcat gggaaaaatc cccatccatg ctttttttttcat gtttttttttcat
30661 caggggggat aaaaatatttccat gtttttttttcat gtttttttttcat gtttttttttcat
30721 ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30781 ctttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30841 cccgttacatc ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30901 ctgttttttcat attttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
30961 ggatggatgtt caggggggatc ttttttttttcat gtttttttttcat gtttttttttcat
31021 acagggccat gatccatccat gtttttttttcat gtttttttttcat gtttttttttcat
31081 tgatccatca ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat
31141 ggacatcatc ttttttttttcat gtttttttttcat gtttttttttcat gtttttttttcat

31201 aaagtccctgc tgggcatcca actctaagaas aaacacttgg tcggggYgcag cggctcatgc
31261 ctgttaatccc agcaccccttg gaggcccagg cgggaggatc acggaggtag gagatcaagg
31321 ccattcttggc taacacatgt aaacccttcgt tgactaaaa atacaaaaaaa aaWtagcccg
31381 atgcgggtgc cggagctgtg agtccccgtc actttggagg ctggggcagg aqaatggcg
31441 gaacccggga ggccggaggtt gcRgtLrgcc gagatcatgc cactgcactc cagctgggg
31501 gacaagcaag actctgtctc aaaaaaaaaa aaaaaaagaaa aaaaaaagaaa aaaaaaagaaa
31561 aacacttttgc tccatggctt cttcccaagca atctttttaa aaggtaacat taacgagca
31621 cttccatgtg tgcaatgtt atgtcaataatc ctttacatgc attactttt ttictctcaca
31681 ataagaatcta atggatgaag aaaggaaaggc agaaatgtg caatgtqctt qcaaactcc
31741 catcaccatgt agatggcaga actgaccctg ccccttggtgg ctcccttcc cttcagctgg
31801 aggtcaatctc ctggccatggc agggacttgg ggaatatttc ctccctgact gctgagagg
31861 acatcttcaatgttccatggc gggggcttgc tgggggggggtt gtgcctyccca gagaaaaacta
31921 gcccaggggaa gatcaggatggc gatcaggccgg gggcccccattt ggaggtaacc ccacgggg
31981 tactctggca attcacggccg agtcaatggcgtt cttccatggc atgtcggcagg
32041 attcacatgt gatcgggtt gactcttcc cggaaatgtt tggggccctt ttcaatgg
32101 ctgttttttcttacttggaa aaaaaaaagca taatgttgg aaaaaatgtg ctacacatca
32161 aatggcattatgttggatggtggcgtt taatcttccctt caacccatgtg tcacatgggg
32221 tattttttgttggggatcaatgttggatggatggatggatggatggatggatggatggatggatgg
32281 tgagaccfata aaccccaatgttggatggatggatggatggatggatggatggatggatggatgg
32341 taaaagatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
32401 aaaaagggcggc aagaatgttggatggatggatggatggatggatggatggatggatggatgg
32461 tgccctccatggc eccttcttcccttgcgttcttcttcttcttcttcttcttcttcttcttctt
32521 cac
32581 agccctggggcagmMtcgtt aacccggggcggcggcggcggcggcggcggcggcggcggcggc
32641 gacccatccatgttggggatggatggatggatggatggatggatggatggatggatggatggatgg
32701 ccacccatgttggggatggatggatggatggatggatggatggatggatggatggatggatggatgg
32761 ccacccatgttggggatggatggatggatggatggatggatggatggatggatggatggatggatgg
32821 tccacccatgttggggatggatggatggatggatggatggatggatggatggatggatggatggatgg
32881 tggtatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
32941 gttatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33001 atatcagatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33061 atataataatataatataatataatataatataatataatataatataatataatataatataatata
33121 Mtagatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatggat
33181 gctgtatccatggatggatggatggatggatggatggatggatggatggatggatggatggatggat
33241 aaggtacaaaatgttggatggatggatggatggatggatggatggatggatggatggatggatggat
33301 atatcagatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggat
33361 aaatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33421 gtatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33481 tgcggggcttcatggatggatggatggatggatggatggatggatggatggatggatggatggatggat
33541 caccacccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggat
33601 tatt
33661 atacccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33721 taactatccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33781 gaggggggatggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33841 ctgttgcatt
33901 ctggggccatggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
33961 ttt
34021 gtt
34081 ttt
34141 aaaaacccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34201 ttt
34261 cactatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34321 atgaacacatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34381 ctggccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34441 aaaaaatcttcatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34501 attttccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34561 ctt
34621 catgtatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34681 gtt
34741 gatgtatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34801 aggccggccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34861 aggccggccatgttggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34921 gatgtatgttggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg
34981 gtggggggatggatggatggatggatggatggatggatggatggatggatggatggatggatggatgg

38881 tggtaacact tggtaaactt ttaactttt gaaaaaaaaa gaacattiac atatggagaac
38941 taaaactctg tggtaaccgt cagtagttaattt aatggttccat ggtaaaagggt ggagggttg
39001 cactggaaa aggaggggga gggataattd ggcctttttt gatggtaaaat agtcggaaa
39061 tactggctc agttaaaggc ataagaattd aatggtaataa aacttcgtatc tagttccat
39121 aacaaccatc ctatcgatc actgtatca tcttaataatg tgggggggaa aaataaaggc
39181 ttggaaagt taatgtatc acctggccgc cttctggatc gagacggccaa agggccaaatcc
39241 aagtggccca tttccatggc acgtactcc actttttttt actgttgcgaa ataaagatat
39301 tatgtaaaga aatgtattdt ccctttttttt aaaaagctggc taggcacact ggttcacatc
39361 tggatcccca gcaacttgg aagctgttgg ggggtggatc cttgggggtt ggaggctcgag
39421 agacggcttgc ccaactatgg gaaacttgc tttttttttt aaaaatggaa attatccgg
39481 gcatgttgtt gcatgttgtt tttttttttt actccgggg cttggggggc agaatggcttgc
39541 gaaaccaggc gttggatgtt gttttttttt aatggatgtt cttttttttt cttttttttt
39601 aacaacatgtt aatgttttttcc tttttttttt aaaaaggaa aatccgttca tttttttttt
39661 ctgtttttttt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
39721 gtatcacctt tttttttttt aatggatgtt tttttttttt tttttttttt tttttttttt
39781 tttttttttt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
39841 gagaatgttg cttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
39901 cttttttttt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
39961 attttttttt tttttttttt aatggatgtt tttttttttt tttttttttt tttttttttt
40021 gtatccatc cttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
40081 ccaacatgtt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
40141 aaggccgtt cttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
40201 accctgtgtt aacccggaaa tttttttttt tttttttttt tttttttttt tttttttttt
40261 caagggttg gcatgttgc tttttttttt tttttttttt tttttttttt tttttttttt
40321 ggttgtttttt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40381 actttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40441 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40501 gagatcaatc ggaaggatgtt tttttttttt tttttttttt tttttttttt tttttttttt
40561 cttttttttt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
40621 tttttttttt tttttttttt aatggatgtt gttttttttt tttttttttt tttttttttt
40681 cccccatcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40741 gaggaaaggc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40801 tattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40861 aatctgtgtt aaggccgttt tttttttttt tttttttttt tttttttttt tttttttttt
40921 acacaaaaaaatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
40981 aatggatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41041 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41101 gaaacttgcg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41161 cagaatataa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41221 agactttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41281 acacaaactt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41341 acatctttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41401 ttggccccc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41461 ccaatccccc aacccggaaa tttttttttt tttttttttt tttttttttt tttttttttt
41521 tgccgttgcg acatccccc tttttttttt tttttttttt tttttttttt tttttttttt
41581 caacctacag ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41641 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41701 ccctttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41761 tcggccatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41821 cccggatctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41881 aatggatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
41941 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42001 gtgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42061 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42121 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42181 agccacaccc gggccatc tttttttttt tttttttttt tttttttttt tttttttttt
42241 acactttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42301 gaatcttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42361 agggccatcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42421 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42481 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42541 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42601 gaatcttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
42661 aatggccatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

42721 tcatcccttct gaggtagtggg aactacaagt gcatacactat gtcaagtcaat cttttttttt
42781 tcatttttgc agagatgggg tÿgtgcatacg ctgcccaggc ttgtctcgaa ctccctgggt
42841 cgaggatgc tccgcattta gctctyctgttcc attagcacgg gaattacagc cttgagccac
42901 aataccctagg ttcctctgagg aatctttaat gaccctggcc ggtcaagttc aacccttaa
42961 ctgggcacac gggctccatc ttccctact gtcctctgcc cacaagtc accttgggtcc
43021 aggtcacacac tgacggccctg ctccctctgg tcccaagggc catctactcc ccccaactcc
43081 atccccagcc tcaggccctt gtcaggctgt ctccctccccc ttggaaatgc tccccccacot
43141 tccccccatc tgcaagtc cccatctccg gaggctcage caaaactgc ttggaccctgc
43201 aggtcccccc agccccccc aggtccccctg agcaacttcg tttccggggg cagctctacc
43261 tccctgtggg tcttggggc ttgttccccc ctgtttaactc tgagcatcg gcagggaccc
43321 tgggggttgc ccaactgcatac cccratacg tgacccggg ggcctctggc ctccgtggca
43381 cagccgtgct gaaatccggag gtgtgggagg cagcacttgg actaaaaga accagccct
43441 ggaccaatcg gcccacgttcc agtttactt ccgttggggg gattgaatgttcc
43501 tactatagat ctatcttctt ttggggggaa aacaaaataag accatgactc tgattitcat
43561 tatttttgtt ggcttatca gttttctggg ttccctttt tttttccccc tgctccccc
43621 agttttatca ctttttgcac gggrraaaaaa aaaaagaaaat ttctaaaaaac acgcgagcc
43681 gcaacacttca gaaatcatacg catgtttca aacgcctccc tccccccacgg caatggccca
43741 ggctctgcatac tggggccaggc tccctccggg tccatggacac rttttatgcac caaaaaacta
43801 ctgcagggg cttttacggg aaagagggtca ttccctctt gcacttggg tgcccttagaa
43861 tacacacaaa aaatgttgc tttttttttt ctgtatggg taccctatgg aatgggtctca
43921 cattttaaaag aagaagaaac aaattttctt cccaaaaataat gtaaatccat cccaaaaggga
43981 tctaaatgtt ccccaagaaag aaaaaataat aactatata gaagaaatgt taaaacaaat
44041 ttggatgttgg gaaagactttt cgaatcaaaa cttcaatccc aagaagactt aagggaaaaat
44101 tgaatagatgttttttttttccatccatccatccatccatccatccatccatccatccatccat
44161 ataaaaatggaa agatggaaac ccacggtttgc caatcttttcaatccatccatccatccat
44221 atccacaaga aatgtctaaac tcaacatggaa aagacttggaa tcaagttttt aaaaatata
44281 ccagtgtccg ctgttgcataac ctgtatggggc agactttgg caggccaaagg cgggtggatc
44341 acctgggttcc agaggatgtca gaccggcttcc acatataatgg tggaaacttcc acttactt
44401 aaatataccaa atttggccgg tttggggggc aaccccccggg tgccctgttgc tgccctgggg
44461 tgagccaggaa gaaatgttgc aaccccccggg tgccctggggc tgccctgttgc agatggcgc
44521 actgcacttc acggccatggc acaaaggccg actccatctcc ataaaaataat aaaaaataat
44581 ataaaaatggta aaaaatggta aaaaatggta ttttttttttccatccatccatccatccatccat
44641 atggaaaggc actcaacgttcc acttttttttttccatccatccatccatccatccatccatccat
44701 ttt
44761 taagggtggc acaagccctt ccactgttgc tgaggatgttgc aagggttctgg tgccctggag
44821 gatctgcggc gataacttgcg aaccccccggg tgccctgttgc tgccctggggc acagcaccca
44881 ctcttgcggc tccatccatccatccatccatccatccatccatccatccatccatccatccatccat
44941 gggccatggc acggccatggg tttatccatccatccatccatccatccatccatccatccatccat
45001 aggaggatgg cgggttccca acatcttgcg ctttttttttccatccatccatccatccatccat
45061 tggccatggc ctgtatccatccatccatccatccatccatccatccatccatccatccatccatccat
45121 gagatcgaga acatccatccatccatccatccatccatccatccatccatccatccatccatccat
45181 ttggccggcc gtt
45241 atccatcttgc cccaggaggcc ggaggatgttgc tgccctgttgc tgccctggggc acatccatcc
45301 ctggccggcaca gcaacacttgc ctt
45361 aaaaatggta gggggaaaaaa aaggttgcatac gaaatggaaag aaaaaatggta aaaaaatgg
45421 gagggtggaa acacagggttcc caatcttgcg aatcttgcg aaccccccggg ccacccgg
45481 tggatgttgc ttt
45541 tt
45601 tcatactggc tcttgcggatc ctt
45661 aaaaatggta gggccatggc acggccatggc acggccatggc acggccatggc acggccatgg
45721 tcgcataatccatccatccatccatccatccatccatccatccatccatccatccatccatccat
45781 gtcacggcc ttt
45841 aacccctggg ctccatccatccatccatccatccatccatccatccatccatccatccatccat
45901 gggggaaaggc caacccatggc ttt
45961 atataatggta attt
46021 ctccctccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat
46081 ggtatgttgc gcaacacccatccatccatccatccatccatccatccatccatccatccatccat
46141 ctccctccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat
46201 aacccatggc ttt
46261 ggccatggcc ttt
46321 gtt
46381 ctcttgcatac ttt
46441 tggatgttgc ggttgcatac ttttttttttttttttttttttttttttttttttttttt
46501 tcatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat

58081 ttttagacag agtctcgctc tgtcgcccag gctggagtgc agtggcacga tctcggtcta
58141 ctgcacccctc cgcttcccaag gttaaqgtga ttctctcqcc ttagoctct gagaqtgcgg
58201 gactacagg ggctgcacc acacccggct aatttttagt attttttagt gagaqgtgtt
58261 ttacccgtgt ctataaaga tggtcctcat ctctgacct cgtgatcccc caaccttggc
58321 ctccaaagt tcttgatgtcaggcgtgtag ctgcacccg cggctaaata cgtttaacaa
58381 aaccacatt cctgtgcctc ttataacgtt ttacccaaa acacatccca ccttttgtca
58441 cagttataac tgcgtggac caataatgtg gacagtaaaa taatttaccc aagacagtca
58501 tggtaaaga aagacagatt tatttagaa aqtaaaga aacattgcac aagtgcata
58561 qtcacqacag caaaqaaggg acgtctqcaa aqgtcaqgg gctgaaaggga aqttcataq
58621 qttgtactg gaggtaccc ttgaaatgg gttcagctg ggctacatgc ggatgtgggt
58681 atttggaa aggatgtcat qdgtatgtt gttctgtat cagctgttca tcagaaacat
58741 tggctcccc caccctgggc ccccttctcg ttgtgttta ctatctt taggactca
58801 cacaatattc tccttacatg attttgcggd ggacaaacag ctgatattt tagcttttta
58861 actttttatc aaaaataac ccctctgtgtt aacccatca cgcgttaactt aggttattac
58921 tgaacccatg atgcgtatg tcccccgtt ctgcgtatc acactagaca gaaatgtgac
58981 taatgttattt tcaatgttatttctt cagggtttaa tcacccctt tccccacggc
59041 acttccttgg ttatgttca aagccctgtt agtacttgc ttatccggat gtatataacta
59101 catqaaacat tggctgtttt attgttcat tttatcttact aaccaacttataatata
59161 gtttttatgtt cctgagaagc ttgtgttca aaaaagaaag ttttagatgt tgaagtatca
59221 actacaatcc tcaaaatgtt ctgcgttgc ccacccat accacacatt tgaagaaacca
59281 gcttcgtatc aatccctgtt gagaatgggg gaaatcaac ctccctaaac ttgttccaaa
59341 cggatcttcat aatccatctg acttttcattt taaaatgtt tttagttaaaa taatttacata
59401 actttgtca aagttacttgc tagtt
59461 aacttaggtt ccaagatgtt atgttacccat ttcataaagg aagaacttct tcatttttt
59521 gaccacaccc atgttgcattt ttt
59581 gacagatgtt cacttgcac tcttt
59641 tcaacacaaa cttccgcctt cggcttcaag cgtatccctt acttcagct cccacgcac
59701 tggatttttttggatgttgc accacccggc gctgttttttttttttttttttttttttttt
59761 ttt
59821 gctccccaat gctgttggat ttcacccgtt gggccacccat gtcgttgc gtcgttgc
59881 ctt
59941 aactatgtatc atggccaaagg aatggagaca atatgtatc ttttttttttttttttttt
60001 attttatgtt ttcccccattt attatgttca ttttttttttttttttttttttttttttt
60061 ctccttcttctt gtcaccaactt tagggatcatc atatgttca agtccaaat atacatgtt
60121 tgaagactca atggtt
60181 tggtt
60241 aattttatcatca aatgttgcac ttttttttttttttttttttttttttttttttttttt
60301 atgttgcatttca tccacgggg ttttttttttttttttttttttttttttttttttttt
60361 tacatcagac aatggcccaaa aatctgcaga ttttttttttttttttttttttttttttt
60421 gaatcttt
60481 gaagtt
60541 aatgttccca actaaacaca ttttttttttttttttttttttttttttttttttttt
60601 ttt
60661 aatcttt
60721 tggcccttcat tggcccaacta gtaatgcac gacccgttgc ttttttttttttttttt
60781 ttt
60841 actaaatccca ctatccatataa aacaatgtt aataatccat aataccat aatgttgc
60901 atccctttataa ctatccatataa gtttttttttttttttttttttttttttttttttt
60961 cccacttcaca ccaactactc aacttccat aattttttttttttttttttttttttt
61021 agggacgatc atacttt
61081 acaaaatgtt ctt
61141 catcaaccaaa atatccatccat aatccat aatccat aatccat aatccat
61201 ttatccatccat aatccat aatccat aatccat aatccat aatccat aatccat
61261 cagttccatccat ttt
61321 aacatctatgtt ttt
61381 atgtatgtatc atgtatgtatc ttttttttttttttttttttttttttttttt
61441 aqcttgcgtt ctgttt
61501 ttt
61561 ttt
61621 catatctatgtt ttt
61681 ctacaaaacc caacatccat aatgttgcac gtttttttttttttttttttt
61741 cataactact gtaacacttgc ttttttttttttttttttttttttttttttt
61801 ttccacttcga actcaattac ttttttttttttttttttttttttttttt
61861 ttt

61921 gtcggaaaagg gccttagata tggataattt ttatttatcc catcagaatg agttttct
61981 gctggatct tcgagcatt caaggctgt ccaatccc gaactcgag gctgtcgacc
62041 tccaaacagg atttaaccttcca ttaaccctt cgaatgccc ctactcaaca tatccatct
62101 ctacgcttgg ggagtatcca ttacctgagc ccatacatgt ttgaaagag aaaacccaaa
62161 acacatactc caaacccat cattacgat tgccctgat atttacttta cacttccca
62221 agccctagaa tgcttccagg caccttccat cacccttcat ggcataatg gctcaacatt
62281 ctatcgct acagatcttcc atggacttcc cgtcatcaat gctcaaccc tcccaacat
62341 ctggcttggt catcaacgaa aattttccatc atcagactyt tgccaaatcc cattgcacat
62401 ctgtctata atcaaaagaca ctttgatctt aattttctt ctaatattac tactcatatc
62461 agtaactgtt tcacttgacc tatttagaga ctgcgaaat tacacccatc caaatccct
62521 caacacaca cccgacatta aaccaggatg gtgccttca ttgcctatg caattctaca
62581 ttaaaccaga agggtgtctt ctatggct atgcatttcc acattaaacc acagatgtt
62641 atttccatgg ccaatcgat tccacatgg accagaatgg caactttcat ttgcctatgt
62701 aatttccatc taaaacccaaatggatctt catttgcata tgcacatcc cacttccatc
62761 ctataatggt aggaggatc ctggggctgt tcttccat tcttacatcc gctgttgttcc
62821 caacacttca catatcaa acaacaaggaa tataattctg accatataggY caatgtctt
62881 ttcgtatctt agtacagacat cttttccatc ttacatggat cggggggccaa ctgttgtt
62941 acctttttat tattttatggc caaggatcgat ccatttgcata cttttccatc atccctt
63001 ttatccat tttactggctt atcggaaaacg agtacttca atgaaaggat ctttgcata
63061 cttaatggt actgtgttgc gtaaaaaaccatggaggac cgggccttcc gggaccatt
63121 ccaggaaaga gctttttgtt ccaacccaggcccaacaaatgg tggaaatccat tttaaatcc
63181 tecctggatt ttglaatggc agtgcataat ttttttttca atcgtcatgtt cagatggaa
63241 aatccacataa aattttatggt gcaactatgtt acatcatgc ttcttgcgtt accccatggaa
63301 ttatcatgtt agtacatgtt gttgcgtatc gtatatttttgc tattttatgtt tgctatcca
63361 aattttccatc ttcattaaat ttttgcgttgc gtaatgttgc cacaacccatc tgctatcat
63421 tcatcaaaaca ttctgcggaa agcgtatcac acatataatc atcatccatg ataataatcc
63481 cttaatattatgg catggacWt tcgtattttgc atgcatttca acatccatgc tcaaaatcat
63541 ttctgcggaa cgcgttattt accttttttca aatccatca actaaacccatc ttggaaatcc
63601 cagcaggccctt ctggaaatgg tttatccatc tttactcccg cccatgcacat ttgggggtt
63661 tttagacttca acataatccgtt gcatcttgc ttcttgcgtt gcccattggg actaaatgt
63721 ttcaatgtt ctctttttatggaaatggatccatc ttttttttgc tgacatccatc ctatgtt
63781 ttggcggaaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
63841 atgtggggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
63901 gtaacactt acacccaccaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
63961 aaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64021 ctccggccatc ttcccttggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64081 agccccaaaaaa caagatcatgtt ataaatccatc ttttttttgc ttttttttgc ttttttttgc
64141 ttgtatccatc aacttacatc acatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64201 acatgttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64261 agtactttaa ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64321 gagaaaaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64381 tgctctatgg ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64441 gtttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64501 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64561 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64621 actaaatgtt ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64681 atttaacccaaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64741 cttaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64801 attttatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64861 gtttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64921 atagcttcaatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
64981 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65041 aacatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65101 tggttccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65161 catccatgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65221 catttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65281 aatttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65341 ctccggccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65401 gtggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65461 ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65521 gcatcgacctt cccaaacttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65581 aatgttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65641 ttataatggatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc
65701 caaaaatccatc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc ttttttttgc

65761 aatcagggca tcagacctat gagtttata tgatcaactt atgcatacttc ccgtggaaaa
65821 acttcttatt ccttactcta gcccatacga tacagaatgt ttaaatatctt gtctataat
65881 ctatgtttccat gccacaatac tggaaatatgt gtctgataag agaggatctt tgacagatg
65941 aattacagag gtttaaatctt tccatattctt ageattacag gaatttgaac tagtccaaag
66001 aagtcaaaaat tccctatgtc atctgtatata ccatgtctca tagtaatacg aycataatag
66061 taaggccacg ttaccctatgt gtatggcag ctaataatgt tattcggcc atacccaa
66121 tagtctRgtt tataccctt ctgtactatac cagtcttca atcttcttca ctatccat
66181 cactatttt atagaacactt taattatgt aatccctta cactgtctt taatctgaaa
66241 ggttttggaaa taaaatgtc aqgtataatc cccataaaag gcacaaacccg ggccggaa
66301 ggtgtctacc acctataatc tcaacatctt ggtgtgtgaa ggtgggtgaa ctgtttaa
66361 ccaggaggc gagacaggc tcggcaatctt cattagggat tgaggccatg ctggtagtg
66421 agtactcat tcaaaatgtt catgttca gggagatctt tagtcttgcg ccccaaaag
66481 ccattctggg acatgtctt tagtgggtt tttggccggg cactcttca ctggggctg
66541 ccccaatggg ttatcatgtc tggtggaaacctt ccgtatgtt gatgtttgt atggccatgt
66601 ctggaaatac ttggccatgtt aaggggggcc tgatgttcat ctgttctt ctgttccat
66661 ttccgtacac taagggccgtt gagacRttc atgSttcca gttgggttgc acgttttaca
66721 ctgaaggccgtt stgttagccctt cattgttgc tccacacagg ttaagtatca ccgttttcc
66781 ccgtcttggg gccccggggc caataaaaatc gatccggcag tccggccacag gttgtatgg
66841 tcgatgtatg tgaccgggtg tggaggggac ctttctatgc gcaagccatgaa acagggtcc
66901 gggttcttgcg cagctgtgtt attatcttgc cagtggccg ggaagccatc agtctttgt
66961 ttggcccccc tcatgtgtc ccctctggg tcgtcttca aaggtagccatgatggcc
67021 ttcccaatgg ggttccatgtt aaccatggga acatgttca gggccgttgc ctctgttatt
67081 ccaggagaca gttttagactt atgtgtatca acRttgatca cttaaatgttccatcat
67141 ttttgttccatgttgcgtt attttgtccatgttgcacccatggc cttcaaaagg ggctggccca
67201 aaccctcccaatgttgcgttccatgttgc ttttttttttgcgttgcgttgcgttgcgttgc
67261 ggtgtcgttgc tccatgttgc cccgttgcgttgc ttttttttttgcgttgcgttgcgttgc
67321 tcatgttgcgtt tgccggccatgttgcgttgc ttttttttttgcgttgcgttgcgttgc
67381 aggtggatctt attcgtatgttgcgttgc ttttttttttgcgttgcgttgcgttgc
67441 actatgttgcgtt ccgttgcgttgc ttttttttttgcgttgcgttgcgttgc
67501 ttgtggccacc cccggggccgtt gtttttttgcgttgcgttgcgttgcgttgc
67561 agggcgttgcgtt ccgttgcgttgc ttttttttttgcgttgcgttgcgttgcgttgc
67621 tatacatgttgc ttttttttttgcgttgcgttgcgttgcgttgcgttgcgttgc
67681 ttgttgcgttgc ttttttttttgcgttgcgttgcgttgcgttgcgttgcgttgc
67741 tcatgttgcgtt ccgttgcgttgc ttttttttttgcgttgcgttgcgttgcgttgc
67801 ctgttgcgttgc ttttttttttgcgttgcgttgcgttgcgttgcgttgc
67861 ctgttgcgttgc ttttttttttgcgttgcgttgcgttgcgttgcgttgc
67921 gccaatgttgcgtt gatgtatatac ctttttttttgcgttgcgttgcgttgcgttgc
67981 ttttttttttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68041 ctcttccatgttgc ttttttttttgcgttgcgttgcgttgcgttgcgttgc
68101 tgaggccctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68161 ggttccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68221 tggtgtgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68281 ctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68341 atttttttttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68401 tggtgtgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68461 gtttgcgtatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68521 gggggccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68581 atttttgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68641 attcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68701 gggttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68761 ctggccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68821 ctttttttttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68881 tggtgtgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
68941 ggaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69001 ctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69061 tcttccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69121 gaaaggccatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69181 agatccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69241 aatgtccatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69301 gtcataaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69361 gtcataaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69421 gtcataaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69481 gtcataaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc
69541 cttccaaaggaaatgttgcgttgcgttgcgttgcgttgcgttgcgttgc

77281 cagttaacgc aattatcaca tggctcttag gtgacataca tcctccctcg ctgacaggat
77341 taggagatta aagttaaagac aggcataga aatccaaagg gtattgtat gggaaatgt
77401 cagtgtccat gaaaatcttc caatttgggt tttagatgtt cggtaaaagac agggatagga
77461 aattttaaaa gtatttaattt gggaaactaa taaaatgtcca tgaaatcttc acaaattcag
77521 ttctcttgcc atggcttcag ccagtccctc cggttgggtt ccctgacttc ccgcacaaat
77581 tgggccttgc ctgtttagt actctgtatgg atatgggtt gctcatttgg atttcttc
77641 agtccltgag ccacactgcg cagcacttcg gtagacttgc attttgccecc ttgtgcag
77701 tccatgtatgt ctgtcacaag gttgactaca tccagcaca caaggacacc tgaatgtgg
77761 ttggccagggt tccggctac ttcttcact atccgggtt gggccccccg tggcttc
77821 gtcacaaca cattatagg tacatatcgca caagcaatca aagggcgtcc aacagtgt
77881 gtcatctcc tgagtgtatg gacatattt gcaatattt ttgtggctt gtcacaaat
77941 atgcaaaagg aaagcacatt ggggtgtatg tcaaycagaa tgccctttaa tgccctcaat
78001 ttgtcagtgc ttgttgtatg cagccgtgtg gctgtatgtt ctgtgcattt tggtatgt
78061 ttccacaggaa tgctggggc catggccccc gggggatgtt ccattccca acccaaccc
78121 gtcgtatgg tgcgtatgtt cagccgtgtt gtaatgggtt ccaacaYaaac gccaatgaca
78181 gacaggatgc cagttggggc agacaccatc ttggcgtatg cgcacccctt tggtggcc
78241 tcaatctccat ttgcataatgc acggacgtt tctatgtact cctgtatattt ccatctt
78301 tgaggaaanct ttcaaaaaacc actccctaaa ttgtgtttt ttttgtctca tgcttttgc
78361 ctcaatagcc acatatggt taagatctt cagacgttca tagagacat ctgcifcttc
78421 cctgttcccaaa taagggacatg attagtaa aaggacgtt actttatctt aaaaatggat
78481 caataagatc tatttcgtat aataatcaga ggtttttttaa taatgtcaat ggaatgt
78541 ttctaaaggaa tataatataa ttccaaaggc cgggygggtt gggtcatgt tgtaatccca
78601 gacttggg aggccggat ggggtgtatca caaggttgg agatccggat catctt
78661 aacacggatgc aaccggctt ctatctaaaaa tacaaaaaaaat tagccaggYg tggtgttgg
78721 tgcttgtatgtt ccacgtact tgggggtgtt gggggggatgtt atggcatgaa tccaggaggat
78781 ggacgttgcgatgtt gtagccggat atccggccatc tgacttccat cctggggccat agacggat
78841 tccatctccaa aaaaatataat taaaatataat tctaYcaaa gttaaatattt ttttgtacaa
78901 catagatatg ccacatgtact tatttgcattt gggaaaaaat aagttttaatg catcttcc
78961 tgcttcttgc tggtgtatgg ttgtatgtatgg atgtccctc atgtcaagggtt ggtcaatgt
79021 atactacca ggggtgtgg agggggaaat cttgttggaa aaacaatgggaaatggtt
79081 agacaaatggaa gaccatccat cagggatcatc tagacatgtt atgaaatgggaaat
79141 gagacatatc ccccttgc tggggccctg aaaaaggatc tctggggccccc tggatgtcc
79201 tgcttgtatg gaacgttctt gttttcttgg tggtttgggtt acaggccatgt atagaatgt
79261 gatgggtatg ggggtgttag ggttattttgg tgcttcatgtt gcttccatcc ggaactgg
79321 actaaaggggg ttagatcttgc gggggggatgtt gggacttca tgcttccat gggggat
79381 tggtatccatgg cccggggatgtt ggttgcattt tgctgtatgtt taagaaatggg atttactt
79441 gccaaatcttccat cccgttgc tggggccctg cccggggatgtt tccatccat
79501 cccatccatc cccgttgc tggggccctg cccggggatgtt tccatccat
79561 tcaattttaga gggatcccccc ccacgttgc tgctgtatgtt acatgttcc tggatgt
79621 cttcacccat tccatgttgc acggactgtc tgacccgttgc ttagggatcc tccgtttag
79681 ccacgttgc agggggccccc cactctgttgc tccctgttgc tgcttccatcc atctggcc
79741 ctttccatccatgg tggtgttgc tgacttcccccc tccatgttgc tgatattgg agctgg
79801 agtctccccc cccgttgcataa acatctgttgc tccatgttgc tgacttccat
79861 tcaYggat ttttttttttgc tggtgttgc tccatgttgc tgacttccat
79921 tgccatccat gacacggggg aacacgttgc cccggggatgtt tccatccat
79981 cccttccatgg cccatccatgg ttttttttttgc tgacttccat
80041 ccacacttgc gcaataacgg tttatgttgc tggtgttgc tccatgttgc
80101 acctgggggggg ggtttaaaaggg
80161 actcgttgc tccatgttgc tccatgttgc tgacttccat
80221 tagaaatgggtt caatctgttgc tgacttccat
80281 ctgtacttgc gggccatggg ccacgttgc tccatgttgc tgacttccat
80341 ctatgttgc tgggttgcataa acatctgttgc tgacttccat
80401 tccaaatcttgc aggggttgc tccatgttgc cccatccat
80461 cccatccatgg tgatgttgc tccatgttgc tgacttccat
80521 atggggatgtt ttttttttttgc tccatgttgc tgacttccat
80581 aagatggatgtt ttttttttttgc tccatgttgc tgacttccat
80641 ttccatgttgc acatctgttgc tgacttccat
80701 tgcttccatccat tccatgttgc tccatgttgc tgacttccat
80761 cccatccatgg tggtgttgc tccatgttgc tgacttccat
80821 tcaatcttgc ggg
80881 ccatgttgc tccatgttgc tccatgttgc tgacttccat
80941 tccatgttgc tccatgttgc tccatgttgc tgacttccat
81001 tccatgttgc tccatgttgc tccatgttgc tgacttccat
81061 cccatccatgg

88801 catagagaca gcacatctcgt tgtttgcag gctgttctga actcttcggcc tcaagtgtac
88861 ttcccgcctc tgccctccac agcacttggg ttacaggctt cagctatagt gctttctatc
88921 ttgtatggca tctttttttt gtgaaaaaaa atcaggccgg gagcggggc tcaacgtctg
88981 aatccccaga ctttggggag ccggggcagg cagatcacaa ggtcgggaga tggagacat
89041 ctggcglaac atgttgaac cccatcttc ctaaaaatac aaaaattatgc cgagtgtatg
89101 ggccggccgc tttttttttt gtactttttt cttttttttt cttttttttt tttttttttt
89161 ggaggccggg ctggcgttg gcagatgtt cggccacttgc ctccggctt gccaacagag
89221 cgagatccR ttcraaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa agaccacac
89281 tcagatttca cagaatttac cccctgtt cttatgtttt ttggcgttc tttatgttt
89341 ctggaggggg aaaaatcttag gctggggggg gagggtactt gcccggatc gcacacgtct
89401 tggagggcag acggggggc aacatcttc cttttttttt tttttttttt tttttttttt
89461 tgattttagt aaatccaaatc tttttttttt tttttttttt tttttttttt tttttttttt
89521 agotctcaat cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
89581 caaatgtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
89641 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
89701 ttgtctctag gggtatccggc aagggtttttt aataatggaa cacaacatc aatgttttt
89761 gggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
89821 ttcatgttag tgaggggggg ggttagttt tttttttttt tttttttttt tttttttttt
89881 tggatggc acatggggat gaatgtttttt tttttttttt tttttttttt tttttttttt
89941 gtccatggttt atgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90001 tcgtatattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90061 caatgtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90121 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90181 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90241 atatggacatc ggccggccctt tttttttttt tttttttttt tttttttttt tttttttttt
90301 gtgtgtgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90361 attttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90421 ggggtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90481 aagggtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90541 gtcgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90601 ccacggggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90661 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90721 aacctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90781 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90841 ctgggggttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90901 gaaacccatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
90961 ggacaaatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91021 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91081 atatggatcat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91141 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91201 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91261 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91321 acacgtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91381 agggacatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91441 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91501 gacccctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91561 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91621 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91681 ctgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91741 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91801 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91861 ctactttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91921 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
91981 ctggggggat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92041 ctggggatgg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92101 gtgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92161 ctatgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92221 gaaaggccctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92281 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92341 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92401 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92461 aatggggccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92521 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
92581 acacgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

92641 gagacgcgaag tcacaggaag atctggggcc cacttatt tcccaaggagg ttggaggc
92701 ttcaacattt aaatgttaa aatccggcag ctgggaaagg aaggaaaggaaa aaaggaaagg
92761 atagtagttt agtcgtatgg tcacattttt gtggggctt gatccgcctt ccctgaaatcc
92821 atagttcca tgtagaaagg ggtagatggaa acatggccat atttcattt ctgtgcaca
92881 gttatctac attttttata agataaaaat aaacagaagaa tagaggaaat aggcatatgg
93001 gcatgttgtc gagytggcc aagaagggtca cttccactt tgcgtatgtt aggttccatgg
93061 caaataaagt tgccatgtt cttttttttt cttttttttt gtcggaaat tttttttttt gtcgggggg
93121 gatataatgg ctccatccat ttggcaaat gttttttttt gtcggaaat aaaaaaaaatcc
93181 ttgggtgact ctgtttccat cttttttttt gttttttttt gtcggaaat tttttttttt gtcgggggg
93241 agatgtttt ttccatccat ttttttttt gttttttttt gtcggaaat tttttttttt gtcgggggg
93301 gtagaaacaa aaaaatccc agtcacgggg ttgttgcgaa ttcttgaaat cttttttttt gtcgggggg
93361 caccctccgt ttgcNtgcg gggttttagaa aaaggacatg ttgtttttt gtcgggggg
93421 agtcggaaa atggagaaa aaaaacaaatg atatgtttt ttggggactt gtcgggggg
93481 aagatttcaa taatcgatgc ggataatgg tacacatata ataaaggcttgg
93541 acaaaatgg aatccatca aacagatgtt atatgtttt tttttttttt gtcgggggg
93601 ctatgtctt atttttccca aacaaatgg atatgtttt gtcgggggg
93661 ttttgcgtt ctaatccatgg ctggctttttt gttttttttt gtcgggggg
93721 gtagaaagg ctctttttttaa atttttttt gtcgggggg
93781 ctcaatggat gcccyyttttttaa accttgcgtt cttttttttt gtcgggggg
93841 ctgtatggaa ttggggatgtt cttttttttt gtcgggggg
93901 ggccgttcggaa aagttttttt tttttttttt gtcgggggg
93961 tatagccaa gggatattaa aaggacttgg atttttttttt gtcgggggg
94021 ctatgtttttaa cttttttttt gttttttttt gtcgggggg
94081 tttttttttttt tttccatgg tttttttttt gtcgggggg
94141 ctgttgcgtt aacaaatgg tttttttttt gtcgggggg
94201 cacacaatgt tgaatgtttt tttttttttt gtcgggggg
94261 cttaggtta ggaatattt accacatattt aatttttttt gttttttttt gtcgggggg
94321 ttgttggaaa tggtttttttt tttttttttt gtcgggggg
94381 tttatgtttttt tttttttttt gtcgggggg
94441 tttttttttttt tttttttttt gtcgggggg
94501 gggttcccaaa tggtttccaa gttttttttt gtcgggggg
94561 gccccccaaa tggtttccaa gttttttttt gtcgggggg
94621 tttttttttttt tttttttttt gtcgggggg
94681 ctgtttttttt aacacatattt aatttttttt gttttttttt gtcgggggg
94741 gaaaacattt tttttttttt gttttttttt gtcgggggg
94801 aaatgtttttt tttttttttt gtcgggggg
94861 tttttttttttt tttttttttt gtcgggggg
94921 caatgtttttt gaaaattStaa tttttttttt gtcgggggg
94981 aacaaatccctt aatattttttt gttttttttt gtcgggggg
95041 gccacagggtt gctgggtatg tttttttttt gtcgggggg
95101 aacatgtttttt tttttttttt gtcgggggg
95161 acatcatatgg tttttttttt gtcgggggg
95221 ggtatattttt catcgatcatgg tttttttttt gtcgggggg
95281 tttttttttttt tttttttttt gtcgggggg
95341 taattttttt cttttttttt gtcgggggg
95401 caatattttt gacatgtttttt gttttttttt gtcgggggg
95461 tttttttttttt tttttttttt gtcgggggg
95521 ggatggaaaatggatggaaa aatgtttttt gttttttttt gtcgggggg
95581 tttttttttttt tttttttttt gtcgggggg
95641 gggaaatccctt atatgtttttt gttttttttt gtcgggggg
95701 tttttttttttt tttttttttt gtcgggggg
95761 tagccatgtt gaaattttttt gttttttttt gtcgggggg
95821 aatgtttttt tttttttttt gtcgggggg
95881 cttttttttttt tttttttttt gtcgggggg
95941 ctggggctgtt gggggggaaaatggatggaaa aatgtttttt gttttttttt gtcgggggg
96001 attcggatgtt tttttttttt gtcgggggg
96061 tttttttttttt tttttttttt gtcgggggg
96121 atccatgtt tttttttttt gtcgggggg
96181 ggtgcacRta ttgtttttt gttttttttt gtcgggggg
96241 aacccatgtt accacaaatgg tttttttttt gtcgggggg
96301 gtatgtttttt tttttttttt gtcgggggg
96361 ccagagggcc ctgtttttt gttttttttt gtcgggggg
96421 tttttttttttt tttttttttt gtcgggggg

[0242] The following cDNA sequences 1-6 show human cDNA structure for transcript variants 1-6 of APOL3. cDNA sequence 1 encodes the longest isoform (1), which is shown in amino acid sequence 1. cDNA sequence 2 differs in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2, which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 3 has multiple differences in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2, which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 4 differs in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2 (amino acid sequence 2), which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 5 differs in the 5' UTR and

coding region compared to the variant in cDNA sequence 1. This results in translation initiation from a downstream ATG and an isoform 3 (amino acid sequence 3) with a shorter N-terminus compared to isoform 1. cDNA sequence 6 differs in the 5' UTR and coding region compared to the variant in amino acid sequence 1. This results in translation initiation from a downstream ATG and an isoform (3) with a shorter N-terminus compared to isoform 1.

APOL3 cDNA SEQUENCE 1 (SEQ ID NO: 2)

NM_145640 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/d, mRNA

APOL3 cDNA SEQUENCE 2 (SEQ ID NO: 3)

NM_014349 Homo sapiens apolipoprotein L-3 (APOL3), transcript variant alpha/a, mRNA

```
1 agcaggaggg tgggaccagaag ggtgtctgtc gaccaaggat gggactgggc caagggtggg  
61 gcttggaaacg atcctgtttt gcatgttta tcaggactgt ctgccaagt gtgactttca  
121 cttttccccctt tgggttcccg ggatatatctc aggcgttggg acgaatgtct ttgttattatg  
181 catatqcacac gtcggaaatc gatcccacac acatccaaatgc aactgttgcat tgcgttccat
```

241 cttcaagag aagttccctt ggacaaaagg accctgcctt ggttgagag tgagggcaga
301 gggagtggaa gcaatgatcaa ttctcttaaa taccagctgg ctggggccca ggagataaa
361 aaaccccggtt cttaggtgtt ctggcattt gctgcacccg aaaggatgg cagagatcca
421 gccccctccaa ccttccttcg tccacagggt gtcacattt cttgttttctt
481 cctccctcaag ggttaagaaa aaaaacgaac cttccagtc aggtcagtgta ctggagagct
541 ccattggaaatg tcttcctcgtt accttggctgc tggcaccatg gactcagaaa agaaacccgtt
601 tactgaagag gcccaccaat acttcggggaa gagagtccg ccaatgcac tcacaaatctt
661 gctgtactaac aatgaagcctt ggaaggatgtt cgtgactggc gctgaatttc ccagggtatga
721 ggcagatgtt ctctacgaaat ctctgaaat gcttagaaaca tatgcagcta ttggagacga
781 atatgttgcg caaaaggatgtt acgttgtt ggtttttttt ttggaaagatgtt ttcccccaatgt
841 caaaggaaatg atccaggatgtt ccataaaaaaa gtttcgtggc ttgtcaaatgtt glatttggaa
901 gggtccacaga ggctgcacca ttccaaatgtt ggtgtccaggc tccactggc ctgcctctgg
961 catcatggcc ttctgtgtt tggltttggc accatttaca gcaaggacgaa gctgttttcc
1021 tactgcgtt ggggtttagggc tggggacgc gtcgtgtgtt actggatca ccacccagcat
1081 cttggacggcc ttccatcatc catcggatgtt acgtgtggc acggacgttgc ctgcacccagg
1141 cttggacggcc ttggaaatgtt ttggaaatgtt tttttttttt ttggaaatgtt ttcccccaatgt
1201 cttttttttttt aattttttttt aattttttttt aaccctttttt aaccctttttt aaccctttttt
1261 gcaacccctt gccaggggcc gactccctgtt gacccatggg ggtttttttt aaccctttttt
1321 ttgttcaacga gagagaacgaa ttgcggcac caccctggcc gttggagacgag gggccggat
1381 cttcgatgtcc accactttcg gcatttttttgc ttgtttttttt gttttttttt gttttttttt
1441 gtcacaaatcc ttgcgtatggc ggcaaaatgtt tttttttttt gttttttttt gttttttttt
1501 tcacggatgtt gggggatgtt ttggggatgtt ttggggatgtt ttggggatgtt ttggggatgtt
1561 ccataccccc ttggcccccggc ccatgtccgc cttttttttt gttttttttt gttttttttt
1621 gcaacaaatgtt cttttttttt attttttttt ttggggatgtt ttggggatgtt ttggggatgtt
1681 gttttttttt aattttttttt aattttttttt aaccctttttt aaccctttttt aaccctttttt
1741 tggcaatgtt accaaaggaga aggccggaaat gttttttttt gttttttttt gttttttttt
1801 actggggatgtt ttggggatgtt ttggggatgtt ttggggatgtt ttggggatgtt ttggggatgtt
1861 ggaaatgtt ggg
1921 tggaaatgtt gaaaccccccggg gttttttttt gttttttttt gttttttttt gttttttttt
1981 cactaccggc ctggccccccggg ttccatgtttt ttccaaatgtt gttttttttt gttttttttt
2041 gtcccccggc ttgtttttttt agtccatgtt gttttttttt gttttttttt gttttttttt
2101 tcacggatgtt ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2161 tttaggtttt tttaggtttt atgtttttttt ctgtttttttt gttttttttt gttttttttt
2221 ttggccatgtt ccggccatgtt ggacccagggtt ttctttttttt cccaaatccatc ttggggatgtt
2281 tggcggaaatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
2341 aaatataatgtt aaaaaggatgtt tagatgtttttt gggggggccggg atctttttttt gttttttttt
2401 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2461 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2521 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2581 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2641 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2701 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2761 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2821 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2881 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2941 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
2961 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
3021 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
361 aaaccccggtt cttaggtttt aaaaaaaaaaaac gaaacctttttt gttttttttt gttttttttt
421 agtccatgtt aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt
481 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
541 tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
601 atggggcaga ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
661 acggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
721 aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
781 aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
841 ctggccatgtt ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
901 ccctttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
961 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1021 ccggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1081 ttggccatgtt ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1141 tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt

APOL3 cDNA SEQUENCE 3 (SEQ ID NO: 4)

NM_030644 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/b, mRNA

1 agcaggaggg ttggaccaag ggtgtgtgtt gaccaaggat gggactggc caagggtggg
61 gctggggaaatc atccctgtttt gcatgtttttt tttttttttt gttttttttt gttttttttt
121 ctttccctt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
181 catcatggcc gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
241 ctggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
301 gggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
361 aaaccccggtt cttaggtttt aaaaaaaaaaaac gaaacctttttt gttttttttt gttttttttt
421 agtccatgtt aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt
481 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
541 tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
601 atggggcaga ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
661 acggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
721 aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
781 aatgtttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
841 ctggccatgtt ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
901 ccctttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
961 gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1021 ccggatgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1081 ttggccatgtt ttgtttttttt gttttttttt gttttttttt gttttttttt gttttttttt
1141 tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt

APOL3 cDNA SEQUENCE 4 (SEQ ID NO: 5)

NM_030644 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/c, mRNA

APOL3 cDNA SEQUENCE 5 (SEQ ID NO: 6)

NM_145641 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant beta/a, mRNA

3541 gttagagac tggggaggc cgatctcta gagccatcct gctgagtgcc ctgtgttaa
3601 gtcctaataa actcacctac tcaccaa

APOL3 cDNA SEQUENCE 6 (SEQ ID NO: 7)

NM_145642 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant beta/a, mRNA

3301 atgtccccctg cttaaacccctt gaaggccagg taatgagcca tggccatttg ccccgactga
3361 ggaccggctg tctttttttttt cccaaacatcc ctggagatgt tgccgagaacc ttcaaaaaaaa
3421 aacatctttt ttactcatat acagccggca aagagcaca aaataatctt aaaaacggttt
3481 tagatggctt gggaggccatc atttcttagat ccatcttgc tggatggccctg ttgttaatgt
3541 cttaataacttta cacttactt ccaa

[0243] The following are human polypeptide sequences for isoform 1, isoform 2 and isoform 3 of APOL3.

APOL3 AMINO ACID SEQUENCE 1 (SEQ ID NO: 8)

NP_663615 Homo sapiens apolipoprotein L, 3 (APOL3), isoform 1, protein

MGLGQGWGWEASCFACLIRS CQCQVTFPFQFGFQGISQSLENVSGYYADARLEVGSTQ
LRTAGSCSHSFKRSFLEKKRFTEEATKYFRERVSPVHLQILLTNNEAWKRFVAAELPR
DEADALYEALKLRLTYAAIEDEYVQQKDCQEFPREWFLKEFPQVKRKIQUESTKLRALAN
GIEEVHRGCITSINVSSSTGAASGIMSLAGLVLAPFTAGTSALTAAGVGLGAASAVTGI
TTSIVEHSYTSSAEAEASRLATSIDRLKFVKFEMRDITPNLLSNNNYYEAQTIGSEIR
AIRQRARARALPVTWIRSAGSGGGQAERTIAGTTRAVSRGARILSATTSGIFLALDVNL
VYESKHLHEGAKSASAELRRQAQELEENLMELTQIYQLNPCHTH

APOL3 AMINO ACID SEQUENCE 2 (SEQ ID NO: 9)

NP_055164 Homo sapiens apolipoprotein L, 3 (APOL3), isoform 2, protein

MDS EKKR FTEEATK YFRER VSPVHLQILLTNNEAWKRFVTAELPRDEADALYEALK
LRTYAAIEDEYYVQQKDEQFREWFKEFPQVKRKI QESIEKLRLANGIEEVHRC TISNV
VSSSTGAASGIMSLA GLVLAPFTAGTSLALTAA GVG LGAASAVTGITSIVEHSYTSSAE
AEASR TSDIRLKVFKEVMDT PNLSSLLNNYEATQTGSEIRAIRQARARALPVT
TWRSIAGSGGQQAERTIAJGTRAVSRGARILSATTSGIFLADVVNLVYESKHLHEGAKS
ASAEELRROAQOELEENLMELTOIQYORLNPCHTH

APOL3 AMINO ACID SEQUENCE 3 (SEQ ID NO: 10)

NP_663616 Homo sapiens apolipoprotein L-3 (APOL3), isoform 3, protein

MSLAGLVLAPFTAGTSLALTAAGVGLGAASAVTGITTSEHSYTSSAEASRLTATSI
DRLKVFKEVMRDITPNNLLSNLNNYYEATQTIGSEIRAIRQARARLPVTWRSIAGSGG
QAERTIAGTTRAVSRGARILSATTSGIFLALDVNLVYESKHLHEGAKSASAELRRQA
QELEENLMELTOIYORLNPCHTH

[0244] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are

within the scope and spirit of the invention, as set forth in the aspects which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0245] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

What is claimed is:

1. A method for identifying a subject at risk of osteoarthritis, which comprises detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-7;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby the presence of the polymorphic variation is indicative of the subject being at risk of osteoarthritis.

2. The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.

3. The method of claim 1, wherein the one or more polymorphic variations are detected within a region spanning chromosome positions 34828750 and 34833750 in human genomic DNA.

4. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions selected from the group consisting of 201, 425, 1095, 2201, 7879, 8395, 8461, 9503, 10304, 10695, 16300, 16444, 17591, 17988, 19116, 19358, 20300, 20669, 20891, 21451, 21978, 22785, 24248, 24770, 24844, 25066, 25096, 25309, 25344, 25529, 25537, 25554, 27963, 28134, 28356, 29648, 29986, 30217, 30267, 30315, 30585, 30724, 30897, 30931, 31080, 31246, 31373, 31463, 31467, 32188, 32288, 32520, 32594, 32657, 32677, 32764, 32784, 32830, 32872, 33121, 33348, 33952, 34184, 34361, 35026, 35192, 35600, 36033, 36289, 38869, 39629, 40530, 41621, 42379, 42802, 42865, 43644, 45051, 45828, 45829, 46257, 47286, 47427, 47963, 48013, 48229, 48282, 48376, 48404, 49900, 52699, 52897, 53414, 53487, 54112, 55492, 59766, 60307, 60701, 60952, 61401, 62379, 62870, 62879, 63499, 64284, 64408, 64760, 65230, 66127, , 6634, 66686, 66694, 67113, 67257, 67403, 67609, 68418, 68610, 69629, 70024, 70848, 71428, 71553, 71633, 71768, 71769, 73039, 73325, 73412, 73547, 73769, 73806, 74467, 74472, 74473, 74482, 74494, 74592, 74670, 74672, 74714, 74723, 74749, 74861, 74892, 74893, 75176, 75705, 75989, 76027, 77949, 77974, 78167, 78310, 78415, 78575, 78590, 78709, 78875, 79864, 81316, 81320, 81409, 81737, 81843, 82102, 82833, 83461, 83624, 83660, 83701, 83708, 83782, 85707, 85717,

86486, 86833, 87115, 87234, 87479, 87561, 87604, 87674, 87958, 87992, 88019, 88074, 88079, 88115, 88118, 88120, 88135, 88142, 88143, 88149, 88340, 88344, 88512, 88521, 88650, 88827, 89230, 89236, 90754, 90984, 91110, 92026, 92954, 93375, 93794, 94937, 95068, 96188, 97092 and 98812.

5. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in SEQ ID NO: 1 selected from the group consisting of 20300, 87958, 89236, 30267, 32657, 36289, 38869, 45051, 46257, 54112, 60307, 63499, 20891, 52699 and 71768.

6. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with one or more positions in claim 3, 4 or 5.

7. The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:

hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;

extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and

detecting the presence or absence of a polymorphic variation in the extension products.

8. The method of claim 1, wherein the subject is a human.

9. The method of claim 8, wherein the subject is a human female.

10. The method of claim 8, wherein the subject is a human male.

11. A method for identifying a polymorphic variation associated with osteoarthritis proximal to an incident polymorphic variation associated with osteoarthritis, which comprises:

identifying a polymorphic variation proximal to the incident polymorphic variation associated with osteoarthritis, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-7;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation;

determining the presence or absence of an association of the proximal polymorphic variant with osteoarthritis.

12. The method of claim 11, wherein the incident polymorphic variation is at one or more positions in claim 3, 4 or 5.

13. The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the incident polymorphic variation.

14. The method of claim 11, which further comprises determining whether the proximal polymorphic variation is in linkage disequilibrium with the incident polymorphic variation.

15. The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with osteoarthritis and determining if the second proximal polymorphic variation is associated with osteoarthritis.

16. The method of claim 15, wherein the second proximal polymorphic variant is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the proximal polymorphic variation associated with osteoarthritis.

17. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-7;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);

wherein the nucleotide sequence comprises a polymorphic variation associated with osteoarthritis selected from the group consisting of an adenine at position 20300, a thymine at position 46257, an adenine at position 89236, a guanine at position 30267, an adenine at position 32657, a cytosine at position 36289, a guanine at position 38869, a thymine at position 45051, a guanine at position 54112, an adenine at position 60307, a thymine at position 63499, a guanine at position 20891, a guanine at position 52699, and a cytosine at position 71768.

18. An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of (a), (b), (c), or (d) in claim 17, wherein the 3' end of the oligonucleotide is adjacent to a polymorphic variation associated with osteoarthritis.

19. A microarray comprising an isolated nucleic acid of claim 17 linked to a solid support.

20. An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 17.

21. A method for identifying a candidate therapeutic for treating osteoarthritis, which comprises:

(a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence in SEQ ID NO: 1-7;

(ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(iv) a fragment of a nucleotide sequence of (a), (b), or (c); or introducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv); and

(b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein,

whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating osteoarthritis.

22. The method of claim 21, wherein the system is an animal.

23. The method of claim 21, wherein the system is a cell.

24. The method of claim 21, wherein the nucleotide sequence comprises one or more polymorphic variations associated with osteoarthritis.

25. The method of claim 24, wherein the one or more polymorphic variations associated with osteoarthritis are at one or more positions in claim 3, 4 or 5.

26. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c); and
- (e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);
whereby contacting the one or more cells of the subject with the nucleic acid treats the osteoarthritis in the subject.

27. The method of claim 25, wherein the nucleic acid is RNA or PNA.

28. The method of claim 27, wherein the nucleic acid is duplex RNA.

29. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a protein, wherein the protein is encoded by a nucleotide sequence which comprises a polynucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c);
whereby contacting the one or more cells of the subject with the protein treats the osteoarthritis in the subject.

30. A method for treating osteoarthritis in a subject, which comprises:
detecting the presence or absence of one or more polymorphic variations associated with
osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variation are
detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in
SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the
amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic
variation; and

administering an osteoarthritis treatment to a subject in need thereof based upon the presence or
absence of the one or more polymorphic variations in the nucleic acid sample.

31. The method of claim 30, wherein the one or more polymorphic variations are detected at one
or more positions in claim 3, 4 or 5.

32. The method of claim 30, wherein the treatment is selected from the group consisting of
administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2
(COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondroitin sulfate, glucosamine or
acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery;
prescribing a weight control regimen; and combinations of the foregoing.

33. A method for detecting or preventing osteoarthritis in a subject, which comprises:
detecting the presence or absence of one or more polymorphic variations associated with
osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a
nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in
SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the
amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic
variation; and

administering an osteoarthritis prevention or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

34. The method of claim 33, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

35. The method of claim 33, wherein the osteoarthritis prevention is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondroitin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

36. A method of targeting information for preventing or treating osteoarthritis to a subject in need thereof, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

directing information for preventing or treating osteoarthritis to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

37. The method of claim 36, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

38. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-7.

39. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO: 1-7.


40. The composition of claim 38, wherein the RNA molecule is a short inhibitory RNA molecule.

Abstract of the Disclosure

Provided herein are methods for identifying a risk of osteoarthritis in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating osteoarthritis, and therapeutic and preventative methods applicable to osteoarthritis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

FIGURE 1

APOL3 – DISCOVERY P-VALUES (female only)



Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	Not Yet Assigned
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF
Attorney Docket Number::	524593009200
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets?::	1
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Steven
Family Name::	MAH
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	12820 Via Nieve #74
City of mailing address::	San Diego
State or Province of mailing address::	CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Germany
Status:: Full Capacity
Given Name:: Andreas
Family Name:: BRAUN
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3935 Lago Di Grata Circle
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Germany
Status:: Full Capacity
Given Name:: Stefan
Middle Name:: M.
Family Name:: KAMMERER
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3825 Elijah Court, Unit 334
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity

Given Name:: Matthew
Middle Name:: Roberts
Family Name:: NELSON
City of Residence:: San Marcos
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1250 Calle Prospero
City of mailing address:: San Marcos
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92069

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Sweden
Status:: Full Capacity
Given Name:: Rikard
Middle Name:: Henry
Family Name:: RENELAND
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 7555 Charmant Drive, #1114
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92122

Applicant Authority Type:: Inventor
Primary Citizenship Country:: United Kingdom
Status:: Full Capacity
Given Name:: Maria
Middle Name:: L.
Family Name:: LANGDOWN
City of Residence:: San Diego

State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3701 Yosemite Street
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92109

Correspondence Information

Correspondence Customer Number:: 25225

Representative Information

Representative Customer Number:: 25225